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Summary
The general aim of this thesis was to advance our understanding of the genetics of 
colorectal cancer. The specific aims were 1) to assess the psychological impact of 
familial adenomatous polyposis and patient attitude to predictive DNA testing, 2) to 
assess the prognostic value of allele loss in colorectal cancer and 3) to assess the 
effectiveness of a family cancer clinic for the taigeted screening of colorectal cancer.
Attitudes to predictive DNA testing and the psychological impact of familial 
adenomatous polyposis (FAP) were documented in 62 affected adults. In the 
majority of cases, FAP, appeared to have a fairly minimal impact on the everyday life 
of the patient. However, in a significant minority (20%), a diagnosis of FAP had a 
devastating effect on psychological well being. Factors which might be important 
include a previous unpleasant experience with an ileostomy, a history of cancer death 
within the family, a poor understanding of the mode of transmission of FAP and a 
perceived delay in diagnosis. With respect to patient views on prenatal testing and 
termination of pregancy for FAP, fifteen (24%) of those questioned stated that they 
would proceed to termination of pregnancy if a prenatal test indicated that the unborn 
baby was affected. Six (10%) of people who had refrained from having children for 
feai’ of passing on the polyposis gene felt that the arrival of prenatal testing would 
enable them to consider planning a family. The majority of patients (93%) said that 
they would like their children tested by DNA analysis at birth or infancy, but felt that 
10-12 year s was the most appropriate time to discuss the diagnosis with the child.
The frequency of allele loss at the APC, P53, Nm23 and DCC gene loci was 
investigated in a panel of 63 colorectal cancer specimens by Southern blotting
19a
analysis and correlation with prognosis studied. Sixty-percent of the specimens 
studied, exhibited allele loss for at least one genetic marker ( 52% at the P53 locus, 
38% at the APC locus and 36% at the DCC locus). No allele loss was found at the 
Nm 23 locus. Univaiiate analysis found that allele loss on chromosome 17p was 
related to prognosis ( P < 0.02), although a multivariate analysis, including other 
accepted prognostic indicators for colorectal cancer, failed to support this association.
The results of screening individuals referred to the Family Cancer Clinie at St Mark’s 
Hospital, London, aie described. Colonoscopy was performed in 644 asymptomatic 
individuals (from 436 families) with a family history of colorectal cancer over a six 
year period. Families were subdivided according to family history and sixty nine 
(15.8%) of the families fulfilled the Amsterdam criteria for the hereditaiy non­
polyposis colorectal cancer syndromes (HNPCC). Seven cases of colorectal cancer 
were diagnosed at an average age of 49 years; six at Dukes' stage A and one at stage 
C; four in HNPCC families. One hundred and forty four (22.4%) subjects had one or 
more adenomas. The prevalence of adenomas in the subjects from Amsterdam 
criteria families was 34 of 127 (26.8%) compared with 110 of 517 (21.3%) in non - 
Amsterdam criteria families. Men were twice as likely to develop adenomas as 
women, and the prevalence of adenomas increased in both sexes with age; the odds 
ratio (G.R.) increasing approximately two-fold for each decade (p < 0.0001). A 
multivariate analysis showed that the number of generations of relatives ( > or = 2 
versus 1) affected by colorectal cancer or adenomas was a highly significant 
independent variable associated with a an increased risk of adenoma development.
As par t of this project, a very large kindred, St Marks' Family 96, was identified, 
which appears to have an autosomal dominant predisposition to an atypical polyposis 
syndrome and colorectal cancer. This syndrome has been called the “ Hereditary 
Mixed Polyposis Syndrome" (HMPS) by the author. Affected individuals usually 
present in the fourth decade with symptomatic polyps or cancer. Although
1 9 b
adenomatous and hyperplastic polyps occur in affected members, the characteristic 
lesion is an atypical juvenile polyp. Some individuals have developed polyps of more 
than one type, and individual polyps may have mixed histological features. Typically, 
fewer than 15 polyps are found at colonoscopy, and there is no extracolonic disease 
associated with the development of polyps. St Mark's Family 96 consist of 10 second 
generation, 35 third generation, 63 fourth generation and 42 fifth generation 
individuals. All surviving members are derived from the third, fourth and fifth 
generations, and updated clinical information has been obtained in 71 patients over 
the age of 21 year's. Thirty three members (13 females, 19 males) ar'e known to have 
developed either colorectal cancer or polyps.
A genetic linkage study was performed on this family using 77 genetic markers 
spanning the genome. Data did not support linkage to the APC locus or any of the 
loci responsible for HNPCC. The most positive LOD score (0.69) was obtained with 
the marker D6S44 which maps to chromosome 6p21-qter.
Although the gene responsible for HMPS was not localised within the time period of 
this project, a subsequent linkage study found significant two-point LOD scores for 
linkage between HMPS and the D6S283 locus. Analysis of recombinants and 
multipoint linkage analysis suggests that the gene responsible for HMPS lies in a 4- 
cM interval containing the D8S283 locus and flanked by markers D6S468 and 
D6S301.
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Chapter 1 
The Clinical Genetics of Colorectal Cancer
" The successive steps in carcinogenesis may be analogous to hurdles in a race in 
which individuals who are genetically predisposed have a head start because one of 
the hurdles has already been jumped " (1)
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Introduction
The incidence of most common cancers varies widely between different populations, 
often by a factor of a hundred or more (2). Evidence from studies on migrant 
populations and correlation of incidence with various lifestyle factors, suggest that 
most of this variation can be attributed to environmental factors. However, genetic 
predisposition is also cleaiiy important as cancer incidence varies markedly within 
both resident and migrating groups. Some authors believe, that in the case of 
colorectal cancer, dietary carcinogens can only initiate or promote malignancy in the 
presence of inherited susceptibility (3).
Studies of familial colorectal cancer suggest that the same genes are involved in the 
pathogenesis of sporadic forms of the disease. In the genetically susceptible 
individual, every cell in the body will possess the critical mutation, whereas in non- 
susceptible individuals, only the cancer cells of the tar'get organ will contain the same 
mutation. Several steps are needed to turn a normal cell into a cancer cell, and so the 
inheritance of one susceptible gene does not make the development of cancer a 
certainty. However, it does mean that the individual carrying the mutation has an 
increased likelihood of developing cancer at an ear lier age than in the general 
population. Therefore, identification of the genes responsible for increased 
susceptibility and their aberrant sequences may define steps critical to cancer 
development in "sporadic" malignancy, bringing the prospect of cure and prevention 
one step closer.
There are at least two main categories of germ-line susceptibility to colorectal cancer; 
firstly, susceptibility due to the inheritance of a high penetrant mutation(s), and 
secondly, susceptibility due to the inheritance of a low penetrant mutation(s).
22
High penetrant disorders, transmitted in an autosomal dominant manner, can be sub­
divided into two main groups:
1) Polyposis Syndromes, such as Familial Adenomatous Polyposis (FAP), the Peutz- 
Jeghers syndrome (PJS) and Juvenile Polyposis (JPS), in which the small and/or large 
intestine is carpeted with hundreds and sometimes thousands of polyps, and
2) Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Syndromes, characterised 
by early onset cancer, a preponderance for right sided lesions, relatively few 
adenomas and extra-colonic malignancies.
Collectively, these syndromes may account for up to 10% of the total colorectal 
cancer burden (4, 5).
Low penetrant mutations, on the other hand, also thought to be dominantly inherited, 
are believed to be much ruore common in the general population, and may account for 
the vast majority of colorectal cancer after the fifth decade (3).
.y
Familial Adenomatous Polyposis
FAP is an autosomal dominant disorder in which affected individuals develop 
multiple adenomatous polyps in the large bowel and elsewhere in the gastrointestinal 
tract. The original report of FAP is attributed to Cripps in 1882 (6). Left untreated, 
the vast majority of patients will develop colorectal cancer before the age of 50 year's 
(7). The gene responsible for this disease, designated Adenomatous Polyposis Coli 
(APC)J, was mapped to chromosome 5q2L22 by linkage studies in families (8) and 
this led to the char acterisation of mutations in affected individuals (9).
Incidence
FAP is uniformly distributed world-wide and occurs in approximately 1:8000 
individuals in all populations (10). This figure is based on data from Denmark where 
completeness of registration approaches 100%. The point prevalence rate has been 
calculated at 35.6 per million inhabitants, the mutation rate between 1:100,000 and 
1:125,000, and the frequency of sporadic cases or new mutants between 20-25% 
(10,11).
Clinical Features
It is now appreciated that FAP is a multi-system disease affecting tissues derived 
from endodermal, mesodermal and ectodermal germ layers. Adenomas ar'e found not 
only in large numbers in the large intestine, but may occur in the stomach, duodenum 
and small bowel, and abnormalities of the skin, connective tissue, teeth, bone, central 
nervous system, thyroid, eye and liver are not unusual (12)
Large Bowel Neoplasia
The number of adenomas in the lar ge bowel is highly variable but there are usually 
between 100 and 5000, with an average of just over 1000 (Fig. 1.1)(13). Maeda et al 
categorised FAP into a sparse and a profuse form based on the density of polyps in 
the colon (14), and Bussey observed that polyp density tends to decrease from the
Human gene names have not been conventionally put into italics
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right side of the colon to the rectum (13). Rectal sparing has been reported, but is 
extremely rare, and has not been documented at the St Mark's Polyposis Registry 
(15).
Although FAP patients may present with symptoms such as abdominal pain, altered 
bowel habit or rectal bleeding, the vast majority are asymptomatic and are diagnosed 
as a consequence of screening those at risk. In a comprehensive study of the Danish 
Polyposis Registry, Bullow found that most large bowel adenomas appeared at a 
median age of 16 year's ( range 5-38 year's). The median age at the time of colorectal 
cancer diagnosis was 36 years ( range 17-64, N=114) (4).
Two main treatment options ar'e available for patients who have been diagnosed with 
FAP without cancer of the middle or distal rectum: total colectomy with ileorectal 
anastomosis (TC + IRA) (16), or restorative proctocolectomy with ileoanal pouch 
formation (17). Balance of opinion holds that preservation of the rectum generally 
affords the patient a better quality of life, and restorative proctocolectomy tends to be 
reserved for patients whose rectums are carpeted with large confluent adenomas, or 
who will not have access to regular follow-up (17). Retention of the rectum, 
however, still leaves the patient with a significant residual risk of malignancy. A 
recent review of 297 patients who had undergone TC + IRA over a 40 year period 
reported a cumulative risk for rectal cancer of 13.1% at 25 years (18). In the St 
Mark's series of 224 patients who have undergone an IRA for FAP since 1948, 10% 
have developed rectal cancer by the age of 50 year's, and 29% by the age of 60 year s 
(19).
Upper Gastrointestinal Tract Neoplasia
It is now recognised that duodenal adenomas are present in nearly all patients who have 
FAP (20-22). These lesions have considerable malignant potential and in some series, 
duodenal cancer is now the most common cancer-related death in patients who have 
undergone total colectomy (23,24).
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The finding of residual adenomatous tissue in some duodenal cancers, and the co-existence 
of adenomas in the presence of the cancer, suggests that duodenal polyps may progress 
through an adenoma-carcinoma sequence analogous to that seen in the colorectum (24,25). 
It has been speculated that bile from FAP patients may contain carcinogens which promote 
adenoma growth (24).
A hamartomatous polyposis of the stomach, known as fundic gland polyposis, has 
also been documented in about 50% of FAP patients (26,27). Fundic gland 
polyposis, i.e. cystic dilated fundic glands without epithelial dysplasia, is not believed 
to be premalignant, although a few reports of FAP associated gastric cancer have 
emanated from Japan where this malignancy is extremely common (28,29).
Adenomas are occasionally seen in the mucosa of the terminal ileum at the time of 
colectomy and cases have been reported in which adenomas have been detected in the 
ileum when inspected by endoscopy (30). Such lesions have also been observed in 
ileo-anal pouch reservoirs but their significance at this site is not known (17). Small 
bowel carcinoma is a rare complication (31).
Congenital Hypertrophy of the Retinal Pigment Epithelium fCHRPE)
Pigmentation of the retinal epithelium occurs in 50-100 % of all patients with FAP 
(32-35). The lesions are usually discrete between 50-200 mm. in diameter (Fig. 1.2), 
and may have a depigmented halo aionnd them. Smaller solitaiy lesions may be seen 
in unaffected people, but it is rare for unaffected individuals to have more than 2-5 
such small lesions (35). Histological information is scanty, but the larger lesions 
probably consist of myelinated axons while the smaller lesions appeal- to be areas of 
enlarged retinal epithelial cells with increased pigment (36). The presence of CHRPE 
in the retina of an individual at a 50:50 risk of inheriting the gene has been taken as a 
positive test for the condition with a specificity of about 99% and a sensitivity of 65%
(37). In a minority of families however, there is no expression of CHRPE in affected 
individuals, and two cases have been reported of paients with FAP and CHRPE in
26
whom an offspring had FAP but did not have CHRPE (36). Such heterogeneity limits 
the value of CHRPE as a reliable diagnostic marker.
Extra-intestinal Malignancv
An increased incidence of extra-intestinal tumours has also been described (12). In 
1959, Turcot et al described two siblings in whom multiple colonic polyps were 
associated with asti'ocytoma and medulloblastoma (38), and since then, there have 
been further reports of an association between colorectal polyposis and the 
development of central nervous system tumours (39). Originally considered a 
separate clinical entity, it is now recognised that Turcot syndrome is due to APC 
mutations (40).
Female patients under the age of 35 years are said to have a 160 fold increased risk of 
developing papillary carcinoma of the thyroid relative to the general population (41), 
although this association has been disputed (12).
Hepatoblastoma has been documented in 35 children of FAP patients (42,43), and it seems 
probable that most of these tumours developed in gene carriers (44-46).
Desmoid Tumours
Desmoid tumours ar e benign proliferative lesions of fibroblasts, arising from fasciae, 
muscles and aponeuroses which show a marked tendency for local growth but never 
metastasise (Fig. 1.3)(47). Although extremely rare in the general population, accounting 
for less than 0.03% of all neoplasms (48), they occur in 4- 29% of patients with FAP (49). 
Desmoids may reach a very lai'ge size, causing death by ureteric obstruction or invasion of 
the small bowel mesentery, resulting in intra-abdominal haemorrhage or intestinal 
obstnrction (50). Histologically, desmoids ar'e indistinguishable from fibromatosis 
elsewhere, but there is a tendency for desmoids associated with FAP to be extremely 
vascular', and this may explain the torrential haemorrhage that sometimes accompanies their 
removal (51).
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It is not known why desmoids should develop in some patients with FAP and not 
others. Desmoids tend to more common in women (3:1), and often enlarge in 
pregnancy or in those taking oral contraceptives. Interestingly, guinea pigs injected 
with high doses of oestrogen develop lesions which are histologically 
indistinguishable from human desmoids (52) and occasionally desmoids regress when 
treated with the anti-oestrogen agents, tamoxifen and torimifene (47,49,51,53). This 
supports the hypothesis that desmoid growth may be hormonally dependent.
Intra-abdominal desmoids ai*e notoriously difficult to treat and do not respond to 
radiotherapy or most forms of chemotherapy (54).
Polyposis Registries
The first polyposis registry was established at St Mark's Hospital, London, in 1925 
(55), and since then, numerous national and regional registries have been established 
throughout the world. The benefits aie shown by the dramatic decrease in the 
aggregated incidence of colorectal cancer in call-up cases (56,57).
The Peutz-.Teghers Syndrome
The Peutz-Jeghers syndrome (PJS) is an autosomal dominant disorder chaiacterised 
by the presence of hamartomatous polyps of the gastro-intestinal tract and 
mucocutaneous melanin pigmentation. First reported by Hutchinson in 1896 (58), it 
was more fully described by Peutz in 1921 (59) and Jeghers in 1949 (60). The patient 
with the PJS typically presents in childhood or adolescence with intussusception, iron 
deficiency anaemia or with a chai'acteristic facial pigmentation. Polyps aie most 
commonly found in the jejunum or ileum, but they may be found throughout the 
gastrointestinal tract (61,62).
Incidence
The exact incidence of the Peutz-Jeghers syndrome is not known. In Scotland, fewer 
than 50 people were discharged from hospital with a diagnosis of Peutz-Jeghers
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syndrome between 1980 and 1994 ( written communication with Dr J Clai'ke, 
Community Medicine Specialist, Scottish Health Services Agency, Trinity House, 
Edinburgh). A family history of this disorder is said to be present in about 55% of 
cases (63).
Histologv
Peutz-Jeghers polyps have a typical histological appearance. The core of the polyp is 
composed of tree-like smooth muscle covered by normal mucosa, and it may be the 
predominant smooth muscle component of these polyps that predisposes the Peutz- 
Jeghers patient to intususseption (64).
Risk of Malignancv
Although, Peutz-Jeghers polyps are classified as hamartomas, the Peutz-Jeghers 
syndrome is associated with a significantly increased risk of malignancy, par ticularly 
of the pancreas, breast and gastrointestinal tract (65). When breast cancer occurs, it 
may be bilateral (66,67). The patient with the PJS also has a predilection for some 
rather unusual tumours such as ovar ian sex cord tumour with annulai’ tubules 
(SCTAT) (68-70), feminising Sertoli cell tumour (71) and adenoma malignum of the 
cervix, a lesion which appears benign histologically, but behaves in a malignant 
fashion (70).
Screening of the index patient and at-risk family members involves colonoscopy, 
radiological studies of the large bowel, regular breast examination, pelvic 
ultrasonography in girls and physical examination of the gonads on boys.
The gene responsible for the Peutz-Jeghers syndrome has not yet been mapped.
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Juvenile Polyposis
The solitary juvenile polyp of childhood is generally considered to be a benign 
inflammatory lesion with a self-limiting course due to spontaneous auto-amputation. By 
comparison, Juvenile Polyposis, first described in 1964 (72), appears to be a heterogeneous 
group of disorders, some of which have considerable malignant potential. There are 
believed to be at least three forms;
1) Juvenile Polyposis of Infancy, which is associated with malnutrition, diarrhoea, 
haemorrhage and intussusception, and death before 2 years (73).
2) Juvenile Polyposis coli ( the most common form ) where polyps are confined to the large 
bowel.
3) Generalised Juvenile Gastrointestinal Polyposis, characterised by the development of 
numerous juvenile polyps in the stomach, small intestine, colon and rectum in various 
combinations. This type may be associated with congenital defects which include 
abnormalities of the heart, cleft palate, cranium, polydactyly, malrotations of the gut, and 
pulmonary arteriovenous malformations (74).
Although non familial cases have been reported (75,76) most forms appear' to be 
transmitted in an autosomal dominant manner (77).
Histology
A typical juvenile polyp is a smooth surfaced lesion with a rounded contour (Fig.
1.5). Macroscopically, it often has an ulcerated outer surface with numerous mucin 
filled cysts present on cut section. Although pedunculated, the pedicle is thin and 
devoid of muscle, making it par ticular ly susceptible to volvulus, venous congestion, 
haemorrhage and auto-amputation. Microscopically, the polyp consists of epithelial 
tubules embedded in a mass of oedematous lamina propria with prominent 
inflammatory cell infiltrates (78).
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Risk of Malignancv
It is now recognised that patients with JP coli have a significantly increased risk of 
developing colorectal cancer. One author has estimated that the cumulative life-time 
risk may exceed 50% (79). Juvenile polyposis has also been reported in association 
with adenocai’cinoma of the stomach ( 80) and pancreas ( 76).
Juvenile polyposis remains a comparatively poorly defined syndrome and no clear* 
guidelines have been established for screening and management of affected families. 
However, the premalignant nature of the disorder suggests that the families should be 
kept under close medical surveillance, and colonoscopy performed on a regular basis.
The Muir-Torre Syndrome
In 1967, Muir described a patient with six primary carcinomas, four in the colon, one 
in the duodenum, and one in the hnynx in addition to multiple karato-acanthomas and 
a sebaceous adenoma of the skin (81). The following year*, Torre reported the cases 
of a 57 year old man who had over* 100 sebaceous adenomas and 2 adenocarcinomas 
of the gastrointestinal tract (82). A hereditary basis for this syndrome was proposed 
in 1971(83).
The Muir-Torre Syndrome (MTS) is an autosomal dominant disorder characterised 
by: 1) at least a single sebaceous gland tumour* ( either* an adenoma, an epithelioma, 
or a carcinoma) (Figs. 1.6,1.7) and 2) a minimum of one visceral malignancy . To 
date, 120 patients with MTS have been documented world-wide (84). The majority 
of internal malignancies in this disorder ar ise in the colorectum (51%) or the 
genitourinary tract ( 25%), but tumours may ar*ise at any site, and an association with 
lymphoma and haematological malignancies has also been described (85-87). Unlike 
"sporadic" colorectal cancer, the majority of colorectal cancers reported in this 
syndrome have occurred proximal to the splenic flexure (58%), and nearly half the 
patients have more than one malignancy. The sebaceous gland tumours may precede, 
appear* concurrently or follow the diagnosis of the patient's caneer and more than 20%
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of the patients also have a kerato-acanthoma. (85). A char acteristic feature of the 
MTS, is the prolonged survival often oberved following the diagnosis of the visceral 
malignancy (88).
Sebaceous adenomas are rare skin tumours, and their occurrence as multiple 
neoplasms is even rarer. In a retrospective review of histo-pathological specimens 
stored within the department of dermatology at the Mayo Clinic over a 60 year* period 
between 1923-83, only 59 patients with one or more of these lesions were found; 42% 
of these patients had one or more visceral malignancies (90).
The Muir-Torre syndrome may be a variant of the Hereditary Non Polyposis 
Syndrome (90).
Cowden's Syndrome
In 1963, Lloyd and Dennis reported the case of a 20 year* old woman who had 
multiple hyperkeratotic papules of the lips and palate, gross deformity of the breast 
with nodularity, discolouration and ulceration, and a rnultinodular goitre. Biopsy of 
the breast and thyroid showed epithelial overgrowth "indistinguishable from 
carcinoma", and ten years later, the patient died from metastatic breast cancer (91). It 
was proposed at the time that this constellation of findings might represent a new 
symptom complex, and it was named Cowden's Syndrome after the surname of the 
propositus. Cowden's syndrome has since been referred to as the " multiple 
hamartoma syndrome" to emphasise the multiple hamartomatous anomalies of 
various organs (92).
There are now 76 reports of Cowden's syndrome in the literature, and of these 15 
(20%) have developed breast cancer ( 5 bilateral), 5 (7%) thyroid cancer and 14 
(18%) malignancy elsewhere (93).
Mucocutaneous lesions ai*e prominent and distinctive, and include facial hair follicle 
tumours, ( Fig. 1.8), keratoses and oral papillomas (94). Polyps of varying histology
32
may occur anywhere in the gastro-intestinal tract but the malignant potential of these 
polyps is believed to be low (95).
The chaiacteristic facial appearance of a patient with Cowden's syndrome is shown in 
Fig. 1.9
Hereditary Mixed Polyposis Syndrome
An atypical polyposis syndrome char'acterised by histologically unusual polyps and 
early onset colorectal cancer will be described in Chapter 3.
Hereditary Non-Polyposis Colorectal Cancer
In 1913, Aldred Warthin, a pathologist at Ann A itor University, Michigan, USA, 
reported a large kindred, "Family G" which appeared to have a dominantly inherited 
susceptibility to colorectal and endometrial cancer (96). Clinical information on 650 
descendants of the proband of this family has been updated over a 75 year* period, 
during which 95 persons have developed malignant neoplasms (19 before the age of 
40 years). Thirteen have developed multiple primary tumours (97-99).
Many similar* families have since been reported, in other par ts of North America, the 
Netherlands, Finland, United Kingdom, Japan and South Africa, suggesting a 
worldwide distribution for* this syndrome (100-104).
The her*editar*y non- polyposis colorectal cancer* (HNPCC) syndromes are now 
regarded as a group of dominantly inherited disorders, char acterised by 1) an ear’ly 
age of onset of colorectal cancer* (40-45 year's ), 2) a preponderance of tumour* excess 
in the right side of the colon ,3) a high risk of metachronous disease and 4) 
sometimes an excess of other adenocarcinomas in the kinship (Fig. 1.10)(5). Extra­
colonic malignancies most commonly include those affecting the stomach, 
endometrium and urinary tract and typically, these cancers present 20-30 years earlier* 
than would be expected in the general population (105-108).
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Incidence
Before 1993, there were no specific genetic maikers for the HNPCC syndrome, and 
the lack of a verifiable biomarker and an easily recognisable phenotype greatly 
hindered documentation of HNPCC in both family studies and population suiweys.
It is now known that the majority of cases of HNPCC result from mutations in at least 
four DNA mismatch-repair genes: the hMSH2 gene on chromosome 2p, the tiMLHl 
gene on chromosome 3p, the PMS1 gene on chromosome 2q and the PMS 2 gene on 
chr'omosome 7 (108-11).
The exact frequency and penetrance of the genes responsible for HNPCC has yet to 
be determined, but most studies estimate that HNPCC may account for between 1-5% 
of all colorectal cancer cases (112-116).
Histology
Despite claims of improved survival for HNPCC compared to a general series of 
patients with colorectal cancer (117), the pathology of adenocarcinomas appears to be 
very similar* to that seen in "sporadic" cancers, and there are no reliable histological 
feature which can identify a cancer* as hereditary in nature (5). However, the relative 
rarity of adenomas in HNPCC, the earlier age at which they occur, the higher 
incidence of villous growth pattern and associated dysplasia, suggests that the polyps 
associated with HNPCC may have a greater potential for* malignant conversion (118).
Anticipation
In a follow-up to his original report, Warthin noted that " in Family "G", there was 
shown a decided tendency for the neoplasm to develop at an earlier age in successive 
generations " (97). Other* authors have also commented that in some families, 
HNPCC appears to skip a generation (119). At least two possibilities exist to explain 
this observation; either* the mutation may exhibit non-penetr*ance, exerting no effect
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on phenotype, or the phenomenon of anticipation may be present, where age of 
disease onset becomes earlier in successive generations.
In some other hereditary disorders such as myotonic dystrophy, anticipation appears 
to result from the expansion of a trinucleotide DNA repeat sequence within the gene 
as the gene defect is passed from parent to child (120,121). It is too eariy to comment 
on whether such a mechanism also operates in HNPCC.
Familial Clustering of Colorectal Cancer
Although the vast majority of colorectal cancer occurs in the absence of any obvious 
pattern of Mendelian inheritance, it has been noted for many years, that this 
malignancy tends to occur more often in some families than in others. This was 
previously attributed either to a chance clustering of cases or to shared exposure to 
environmental carcinogens. However, several different modes of investigation, 
involving mortality, family history and endoscopy studies, have consistently 
demonstrated a 2-4 fold increase in colorectal neoplasia in first degree relatives of 
cases, making a hereditary explanation more likely ( Tables 1.2-1.3). (112,122-129).
Pedigree Analysis Studies
Pedigree analysis is a useful technique which utilises hypothetical mathematical 
models to assess patterns of disease within families for different models of 
inheritance.
In 1985, Burt et al conducted a pedigree analysis study of a lai'ge kindred in Utah, 
which appeared to have an increased susceptibility to colorectal cancer. This kindred 
included more than 5000 subjects spanning 6 generations, and 4 branches of this 
family were studied. Although there were several cases of colorectal cancer among 
kindred members, initial pedigree analysis failed to elucidate a recognised pattern of 
inheritance, with tumour distribution within the family being similar* to that seen in 
the Utah Cancer Registry. However, when kindred members were selected and
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examined for adenomatous polyps using the 60 cm fibre-optic sigmoidoscope 
(F.O.S.), a statistically significant difference was observed between the family 
members and spouse controls. A repeat analysis of the data, then provided strongest 
evidence for an autosomal dominant mode of inheritance, with little evidence for 
autosomal recessive inheritance or chance occurrence (3).
Burt's original study was then extended to estimate the frequency of inherited 
susceptibility to adenomas in the general population . This study also supported the 
theory that susceptibility was probably inherited in an autosomal dominant manner. 
Gene frequency in the Utah population was estimated to be 19% with a life-time 
penetrance of 0.4 for adenomas or colorectal cancer in susceptible individuals 
(Fig.l.ll)(130). In an Italian population, however, the penetrance of the gene was 
estimated to be only 0.1, and the true penetiance therefore may lie somewhere 
between these values (131).
Genetic predisposition to adenoma formation may yet turn out to be the most 
important factor in the pathogenesis of colorectal cancer, with dietery carcinogens 
acting as promoters in the adenoma-cai'cinoma sequence. Once the susceptibility 
locus has been identified, gene cairiers who develop colorectal cancer can be 
compared with carriers who develop adenomas and those caiTiers who remain 
adenoma free. This may shed more light on the mechanisms underlying gene-diet 
interaction, and provide a more rational basis for developing cancer prevention 
strategies.
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Fig 1.1 A colectomy specimen from a patient with Familial Adenomatous
Polyposis.
Fig 1.2 Congenital Hypertrophy of the Retinal Pigment Epithelium
%
Fig 1.3 A desmoid tumour from a patient with FAP. Note the homogene - 
ous appearance of the cut surface resulting from high collagen 
content of the stroma.
Fig 1.4 A typical Peutz-Jeghers polyp
Fig 1.5 A typical juvenile polyp
Fig 1.6 Macroscopic appearance of a sebaceous adenoma
m m
Fig 1.7 Microscopic appearance of a sebaceous adenoma
Fig 1.8 Histological appearance of a hair follicle tumour in a patient with 
Cowden's syndrome.
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Fig 1.9 Facial appearance of a patient with Cowden's syndrome.
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Fig 1.11 The probability of detecting adenomas in endoscopically 
screened relatives and spouses.
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Reference Relatives of cases who 
developed CRC
Relatives of contr ols who 
developed CRC
Relative
Risk
(132)
18% 2% 9
(133)
19% 3.5% 5.3
(114) 20.9%
5.4% 3.9
(134)
11.3% 5.1% 2.4
(112) 23% 5% 4.6
Table 1.1 A Summary of Family History Studies of Colorectal Cancer.
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Reference Mean Age Sample Size Method Neoplasia Trial
(135) N.S. 125 Colonoscopy 12% P
(136) 51 114 Colonoscopy 20% P
(137) 54 154 Colonoscopy 18% P
(124) 55 201 Colonoscopy 27% R
(138) 54 49 Colonoscopy 63% R
(139) N.S. 48 Colonoscopy 25% R
(140) 41 644 Colonoscopy 22.4% P
Table 1.2 Uncontrolled endoscopy studies in first degree relatives of colorectal 
cancer cases. N.S. = not stated. P= prospective. R = retrospective. 
F.O.B.T. = faecal occult blood testing. F.O.S. = fibre-optic 
sigmoidoscopy.
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Reference Group Mean Age Sample Size Method Neoplasia
(130)
Relatives 51 407 F.G.S. 19%
Controls 52 265 F.G.S. 12%
(125)
Relatives 50 128 Colonoscopy 12%
Controls 54 49 Colonoscopy 8%
(123)
Relatives 46 471 F.G.B.T./F.G.S 8%
Controls 57 457 F.G.B.T./F.G.S 4%
(363) Relatives 58 92 F.G.S. 15%
Controls 63 30 F.G.S 10%
Table 1.3 Case-controlled studies of adenoma incidence in first degree relative of 
colorectal cancer cases. F.O.B.T.= Faecal Occult Blood Testing.
F.G.S. = Flexible Sigmoidoscopy.
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Chapter 2 
The Molecular Genetics of Colorectal Cancer
" Eventually, the techniques of nucleic acid chemistry should allow us to itemise all 
the differences in nucleotide sequence and gene expression that distinguishes a cancer 
cell from its normal counterpait, and perhaps at that point the steps in caicinogenesis
will cease to be in doubt " (141)
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Introduction
Although Theodore Boveri suggested at the beginning of this century that 
chromosomal abnormalities might be the basis for cancer (142), it was not until the 
src gene of the Rous sarcoma virus was characterised, that a conclusive link between 
genes and cancer was demonsti'ated (143). Since then, there has been a virtual 
explosion in our knowledge of cancer genetics, offering real hope for earlier 
diagnosis, more effective therapy and accurate assessment of prognosis.
Cancer is now considered to be a genetic disease which develops as a result of a 
stepwise accumulation of errors in the genome. Such errors may be due to the 
integration of viruses, radiation damage, exposure to chemical caicinogens or may be 
inherited in the germ-line. Regardless of the mechanism involved, the end result is 
usually the same; alterations in certain DNA sequences lead to unregulated cell 
growth, proliferation and differentiation, transforming a normal cell to a malignant 
one.
Two features of colorectal cancer make it a pai ticulaiiy good model for studying 
neoplasia. Firstly, abundant clinical and histo-pathological data support a theory that 
the majority of cancers arise from pre-existing adenomatous polyps, making it 
possible to study genetic changes at different stages of carcinogenesis. Secondly, 
there aie well defined hereditaiy bowel syndromes which predispose to colorectal 
cancer, and which are particularly suitable for gene mapping using linkage analysis.
In 1987 it was demonsti'ated that the APC gene was mutated in a significant 
percentage of "sporadic " colorectal cancer specimens (144-146). This landmark 
observation formed the basis for a genetic model for colorectal cancer, and 
established a common link between the hereditai'y and sporadic forms of disease.
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It is now hypothesised that colorectal cancer results from a net accumulation of 
genetic errors involving the activation of growth promoting oncogenes, and/or 
inactivation of growth restraining tumour suppressor genes (147). The tendency for 
such mutations to occur may be accentuated by mutations in mismatch-repair genes 
conferring a mutator phenotype (148).
Clonalitv of Colorectal Cancer
There are at least two scenarios by which a cancer might develop from normal tissue. 
In the first scenario, a lai'ge cohort of normal cells may be recruited en masse by 
some unknown agent into becoming cancer cells. In the second scenario, the cells in 
the tumour may descend from a single cell that has gained a selective growth 
advantage and undergone clonal expansion. In the latter situation, cells making up 
the tumour nrass will be members of a single lineage forming a monoclonal 
population. Present evidence suggests that the monoclonal theory is the more likely. 
Monoclonality has been demonstrated for lymphomas, uterine leiomyomas and 
bladder cancer (149-151), and there is some evidence to suggest that colorectal cancer 
might also be monoclonal (152).
Multistep Nature of Cancer
Measurements of age dependent cancer incidence predict that at least 4-6 rate limiting 
independent steps are necessary for most common cancers to develop (153). 
However, it has been difficult until recently to reconcile this observation with current 
cancer models. Each postulated genetic change is a low probability event occurring 
perhaps once in a thousand to more typically once in a million times per cell 
generation (154). The likelihood of all events occurring together therefore (the 
product of the probabilities) would seem extremely small and the 10 to 30 years that 
it actually takes for most tumours to develop, would seem too short a time period for 
such mutations to occur at random.
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It is now appreciated that the cancer genome is extremely unstable, with dramatically 
increased mutation rates per cell generation (155). While normal cells maintain a 
fixed stable complement of chromosomes over dozens of cell generations, cancer cell 
seem intrinsically erratic, with a tendency to reanangement, duplication, and deletion 
during cell division. As a consequence they often display novel, bizaire traits in their 
progeny cells (156). This suggests that the cellulai' machinery required to maintain 
the number and configuration of genes often breaks down in cancer cells.
Cunent thinking is that certain genes, when altered, may have the ability to confer a 
mutator phenotype. Lane has proposed that the p53 gene may function as a 
"moleculai* policeman", by regulating the onset of DNA replication at the Gl-S 
interphase of the cell cycle. When the p53 gene is functioning normally, cells with 
potentially damaging mutations aie prevented from entering the cell cycle, and the 
damaged cell can either have the mutation corrected or be directed into programmed 
cell death or apoptosis . However, in cells with deficient p53 function, the narrow 
limits under which plasticity is controlled, breakdown, and the genome becomes 
hypermutable (157).
The mismatch- repair genes, hMSH2, hMLHl, PMSl and 2 may serve a similai- 
genome surveillance function by correcting DNA replication errors (108-111)
Gain of Function Mutations
In 1910, Peyton Rous, working at the Rockefeller Institute for Medical Reseaich, 
demonstrated that a cell free filtrate from a chicken sarcoma could induce the same 
tumour in other chickens, raising the possibility of a transmissible agent with the 
potential to induce malignant change (159). However, it was not until Bishop and 
Varmus described the first human oncogene over 70 yeai's later that the full 
significance of Rous’s observation was appreciated (160,161).
Oncogenes are a family of unique sequences of DNA whose abnormal expression is 
associated with uncontrolled cell proliferation and differentiation arrest. These
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sequences have been shown to transform normal cells in- vitro and to cause tumours 
after a short latency period at the site of inoculation in-vivo (162,163). In contrast to 
tumour suppressor genes, oncogene mutations aie capable of inducing tumours with 
single hit kinetics in susceptible hosts (164). Although first demonstrated in rapidly 
transforming RNA vimses (v-onc), their importance lies in the discovery that their 
DNA sequences are derived from normal cellular DNA (c-onc). Each viral oncogene 
has a region of highly conserved sequence homology to normal vertebrate DNA, and 
it is believed that they arose thi'ough illegitimate transduction of the normal cellular' 
proto-oncogene into the viral genome. Over three dozen oncogenes have now been 
described, several of which aie implicated in colorectal cancer (165).
It is still not known exactly how all the known oncogenes exert their effect, but some 
interesting clues ai'e appearing (165,166). Normal cells produce growth factors, 
which promote cell division, differentiation and development. These proteins act 
thr ough a chain of command on their tai’get cells. After binding to surface receptors, 
their activity is modified by kinases which are part of the cytoplasmic domain of the 
receptor. They then interact with intracellular' second messenger systems, which in 
turn can influence the activity of other proteins, bind directly with nuclear' DNA, and 
regulate gene expression. However, this intricate means of communication often 
breaks down in malignancy, and growth factors can form self-perpetuating autocrine 
feedback loops, leading to unregulated cell growth (166).
Proto-oncogenes may be activated by point mutation (167), translocation (168), or 
gene amplification (169).
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Ras gene mutations
The ras family of oncogenes was originally discovered in two murine retroviruses 
known as the Harvey and Kirsten murine sarcoma viruses. To date, three members, 
Ki-ras, Ha-ras and N-ras, have been identified and the molecular* weight of their 
encoded proteins is 21 kiloDaltons (170,171). Present evidence suggests that the 
principal role of ras genes is to regulate signal transduction across the cell membrane . 
A cytoplasmic protein called GAP (GTPase activating protein) has been identified 
which can interact with the p21 ras protein to amplify its hydrolytic GTP activity by 
as much as 50 fold (172). Diminished GTPase activity as a result of ras mutation 
therefore could interfere with signal transduction from surface cell receptors, leading 
to enhanced ATPase activity and increased cell metabolism (173).
In 1982, it was established that the transforming sequence from a human bladder 
cancer was a modified form of H-ras, with a point mutation at codon 12 which 
resulted in the substitution of a glycine for a valine residue, altering the conformation 
of the oncogene encoded protein (167). Other transfection assays have demonstrated 
that ras point mutations invai’iably cluster aiound codons 12,13 and 61 (174). Ras 
gene DNA extracted from bladder cancer on its own does not have the capacity to 
transform normal cells, and in animal model systems, ras gene point mutations 
require combined co-transfection with c-myc or P53 for malignant conversion to 
occur (175).
Ras genes aie the most coimnonly mutated oncogenes in colorectal neoplasia, 
occurring in between 40-60% of all caicinomas, and a similai* number of adenomas 
greater than 1cm (170,176). Although these mutations appear to be an eai'ly event in 
the adenoma-caicinoma sequence (147), they may be absent from the most poorly 
differentiated cancers suggesting that ras gene activation may be switched off in the 
more advanced stages of malignancy (177). No difference in ras mutation frequency 
has been observed between proximal and distal tumours (178), and there appears to be
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no correlation between the presence of ras oncogene expression and prognosis 
(179,180).
The polymerase chain reaction (PCR) can detect neoplastic ras point mutations in 
DNA from shed epithelial cells in patients' stool samples, but the usefulness of this 
test for diagnosis and screening remains uncertain (181).
C-Myc Oncogene
C-myc is the oncogene of the avian leukosis virus, which in chickens leads to the 
development of myelocytomas, lymphomas, saicomas and caicinomas (182). The 
protein product of the c-myc oncogene is a 62kD nuclear phosphoprotein which 
functions as a transmembrane regulator of transcription (183,184). Abnormal levels 
of c-myc mRNA levels and the c-myc protein in colorectal cancer have been reported 
in between 6-98% of cases (185,186), but deregulation of c-myc gene expression does 
not appeal' to be associated with amplification or reairangement of the gene (187). 
Some correlation has been claimed between c-myc oncogene expression and tumour 
differentiation, but the correlation between c-myc expression and prognosis is poor 
(188).
Other oncogene products less frequently altered in colorectal tumours include c-src, 
overexpressed in 62% of cancers: c-myb deleted in 9% and c-erb2 amplified in 3-4%. 
(189-191)
Loss of Function Mutations
The concept that tumours may ai'ise as a result of a loss of genetic material was first 
proposed by Boveri in 1914, who concluded, after studying abnormal mitoses during 
the development of sea urchin embryos, that malignant cells were mutant clones that 
had acquired an unbalanced chromosome complement:
" Another possibility is that in eveiy normal cell there is a specific arrangement for  
inhibiting, which allows the process o f division only when the inhibition has been
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overcome by a specific stimulus. To assume the presence of definite chromosomes 
which inhibit division would harmonise best with my fundamental idea " (142).
Nonetheless, it was not until the somatic cell hybridisation experiments of the late 
1960s that strong evidence emerged to support Boveri's hypothesis (192). Somatic 
cell hybrids have inherently unstable karyotypes and frequently shed chromosomes 
arising from one or other par'cnt cell. The expulsion of mouse chromosome 4 in the 
studies of Hariis and Klein, led to reversion to the malignant phenotype, strongly 
suggesting that a gene (or genes) from a normal cell might replace a defective 
function in the cancer cell (193).
In the 1970s, methods were developed which permitted the transfer of a single 
specific chromosome which would be retained as a complete structural unit in 
succeeding gerrerations of recipient tumour cell lines (194). In most cases it was 
found that transfer of the missing normal chromosome region in the tumour was able 
to temporarily suppress the immortalised phenotype, whereas the transfer of 
irrelevant chromosomes had no such effect (195). In colorectal cancer, the transfer of 
chi'omosomes 5,17 or 18 into tumour cell lines, can significantly inhibit growth in- 
vitro, abolish anchorage independent growth, and completely suppress tumour 
development (196,197).
In the 1980s, Cavanee, demonstrated a molecular basis for tumour suppressor gene 
inactivation using restiiction fragment length polymorphism analysis (198). The 
steps that lead to homozygosity in a cancer cell usually involve flanking 
chromosomal regions as well as the genetic region of interest, and accordingly, 
anonymous DNA probes mapping to neaihy chromosomal sites, which show 
heterozygosity in normal cells, may suffer a parallel reduction to homozygosity ( Fig
2.1). A low level of non-specific allele loss occurs thioughout the genome in a wide 
vai'iety of tumours, but regions which consistently demonstrate a high frequency of 
fractional allelic deletion (>10%) frequently harbour tumour suppressor gene loci 
(199,200). Such mutations may either be inherited in the germ-line, or occur in
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somatic tumour cells. Loss of heterozygosity (LOH) studies using matched 
tumour/normal DNA samples have proven to be an extremely useful tool for 
identifying genes involved in inherited cancer syndromes (201).
The Retinoblastoma Pai'adlgm
The childhood tumour retinoblastoma serves as a pai'adigm for understanding the 
recessive nature of tumour suppressor gene inactivation. This malignancy has been 
observed in two distinct forms (202). In 25-30% of retinoblastoma cases, tumours 
appeal' bilaterally, may be multifocal in each eye and appeai* at a very young age. In 
the remaining 70-75% of cases, tumours aie unilateral, unifocal and tend to develop 
later. In a statistical study, Alfred Knudson proposed a two hit model to explain the 
differing age of onset of this malignancy between children with and without a positive 
family history (203). The essential feature of Knudson's hypothesis is that in the 
familial form of retinoblastoma, the affected individual inherits a mutant loss of 
function allele from the affected paient, and then a somatic event inactivates the 
normal allele from the other paient; the implication being that any somatic cell of the 
gene carrier can be examined for this first mutation.
Several mechanisms have been proposed to explain the way in which the surviving 
wild-type allele may be inactivated after the first copy has been inactivated. These 
include, complete loss of the normal chromosome, loss and reduplication of the 
abnormal chromosome, chromosomal non-disjunction, mitotic recombination and 
reduplication of the mutant allele, gene deletion or point mutation (Fig 2.2).
Isolation of the Retinoblastoma (Rb) gene was made through a series of family, 
cytogenetic and moleculai’ studies (198,204-207). A germ-line mutation in the 
retinoblastoma gene has been found to confer a 90% chance of malignancy, as the 
background somatic mutation rate is sufficiently high for the normal allele to be 
inactivated (202).
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The Rb gene encodes a 110 kDa protein product which is believed to be principally 
involved in cell-cycle regulation (208). It has the ability also to bind DNA and form 
specific complexes with the transforming proteins of several DNA tumour viruses, 
including SV40 large T, adenovirus E l A, and human papilloma virus (209-211).
Rb gene inactivation does not appear to be a frequent event in colorectal cancer. 
Indeed, cytogenetic studies have found 48-55% of colorectal tumours exhibit non 
random gains of chromosome 13, (212,213), suggesting that an increase in Rb gene 
copy number, may be one explanation for increased Rb gene expression observed in 
some colorectal cancers (214).
The APC Gene
The key clue to the localisation of the gene responsible for FAP appeared in 1986 
when Herrera and colleagues reported the case of a mentally handicapped patient with 
FAP who had a cytogenetically visible interstitial deletion on the long arm of 
chromosome 5 (215). (Fig 2.3 ). This observation was quickly followed up by 
Bodmer et al in London and Leppert et al in Salt Lake City, who regionally localised 
the APC gene by linkage analysis to chromosome 5q21-22 (8,216). It was 
demonstrated subsequently that LOH was present in this region of the genome in 40- 
80% of "sporadic" colorectal tumours suggesting a tumour suppressor function for the 
APC gene in both hereditaiy and sporadic colorectal cancer (144,145).
Using a combination of yeast artificial cliromosome (YAC) vectors and chromosome 
walking techniques, a large region of 5q21 was then cloned (217). Three candidate 
cDNAs were identified which mapped within a lOOkb constitutional microdeletion in 
one FAP patient, and point mutations were detected using a polymerase chain 
reaction strategy in the germ-line DNAs of one of these genes. Transmission of a 
mutation was found to produce the FAP phenotype in the offspring of one of the 
patients thus confirming that APC was the gene responsible for this disorder (9).
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The APC gene consists of 15 exons and has an 8.5 kb coding sequence, encoding a 
predicted protein product of 2843 amino-acids. The coding region can be examined 
by PCR using 31 pairs of primers. Exons 1-14 are small, but exon 15 is large, 
accounting for 77% of the coding region (9) (Fig 2.4 ).
To date, examination of more than 400 unrelated individuals with FAP has revealed 
126 germ-line mutations, 61 of which aie unique (218). More than two-thirds of the 
mutations aie clustered in the 5' half of the last exon, with the most common mutation 
being a 5 bp. deletion at codon 1309 (219,220). Thirty- four percent of the mutations 
aie point mutations which generate stop codons, 59% aie insertions or deletions 
resulting in frame-shift mutations , 5-7% occur at splice junctions, and fewer than 2% 
aie lai'ge deletions which remove pai t or all of the APC gene from the chromosome. 
More than 90% of the mutations detected can be considered "knockout" mutations 
resulting in premature termination of ti anscription and a truncated protein product.
Function of the APC Gene and its Role in Car cinogenesis.
The protein product of APC contains a potential coiled structure in the NH2 -terminal 
region, a repeated 20 amino acid sequence in the central region, and a stretch of basic 
amino acids in the COOH- terminal region (9). A search of the protein database 
predicted weak sequence homology to the G-proteins, and originally it was thought 
that the APC protein might be involved in signal transduction across the cell 
membrane, given the function of G proteins as coupling factors (221).
APC protein is localised in the cytoskeleton (222) and the presence of short coiled 
regions within the APC protein suggests that the molecule may have the ability to 
form dimers with other molecules as well as APC protein itself (223). This means that 
the site of the mutation, and hence the length of the truncated peptide may determine 
the ability of mutant APC protein to form dimers, modifying function and 
influencing phenotypic expression.
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It is now known that APC protein associates with alpha and beta catenin- components 
of the adhesional cell molecule E-cadherin complex (223,224). Cadherins are cell 
surface molecules that mediate calcium-dependent intercellular interactions, and are 
important for morphogenesis (225). Loss of E-cadherin function or alpha catenin has 
been shown to be associated with invasion and metastasis in colorectal cancer models 
(226). Binding to catenins is essential for E-cadherin function and it has been 
suggested that catenins bind the cadherins to the cytoskeleton (227). It is postulated 
that the APC protein may modulate interactions between the catenins and the 
cadherin molecules, and control pathways critical for epithelial growth (228).
Mutations of the APC gene have been identified in 60% of sporadic colorectal 
cancers and 63% of sporadic adenomas, with nearly 2/3rd of the mutations occurring 
in exon 15 (146). This frequency may be an underestimate, as the promoter region 
and introns of the genes have not been studied, and present methods of analysis may 
miss mutations.
APC mutations have also been identified in breast, pancreatic, gastric and 
oesophageal cancer , suggesting a more general role for the APC gene in malignant 
disease (229-231).
Animal Models
A murine equivalent of FAP has been described, which has been named " multiple 
intestinal neoplasia" or M.I.N.. Mice expressing this trait develop large number of 
adenomas in the small and large bowel and aie susceptible to gastro-intestinal cancer 
(232). Like FAP, this trait is transmitted as an autosomal dominant, and linkage 
analysis has shown cosegregation with a nonsense mutation in the murine homologue 
of the APC gene (233). Furthermore, inactivation of the remaining allele of the 
murine APC has been demonstrated in 100% of tumours from Min mice supporting 
Knudson's hypothesis (234,235).
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Recently, a frame-shift mutation was introduced at codon 1638 of the mouse APC 
gene by homologous recombination in embryonic stem (ES) cells. Both the 
corresponding chimeric and heterozygous animals developed epithelial hyperplasia, 
adenomas and adenocar cinomas of the small intestine within 20 weeks of birth (236).
Predictive DNA Testing
Linkage analysis is a powerful diagnostic tool which permits presymptomatic 
diagnosis in 95% of at risk individuals with a predicted accuracy of 98% ((Fig. 
2.5)(237). A disadvantage of this technique is that a DNA sample has to be available 
from at least two affected family members to establish linkage relationships. When 
linkage analysis is not possible, other methods of presymptomatic diagnosis are 
required to identify the mutations within each family. These methods include single 
strand conformational analysis ( SSCP) (238) denaturing gradient gel electrophoresis 
( DGGE) (239), in-vitro reverse transcription assays (240), functional assays (241) 
and heteroduplex analysis (242). Each of these methods has advantages and 
disadvantages, and it is difficult to apply specific tests to an extended group of 
unrelated individuals as the spectrum of mutations identified is very large. Once a 
nucleotide alteration has been detected however, the region of interest can be 
sequenced, the exact site and character of the mutation identified, and a more user 
friendly direct method developed for screening family members.
Overall, the causative APC mutation has been identified in only 30% of the patients 
with FAP reported in the literature (243).
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MCC gene
While searching for the APC gene, another gene termed MCC (Mutated in Colorectal 
Cancer), centromeric to APC was cloned from the region of chromosome 5q21 (244). 
MCC has a 2.5 kb coding sequence, 17 exons and encodes an 829 amino acid protein 
with a very short region of homology to the G protein m3 muscarinic acteylcholine 
receptor. A rearrangement disrupting the coding region was found in one colorectal 
tumour, and two additional tumours were found to contain somatically acquired 
mutations which resulted in amino-acid substitutions (244). Up to 55% of lai'ge 
bowel cancers contain deletions involving the MCC locus (245,246), and it has been 
postulated that MCC may represent another tumour suppressor gene. In common 
with the APC gene, the MCC gene also contains many coiled regions, and it has 
been proposed that the two gene products may have the capacity to dimerise with one 
another to form a biologically active complex (247). If this is the case, a mutation in 
either gene might have the potential to inactivate the entire complex.
The P53 Gene
The P53 gene is the most ubiquitously mutated gene in human malignancy, and 
increased expression of this gene has been identified at both mRNA and protein level 
in a wide variety of tumours (248). The product of p53, a 393 amino-acid nuclear 
phosphoprotein, was originally identified in 1979 by Lane and Crawford through its 
ability to form a tight complex with the large T antigen of SV40 DNA virus (249). 
The p53 oncoprotein was found to be present in lai'ge quantities (5-100 fold) in 
transformed cells in culture, but in very low quantities in normal tissues. This was 
principally because mutant p53 oncoprotein is stable, whereas wild-type p53 is 
unstable with a very short half life (250).
The p53 gene maps to chromosome 17pl3.1, encompasses 16-20 kb of DNA, and is 
composed of 11 exons, the first of which is non-coding and is localised 8-10 kb from 
exons 2-11 (251). There are five highly conserved regions among the amino-acid
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residues, 13-19, 117-142,171-181, 234-258, and 270-286 (252). All point mutations 
affect the sequence specific binding domains of the p53 gene and result in amino acid 
substitutions (251). The spectium of mutations appear to be tissue specific and in 
colorectal cancer, the majority of mutations occur in codons 175, 248, 278 and 282 
(252,253).
Evidence for a role for p53 in malignancy is derived from at least 6 lines of 
experiment;
1) Loss of heterozygosity in the region of the p53 locus can be demonstrated in over 
70 % of all sporadic and familial colorectal cancers , and sequence analysis reveals 
point mutations in nearly 80% of all tumours (177,254-255)
2) Wild type 53 transfected into colorectal cancer cell lines is capable of reverting the 
transformed phenotype (197)
3) Germ-line mutations in the p53 gene aie associated with the rare autosomal 
dominant Li-Fraumeni syndrome, in which affected individuals have an increased risk 
of developing breast cancer, soft tissue sarcomas, brain tumours and leukaemia 
(256,257). However, for reasons not yet cleai", patients with the Li-Fraumeni 
syndrome do not appear to be at increased risk of developing colorectal cancer (258).
4) Total loss of normal p53 function in transgenic mice significantly increases the 
susceptibility of the mice to a broad spectrum of tumours including saicoma and 
lymphoma, although the mice are born normal (259). This contrasts with total loss of 
Rb gene function which has been shown to be essential for normal mouse 
development (207,260).
5) Loss of function due to the formation of stable complexes between wild type p53 
and viral oncoproteins is linked to virus mediated tumourogenesis (261,262).
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6) Loss of function due to the formation of stable complexes between wild type p53 
and specific amplified cellular oncoproteins, such as the MDM2 oncogene product, is 
associated with p53 over-expression, and the development of malignancy (263-265).
Function of the P53 Gene
Although initially thought to be an oncogene, it is now recognised that p53 invariably 
acts in a dominant negative manner, and can perhaps more accurately therefore be 
classified as a tumour suppressor gene (157). The p53 protein normally exists as a 
tetramer or a higher order aggregate, meaning that 4 or more identical copies of the 
p53 protein assemble to form a single functional unit. This molecular architecture 
renders the p53 protein particularly susceptible to mutational inactivation, for 
heterodimer formation may compromise the function of the entire molecule, 
explaining the spectrum of inactivation caused by over a hundred mutations, 
characterised in this gene (252).
Current thinking is that p53 plays a vital role in cell cycle regulation (266), DNA 
transcription (267), genome surveillance (157), and progranmied cell death or 
apoptosis (268). Such pleiotropy may be due to the fact that the p53 protein induces 
the transcription of several different genes containing a specific DNA sequence in the 
upstream regulatory region (269,270). Recently it has been demonstrated that p53 
promotes the expression of a gene called WAFl/Cipl, whose protein product p21 
can bind to cyclin dependent kinase and halt cell division in mid-cycle (271). This 
gives the cell an opportunity to either to correct DNA errors or trigger programmed 
cell death. A point mutation can eliminate this surveillance capability of the p53 gene 
leading to a pool of proliferating cells, increased mutation and neoplasia.
P53 mutations may be caused by ultraviolet light (272,273), radiation (274) or fungal 
toxins (275). The cancer specific spectrum of these mutations makes it possible to 
generate hypothesis regarding the nature of the carcinogen in a series of tumours 
(251).
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The DCC Gene
Chi’omosome 18 is a common site of cytogenetic abnormalities in colorectal cancer 
(276), and non random allelic deletion on chromosome 18q is observed in over 70% 
of large "sporadic" adenomas and carcinomas (277). This suggests that this region 
may be mutated at an intermediate stage of the adenoma-carcinoma sequence. A 
mapping study identified that most allele loss was centred at thel8q21 locus , and a 
contiguous stretch of DNA comprising 370 kilobases was cloned in this region. One 
probe known as p i5-65 pinpointed a homozygous deletion in one of the cancers 
examined, and a large gene, called DCC (Deleted in Colorectal Cancer) was 
subsequently identified (277).
The DCC gene is approximately 1.2 megabases in length, and encodes a transcript of 
12.5 kb . The predicted amino acid of the specified cDNA was highly similar to the 
neural adhesion molecules and related surface glycoproteins, containing 4 
immunoglobulin like domains, multiple repeats of fibronectin type IH domain, and a 
cytoplasmic domain not related to any previously identified gene product (277).
Neural adhesion molecules may be important in the regulation of cell to cell 
interaction, alterations of which have been noted in several studies of neoplasia (278- 
280)
Three lines of evidence suggest that DCC has a tumour suppressor function. Firstly 
this gene is expressed in most tissues, including normal colonic mucosa, but has 
reduced expression in colorectal cancer (277). Secondly, there is a high frequency of 
allele loss in LOH studies (177). Finally, the transfer of chromosome 18 into a 
colorectal cancer cell line has been found to suppress tumour growth on soft agar’, and 
tumour formation in athymic nude mice (196).
There ar e no reports of germ-line mutations in the DCC gene in HNPCC kindreds, but 
the DCC gene is very large and mutations may be difficult to identify (281).
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Mismatch-Repair Genes
In an exhaustive linkage analysis study involving over 350 genetic maikers in two 
lai'ge HNPCC kindreds from USA and New Zealand, it was demonstrated that 
predisposition to early onset colon cancer was unequivocally linked to a marker on 
chromosome 2p (282). This locus was subsequently designated COCAl in the 
Genome Database (283).
Loss of heterozygosity for 2p markers in HNPCC tumours was investigated because a 
tumour suppressor mechanism was presumed to be responsible for increased 
susceptibility to cancer in these families. Surprisingly, LOH was not observed in any 
of the 14 HNPCC tumours studied. Instead, for microsatellite markers, tumour DNA 
exhibited alleles that were not present in noi'mal tissue DNA, suggesting that 
replication errors (RER) had occurred during tumour development (284),
Complex repair mechanisms exist within all cells to correct errors of replication 
during mitosis. One such system. Long patch mismatch repair, has been well 
characterised in bacteria, and the family of proteins that comprise this repair system 
ai'e highly conserved through evolution with homologous systems in the yeast 
Sacchaiomyces Cerevisiae and in humans (285). Studies in yeast and bacteria had 
shown that mutations affecting these systems could lead to microsatellite instability
(286), and this suggested that similai* mutations might be responsible for the 
microsatellite instability observed in a significant percentage of HNPCC tumours.
By exploiting homology to the yeast proteins, the human homologue of MSH2 was 
finally mapped to the COCAl region on chiomosome 2p. Candidate genes within 
this region were identified and sequenced, and a seai'ch was made for germ-line 
mutations in HNPCC kindreds. In one of these genes, hMSH2, mutations were 
identified in a highly conserved region between codons 615-788, which cosegregated 
with colorectal cancer in the HNPCC kindreds, thus proving that hMSH2 was one of 
the HNPCC genes (110).
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It has been shown since that purified hMSH2 protein efficiently and specifically 
binds DNA containing Insertion-Deletion-Loop (IDL) mismatches of up to 14 
nucleotides, suggesting a direct role for hMSH2 in mutation avoidance in human cells
(287).
Replication errors have not only been identified in colorectal cancers derived from 
chromosome 2p linked families (288), but have also been found in endometrial 
tumours from HNPCC patients (289). Furthermore, adenomas from HNPCC families 
often exhibit RER, whereas in sporadic adenomas, RER is rare (290). Thus, the 
presence of RER in colorectal tumours may prove valuable for identifying those 
individuals likely to caiTy a mismatch-repair mutation.
It has been shown also that RER phenotype in colorectal cancers may reflect a more 
general defect resulting in hypermutability of expressed genes. Mutations at the 
hypoxanthine phosphoribosyl transferase ( hprt) gene were studied in RER and non 
RER colorectal cancer cell lines. Increased mutation rates of greater than 100 fold 
were found in RER compaied to non RER cell lines (291).
A second locus that segregates with some cases of HNPCC was mapped using linkage 
analysis to chiomosome 3p21-23, and RER was shown to occur in a tumour from a 
family that was linked to this locus (111). The gene responsible, hMLHl was 
subsequently cloned. It has been shown to cover approximately 58 kilobases of 
genomic DNA and contain 19 exons, and has homology to the bacterial mutL 
homologue (109).
Two other human mismatch-repair genes, PMSl and PMS2 have since been 
identified (108).
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Clinical Application
In large HNPCC kindreds, linkage analysis with chromosome 2p and 3p markers may 
be sufficient to provide adequate data for clinical use. The nature of the disease, 
however, means that such families are relatively rai'e, and a direct search for germ- 
line mutations in affected individuals using mutation analysis will probably be the 
most coimnon method of investigation (110).
It is too early to speculate whether the identification of hMSH2, hMLHl, PMS 1 and 
2 genes will have any implications for population screening, as relatively little is 
presently known about the frequency and penetrance of these genes.
Putative Colorectal Cancer Genes
Chromosome 8p is the third most common site of LOH in colorectal cancer studies 
(177), occurring in about 10% of adenomas (292), 50% of cancers (293) and 90% of 
colorectal cancer cell lines (294). The lower frequency of LOH detected in adenomas 
suggests that putative genes( s) may be involved in progression to a more malignant 
phenotype. Abnormalities on chromosome 8p have also been reported in 
hepatocellulai' and lung cancer (295), prostate cancer (296), bladder cancer (297) and 
glioblastoma (298). In the case of colorectal cancer, at least two tumour suppressor 
loci may be implicated (299).
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Chapter 3 
Strategies for Prevention
" The best single measure of progress against cancer is a change in the age-adjusted 
mortality rate associated with all cancers combined in the total population. According
to this measure, we ar e losing the war against cancer............................A shift in
reseai'ch emphasis, from research on treatment to research on prevention, seems 
necessary if substantial progress against cancer is to be forthcoming" (300)
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Introduction
In 1992, there were approximately 20,000 deaths from colorectal cancer in the United 
Kingdom, and 30,000 new registered cases (301). Scotland has one of the highest 
incidence of colorectal cancer in the world with one in twenty- three men and one in 
thirty-three women expected to develop colorectal cancer during their lifetime (302). 
Within Scotland, colorectal cancer is three times more common in the north than in 
the south of the country (303). Approximately three-quarters of all patients ar e 
beyond hope of a cure at presentation, giving a poor overall five year survival rate 
(304,305).
Primary Prevention
Epidemiological and migration studies suggest that nutritional factors account for the 
vast majority of "sporadic "colorectal cancer cases, although, as discussed previously, 
there may be wide genetic variation on the effects of dietary carcinogens within 
different populations. Puerto-Rican born residents in New York, for example, are 
twice as likely to develop colorectal cancer as those living in Puerto-Rico, and similar 
changes in incidence and mortality have been observed for Hispanic migrants to New 
Mexico and Los Angeles (306).
Pin-pointing the specific carcinogens responsible has proven to be an elusive goal. 
Epidemiological studies of colorectal cancer have well recognised limitations (307), 
and there is some evidence that different carcinogens may be involved at different 
stages of carcinogenesis. An autopsy study in Northern Norway, found no difference 
in the prevalence of adenomas compared to the population of Oslo, yet the incidence 
of colorectal cancer was 70% higher in Oslo (308,309)
In 1971, Denis Burkitt put forward his now famous hypothesis of a fibre depleted 
aetiology for colorectal cancer. This was based on his careful clinical observations of
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the difference of patterns of disease between Western and traditional African 
societies. Burkitt noted the raiity of colorectal cancer in Africa compaied to the 
Western countries and observed that African diets were generally higher in fibre and 
lower in refined carbohydrates than in Western equivalents (310).
Kune et al compared quantitative dietary history in 715 cases and 727 age and sex 
matched community controls, and found that a diet containing a high intake of fibre, 
vitamin C, fish and pork exerted a protective effect, whereas the converse was true 
when a lar'ge amount of beef was eaten (310).
Since these pioneering observations, there have been many other similar fibre related 
epidemiological studies, although many have failed to support Burkitt's attractive 
hypothesis (311,312).
A meta- analysis of 12 methodologically sound and descriptively complete case 
controlled studies demonstrated only a slight protective effect for a high fibre diet 
with an odds ratio of 0.57 (313).
Willett et al reported important information on the 10 year follow up of 98,464 nurses 
who completed a dietary questionnaire in 1980. Of the 88,751 responses, 150 came 
from nurses who had developed colorectal cancer. After adjusting for energy intake, 
the trend for risk for total fat intake ( p< 0.05 ) and animal fat intake ( p< 0.01) was 
significant. Relative risks were highest using a ratio of total intake of red meats to 
total intake of fish, the highest versus the lowest quintile for this ratio gave a relative 
risk of 2.49 (314)
Winawer conducted a time trend case controlled prospective study in which serum 
cholesterol studies were available for up to a 10 year' period prior to a diagnosis of 
colorectal cancer. Although the cholesterol level tended to increase slightly over time 
in the general population, the level of cholesterol in patients destined to develop 
colorectal cancer fell on average by 13%, a difference which reached statistical 
significance at the time of diagnosis (315).
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Eskimo populations whose main source of fat is fish oil ( omega 3 fatty acids) have a 
low incidence of colorectal cancer, and this has been attributed to the anti­
prostaglandin effect of these oils (316).
Attempts to modify experimental carcinogenesis in animals have demonstrated a 
lar ge ar senal of pharmacological agents which can inhibit or block the various steps 
of carcinogenesis (317-322). In humans, several retrospective studies have suggested 
a possible protective effect for aspirin therapy (323,324).
Demonstrating benefit prospectively for a chemopreventive agent is riddled with 
complexity There may be little information regarding appropriate dose and schedule 
of the ehemotherapeutic agent to be studied, and end points other than mortality may 
be difficult to measure and interpret. The value of histological biomarkers as end­
points has been questioned (325).
The greatest barrier to effective primary chemoprevention measures, however, are 
probably both educational and psychological in nature. A recent Scottish Opinion 
Survey, for example, showed that 69% of Scottish men claim to be extremely healthy 
eaters, and would not consider changing their eating habits, yet up to a fifth of men 
and an eighth of women never eat fresh fruit or green vegetables. Even more 
alarming was the finding that a high proportion of Scottish children eat neither green 
vegetables or fruit (326).
Thus, primary prevention is unlikely to be successful until a) specific dietary 
carcinogens have been identified, b) there is a willingness to modify diet at 
population level and c) the general public perceive colorectal cancer as a major health 
problem (327).
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Secondary Prevention
Secondary prevention is the detection of early, usually asymptomatic disease using a 
test which allows eailier treatment and results in improved outcome. The main 
technique used is screening, where an attempt is made to divide the population into 
those who test positive, and therefore likely to have or develop the disease in 
question, and those who aie test negative, and probably do not have the disease. Test- 
positive cases require further investigations to establish whether they actually do have 
the disease, while test negative cases should require no further investigation. The 
ability of any screening test to detect those with the disease is expressed by its 
sensitivity; exclusion of those without the disease is defined as its specificity.
Colorectal cancer fulfils only some of the criteria considered important by the World 
Health Organisation for screening (328). It is undoubtedly a major health problem in 
Western Europe and North America, and technology exists to identify and treat early 
disease with minimum morbidity. It does not meet other criteria, in that presently, 
there are not adequate resources in the community for treating those who give a 
positive test, and the cost effectiveness of colorectal cancer screening has not been 
determined.
Adenoma-Carcinoma Sequence- The Basis for Screening
Colorectal Cancer is an unusual malignancy in that it has a clearly identifiable 
precursor lesion, the adenoma, which has a relatively long premaiignant phase (Fig
3.1). The ease with which this lesion can be detected and removed using fibre-optic 
technology means that colorectal cancer can truly be considered a preventable disease 
(Fig 3.2).
Histo-pathological and epidemiological evidence for an adenoma-carcinoma 
sequence is considerable:
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• The development of CRC in patients with FAP is almost inevitable if colectomy is 
not perfoiined and the risk of caicinoma increases with increasing interval from the 
time of FAP diagnosis (329).
• When the incidence of CRC and adenomas in a population aie plotted against age, 
the curves for adenomas and caicinomas aie very similai', with the peak in incidence 
for adenomas preceding that for caicinoma by 4 years (330).
• Patients with CRC frequently have benign adenomas elsewhere in the bowel at the 
time of diagnosis of the index cancer (331,332).
• At 25 year follow up, metachronous primary cancers aie more common in those 
who had pre-existing adenomas at the time of the index primaiy than those who did 
not (333), and patients with a histoiy of colonoscopic polypectomy have a six-fold 
increased risk of subsequently developing colorectal carcinoma (334).
• Elements of benign adenomatous tissue are found at the periphery of about 14% of 
carcinomas (Fig. 3.3). In a series of 1,961 malignant tumours examined at St Mark’s 
Hospital between 1957 and 1968, there were 278 (14.2%) in which there was 
evidence of contiguous tumour with either a tubular or predominantly villous 
component. In all cases the benign component had identical histological features to 
adenomas which were wholly benign (332).
• Populations with little or no risk of developing carcinoma (for example some ai'eas 
of Japan and the South African Bantu) have a very low incidence of large bowel 
adenomas. In one study involving 14,000 autopsies of South African Bantus, not one 
single adenomatous polyp was identified, and during a 12 year' period at the 
Baiagwanath Hospital (2,000 beds), only 6 adenomas were submitted to the hospital 
laborator'y for pathological examination (335).
• Areas of epithelial dysplasia are only seen in adenomas or in long-standing 
ulcerative colitis (332).
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Post-mortem and colonoscopy studies suggest that 20-30% of asymptomatic persons 
in the fifth decade and 40-60% thereafter develop colorectal adenomas (336-338). 
Cleaiiy the vast majority of adenomas do not turn malignant, but certain pathological 
features such as size (>1 cm.), villous architecture and severe epithelial dysplasia are 
associated with increased risk of malignant conversion (332). Morson established 
that malignant conversion in polyps under 1 cm. in diameter is extremely rai'e, 
occurring in about 1 in 100 polyps; between 1 and 2 cm., the risk increases to about 1 
in 10, and over 2 cm there is over a 50% malignancy rate (332).
Evidence documenting adenoma growth rate is scanty, as polyps diagnosed during 
life are usually removed at colonoscopy. In a retrospective radiological study of 226 
symptomatic patients with untieated laige adenomas ( >1 cm.), a cumulative risk of a 
diagnosis of cancer at the site of the index polyp as 2.5% at five yeai's, 8% at 10 
yeai's, and 24% at 20 years has been calculated (339). Winawer has recently shown 
that an interval of three yeais between colonoscopy examinations in those found to 
have adenomas can be considered safe in the vast majority of cases (340).
Polvpectomy and Colorectal Cancer Reduction
There have been no reported randomised colonoscopy studies demonstrating that 
polypectomy reduces population mortality from colorectal cancer. The ease with 
which polyps can be removed at colonoscopy would make such a study in many 
people's minds unethical. Nonetheless, there is strong circumstantial evidence to 
suggest that this hypothesis is true.
Murakami et al compared relative risks for cancer over a mean period of 6 yeai's in 
patients who had total colonoscopy in Osaka, Japan. With age and sex matched 
standardised population indices: relative risk in 760 patients in whom no polyps were 
found at initial colonoscopy was 1, while the risk in whom polyps were found was 
5.1. The latter group was subdivided into those having a polypectomy ( relative risk 
2.3) and those who had only biopsies ( relative risk 8 ). Although those treated by
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biopsy only had small adenomas, they still had an excessive risk for cancer, with the 
polypectomy group having incomplete but some protection (341).
In a further study, a cohort of 1418 patients who had adenomas removed at 
colonoscopy were followed up for a mean period of 5.9 years, during which the 
patients underwent further colonoscopy. The incidence rate of colorectal cancer was 
compared in this cohort with that in three reference groups; two cohorts in which 
polyps were not removed, and one general population registry after adjustment for 
age and sex. Five asymptomatic and no symptomatic cancers were diagnosed in the 
follow-up cohort. In contrast, number of cancers expected on the basis of the rates in 
the thi'ee reference groups were 48.3, 43.4 and 20.7, for reduction in the incidence of 
colorectal cancer of 90, 88/and 76% respectively (P < 0.001) (340).
Mass Screening
Most attempts at mass population screening for adenomas and curable Dukes A 
caicinomas have depended on faecal occult blood testing ( FOBT), the detection of 
occult blood in the faeces using a guaiac based test that detects the peroxidase like 
activity of haematin (342,343). The advantages of FOBT as a test aie that it is cheap, 
safe and relatively simple to use and interpret. Its main disadvantages aie its low 
sensitivity, low specificity, and poor compliance (344-47).
Mortality is the only truly reliable indicator of a successful cancer screening 
programme, because the stage of the cancer detected and the length of survival are 
affected by:
1) lead time bias, in which screening brings forward the date at which the diagnosis 
of the cancer is made, and this will appear to prolong survival even if the date of 
death is the same and.
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2) length bias, in which screening detects a disproportionate number of slow growing 
tumours, automatically reducing the distribution of stage and increasing survival 
times.
There are presently five on-going prospective randomised clinical trials to determine 
whether mass screening with FOBT will reduce population mortality from colorectal 
cancer (348-352). Collectively, these trials involve over 250,000 subjects. No 
survival benefit has yet been announced from the Nottingham study which is the 
lai’gest of these trials.
Targeted Screening
Using mathematical models to determine the best approach towards decision making 
and screening, Eddy has proposed that detection rate for early asymptomatic disease 
could be improved several fold if the screening programme concentrated on patients 
with known high risk pai*ameters, such as strong family history, a histoiy of adenomas 
or cancer, or long-standing ulcerative colitis (353).
Individuals with inherited susceptibility undoubtedly constitute the largest high risk 
group, and it is now possible to identify some gene carriers using genetic markers, 
making family histoiy even more relevant. The Kings Fund Forum has recommended 
that a comprehensive family history should be taken as par t of the assessment of all 
individuals with colorectal cancer (354).
The experience of the United Kingdom's first clinic specifically established to counsel 
and screen individuals with a strong family history of colorectal cancer will be 
discussed in the next chapter.
'V
Fig 3.1 Benign tubular adenomas
ID.h-0:_ NAME:
/ #
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Fig 3.2 Appearance of adenoma at colonoscopy
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Fig 3.3 A lies to carcinoma side of adenoma/carcinoma junction.
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Chapter 4 
The St Mark’s Family Cancer Clinic
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Introduction
In 1986, a clinic was established at St Mark's Hospital, London, to provide genetic 
counselling and screening for relatives of patients who had a strong family history of 
non-polyposis colorectal cancer (103). Families with familial adenomatous 
polyposis, the Peutz-Jeghers and juvenile polyposis syndromes were followed up at a 
separate clinic in the same hospital. Although, the primary interest of the clinic was 
colorectal cancer, advice and counselling were also provided for persons with a 
strong family history of breast, gastric, ovaiian cancer and melanoma.
Patients and Methods
The St Mark's Family Cancer Clinic was financially supported by the Imperial Cancer 
Research Fund and the National Health Service and individuals could either refer 
themselves directly or be referred by a hospital consultant or general practitioner.
The clinic took place twice a month, and was staffed by a consultant in clinical 
genetics, a genetic nurse counsellor, a clinical research fellow, a secretary and a 
laboratory assistant, who received,processed and stored blood samples for DNA 
extraction. Information about the existence of the clinic was publicised both in the 
national press and in women's magazines. The endoscopic service was provided by 
Dr C.B. Williams, Consultant Gastroenterologist, and surgical expertise was provided 
by Mr J.M. Northover, Consultant Surgeon, St Mai'k's Hospital, London.
At the time the clinic was initiated, there was no universally accepted protocol for 
screening first degree relatives with a strong family history of colorectal and other 
cancers. The observed two to four-fold relative risk of developing cancer in first 
degree relatives of cases was not considered accurate enough for screening purposes, 
and risk estimates were calculated and stratified using pedigree analysis (Table 
4.1)(103).
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At interview, information was obtained about the age, number and relationship of 
relatives affected by colorectal cancer or adenomas. Family history was ascertained 
for at least three generations and verified where possible from death certificates, 
pathology and medical reports. For the pmposes of classification and research, the 
"Amsterdam criteria" were adopted for the diagnosis of the HNPCC syndrome, 
although the limitations of these criteria are well recognised (355).
Using a protocol drawn up by Slack and colleagues(103), individuals with two or 
more first degree relatives (FDRs) with CRC, or one FDR affected under the age of 
45 years, or a family history of more than two generations affected by CRC, were 
offered surveillance by colonoscopy on a five yearly basis from the age of 25 years, 
increasing to 3 yeaify if colorectal adenomas were detected at any stage. In numerical 
terms, this was estimated to represent an increased life-time risk of one in ten or 
greater, a threshold chosen for pragmatic as well as economic considerations. Some 
individuals who were excessively anxious were offered screening by colonoscopy, 
even if they did not fulfil the stated criteria. At total colonoscopy, all polyps detected 
were removed for pathological examination except where surgery was required. In 
this situation, the polyp was biopsied only, and further histology was obtained from 
the surgical specimen. All polyps were reported by Dr Jeremy Jass and Dr Ian 
Talbot, Consultant Pathologists at St Mai'k's Hospital, and classified according to the 
WHO criteria (356). Where colonoscopic surveillance was not offered, screening for 
faecal occult blood was airanged on an annual basis. If the F.O.B.T. test was positive 
on any occasion, or the patients developed symptoms suggestive of large bowel 
neoplasia, they were referred for urgent colonoscopy. Any patient who gave a 
history of rectal bleeding, altered bowel habit or other symptoms suggestive of lai'ge 
bowel neoplasia was referred for further investigation and treatment. On average 8- 
10 individuals were counselled during each clinic session, and each interview lasted 
30-40 minutes.
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Statistical Analysis
A multivaiiate analysis was performed to assess the association between family 
history variables and the frequency of adenomas or cancer detected at colonoscopy 
using a forward stepwise logistic regression (BMDP-LR computing Facility, UCLA) 
(357). A significance level of p< 0.05 was used for the inclusion of a variable in the 
model. In the multivaiiate analysis the family history variables were coded as shown 
in Table 4.2. Age was entered either as a continuous or categorical variable (with 
categories 25-34, 35-44, 45-54,>55). Statistical Analysis was performed by Drs 
Wendy Atkin, and Pierro Gaglia, ICRF.
Opthalmological Examination.
Patients who had developed colorectal cancer under the age of 40 year's or who had 
been found to have multiple adenomas at colonoscopy were referred for 
opthalmological evaluation to Professor Barry Jay, Moorfields Hospital, London, to 
determine whether retinal pigmentation diagnostic of CHRPE was present.
Skin Examination
Patients suspected of having the Muir-Torre, Cowden's , the Dysplastic naevus 
Syndromes or any skin lesion with features of malignant melanoma were referred to 
Dr Julia Newton, Consultant Dermatologist, Royal London Hospital, for further 
opinion .
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Results
Between August 1986 and March 1993, 1283 persons attended the St Mark's Family 
Cancer Clinic. Twenty-seven per cent of referrals came from general practitioners, 
27% were self referrals, 25% were from members of families previously ascertained, 
19% were from hospital consultants and 2% were from other registries.
636 individuals from 436 families fulfilled the stated criteria for colonoscopy. Seven 
declined the offer of colonoscopy (compliance rate = 99%), so 629 individuals were 
available for study. The family history characteristics are summarised in Table 4.2.
In addition, 3 families with FAP were identified, one family with possible attenuated 
FAP, one with the Muir-Torre syndrome and one with possible Cowden's syndrome.
The age at colonoscopy varied from 25 years to 77 years (median = 41 years). Two 
hundred and sixty five (41.1% ) subjects were male; the percentage of males was 
similar in each group category (range 39.5% - 42.8%)
Repeat colonoscopies were performed in forty-two cases, six after a 5 year interval 
(initial screen normal), and the others after a 3 year’ interval.
Incidence of Adenomas Diagnosed
One or more adenomas were found in 144 (22.9%) subjects and of these, 21 had 
synchronous metaplastic polyps. Twenty- nine (4.6%) patients had metaplastic 
polyps only. Of subjects with adenomas, 91% had a single adenoma and 7 (4.9%) 
had five or more adenomas ( range 6-300). Such multiple adenomas were more 
frequent in patients with "Amsterdam criteria" families than from other families 
(11.8% and 2.7% respectively; p=0.03) (Table 4.3).
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Distribution of Adenomas in the Lai’ge Bowel
Forty-six of the subjects with adenomas (31.9%) had lesions proximal to the splenic 
flexure only. There was a significant difference in the proportion of right sided 
adenomas between patients from the families with "Amsterdam criteria" and from 
other families (47.1% and 27.3% respectively; p=0.03), whereas no significant 
difference was found between males and females (30.4% and 33.8% respectively) 
(Table 4.3)
One 50 year old woman with a pedigree consistent with HNPCC was found on 
colonoscopy to have about 300 adenomas. There were no adenomas present in the 
rectum and she did not have the retinal pigmentation chaiacteristic of FAP. Her 
affected relatives had less than 10 adenomas present on examination of the colon.
Size and Histologv of Adenomas Detected
Fifty nine (41.0%) of subjects with adenomas had only a single diminutive adenoma 
(< 5 mm.) ( 32.9% males and 50.8% females, p=0.03). Thirty nine (27.1%) of 
adenoma patients had an adenoma which was large ( > 10 mm..), tubulovillous, 
villous , moderately severely dysplastic or malignant. The frequency of these 
unfavourable pathological features was higher in men than in women ( 31.6% and 
21.5% respectively) and in the "Amsterdam criteria" versus other families ( 35.4% vs. 
24.5%), but the numbers were too small too reach statistical significance (Table 4.3).
Age and Sex Distribution of Adenomas Diagnosed
The prevalence of adenomas increased with age, being less than 10% under the age of 
35 years and rising to over 40% from 55 yeai’s, with an increasing odds ratio( OR) of 
approximately two fold for each decade ( p<0.0001). The prevalence of adenomas 
was about two-fold greater in males than in females (OR=2.05, p=0.0002) (Table 4.4)
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Cancers Detected
Seven cancers ( six Dukes' stage A and one Dukes' C) were diagnosed. Five of the 
cancers appeared to ai'ise within adenomas and two developed in the presence of 
synchronous adenomas). The median age at diagnosis was 49 years ( range 34-63 
years); three patients were male. Four of the patients belonged to an "Amsterdam 
criteria family", three did not. All cancers,but one ( in a 63 year old woman), 
occurred proximal to the splenic flexure, and none of these cases were associated with 
the presence of distal adenomas (Table 4.5.).
Familv Vaiiables Associated with Increased Risk of Adenomas
Eight family history vaiiables were chosen and the age and sex adjusted odds ratio of 
having adenomas or cancer for each was examined (Table 4.6) After adjustment for 
age and sex, the most significant indicators of the risk of having adenomas was:
• The number of generations in the whole family affected by either CRC or adenomas 
(OR for >2 generations = 2.16, p=0.0006).
• The pedigree type ( "Amsterdam criteria" families versus other families = 1.76,
p=0.02).
Screening individuals with > 2 generations affected by colorectal cancer (390 
individuals, 60.6% of the screened population; adenoma prevalence = 24.9%), 
identified 97/144 of all adenomas (67.4%) and 5/7 eancers.
Screening individuals with a history of >2 generations affected by CRC or adenomas 
(431 individuals, 66.9% of those screened; adenoma prevalence = 30.0%) identified 
112/144 ( 77.8%) of adenomas and all seven cancers ( Table 4.7).
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Multivariate Analysis
The results of the forward stepwise logistic regression multivariate analysis are shown 
in table 4.8. Age, sex and all eight family history vaiiables were considered.
The vaiiables selected by the procedure to enter the model were (in order of entry): 
age ( p = 0.0001), sex (p=0.0002), and the number of generations in the family 
affected by either CRC or adenomas (p = 0.0006) (Table 4.8). For a given age group, 
the presence of one "unfavourable" condition, either male sex or > 2 generations 
affected by CRC or adenomas, about doubled the risk of finding adenomas, whereas 
the presence of both variables raised the OR to a value of 4.6 [ OR = exp.(0.76 + 
0.77)] (Table 4.9) .
Faecal Occult Blood Testing
Of 310 F.O.B.T. tests performed ( compliance 32%), 5 were abnormal. When these 
patients were further investigated by colonoscopy, one patient was found to have a 
normal colon, one had an adenoma plus infective colitis, one had inflammatory bowel 
disease without polyps, one had a tubulai' adenoma in the ascending colon, one had 
multiple adenomas plus a Dukes A caicinoma in the ascending colon.
Between 1986-93,40 patients who fulfilled the screening criteria for colonoscopy, 
requested F.O.B. testing while awaiting colonoscopy. Two tests were positive due to 
ulcerative colitis. 10 of 38 patients with negative F.O.B.T. tests had adenomas, one 
of which contained a focus of carcinoma in situ.
Dermatological Findings
One patient, who developed caicinoma aged 42 yeais and who belonged to family 
with a strong history of colorectal cancer, was found to have a sebaceous adenoma, 
and by definition had the Muir-Torre syndrome (Fig. 4.1)
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Twelve patients were found to have solitary dysplastic naevi, and five patients were 
diagnosed with dysplastic naevus syndrome. A 53 year old woman was found to have 
a superficial spreading melanoma of the lower leg.
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Variable Category Coefficient OR (95% c n
Age 25-34* 1
35-44 0:94 2.56 (1.36,4.81)
45-54 1.52 4.59 (2.44,8.36)
>55 2.28 9.76 94.96,19.22)
trend 55.46
(p~value) (<  0,0001)
Sex Female* 1
Male 0.76 2.14 (1.44,3.19)
14.20
(P-value) (0.0002)
No.of 1* 1
Generations
affected by 
CRCor
Adenomas
>2 0.77 2.16 (1.37,3.43)
X^ 11.66
(p-value) (0.0006)
Table 4.8 Multivariate Analysis ( Stepwise Logistic Regression )
Reference category, OR = Odds Ratio, Cl = Confidence interval.
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Discussion
It has been estimated that one in four individuals in the western world, will develop 
cancer at some stage in their lifetime (358). The majority of the population will have 
at least one relative affected by cancer at some stage, and by chance, some individuals 
will have many. In one survey in the USA, 6% of patients with cancer and 1.5% 
without, said that they had 3 or more relatives who had cancer (359). In a second 
survey, involving 200 consecutive patients attending an adult oncology clinic, 50% 
reported having at least one first degree relative with cancer (360). Dunlop has 
estimated that as many as a third of the population over the age of 40 yeai's may have 
a single first degree relative with cancer of the breast, uterus or colon (361). Cancer 
is therefore an extremely common disease process, and clearly counselling all 
individuals with a family history of cancer would be a foimidable undertaking. 
Furthermore, not everyone with inherited susceptibility will go on to develop cancer, 
and not every form of cancer will be due to inheritance. The prinicipal object of the 
clinic therefore, was to try and identify those individuals at most genetic risk.
It was the policy at the St Mai'k's Family Cancer Clinic to offer colonoscopy to those 
individuals with a family history consistent with a 1 in 10 chance or greater of 
developing colorectal cancer. In practice, the screening criteria were slightly more 
elastic as some extremely anxious individuals would only be reassured by a normal 
finding at colonoscopy.
Eveiy effort was made to verify the cause of death in relatives by pathology and 
medical reports where possible. It has been noted elsewhere however, that most 
people recall the fates of first degree relatives with great accuracy (134).
The overall prevalence of adenomas in the present series was 22.4% ( median age 41 
years), and this compaied with a rate of between 12-27% in other colonoscopy series 
where the individuals had at least one relative with colorectal cancer (124,125,135- 
138,362). In individuals who do not have a family history, adenomas are also
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common after 50 years ( 337), but are relatively rai'e before this (125). Thus, those 
with a positive family history of colorectal cancer or adenomas appear to develop 
adenomas one decade earlier. With the exception of the youngest age band studied 
(25-34 yrs), the prevalence of adenomas in males was the same as that observed in 
females one decade later. The higher prevalence with increasing age and male sex 
was consistent with data from other studies involving persons with and without a 
family history. There was no sex difference in the size or morphology of adenomas 
identified. It can be seen from Table 4.3 that adenomas were more common, more 
often multiple and right-sided in patients belonging to families fulfilling the 
"Amsterdam" criteria for HNPCC, a characteristic feature of HNPCC. For reasons 
presently not understood, hyperplastic polyps were more common in those individuals 
who did not have a family history conforming to HNPCC, although there is general 
agreement that these lesions are not premalignant (332). Previous studies have shown 
that although hyperplastic polyps may increase in prevalence up to the 5th decade, 
they tend to be constant in frequency thereafter (336,338).
The limitations of the "Amsterdam" criteria aie well recognised; extra-colonic 
malignancies are not taken into account and many small HNPCC families are not 
identified. In this study, if the "Amsterdam criteria" had been adopted for screening 
by colonoscopy, only 23.6% of adenomas and 4 of 7 cancers would have been 
detected. In an effort to refine the screening criteria, the St Mark's pedigrees were 
studied for more accurate predictive factors which might increase the adenoma and 
cancer detection rate. The only pedigree vaiiable investigated previously has been the 
number of relatives ( either FDRs only or FDRs and SDRs) with colorectal cancer
(125,362) or colorectal cancer and adenomas (123). In all these studies, an increased 
risk of about two-fold was observed in subjects with > 2 versus 1 affected relatives. 
The predictive power of the number of generations has not previously been addressed. 
At the St Mark's Family Cancer Clinic, the most powerful pedigree predictor of 
adenoma prevalence identified was the number of generations (>2 vs. 1) affected by 
either CRC or adenomas, irrespective of i) the total number of relatives or FDRs
106
affected ii) early age of onset (<50 yrs) of cancer in the relative or ill) the presence of 
the "Amsterdam " criteria for HNPCC ( Table 4.6). However, people with >2 
generations affected by CRC or adenomas had more relatives with CRC than those 
with one affected generation only ( mean number of FDRs and/or SDRs 3.1 and 1.6, 
respectively, P<0.001), and a greater number of FDRs affected by CRC or adenomas 
(40.2% with > 1 FDRs in > 2 generation families vs. 23.8% with > 1 FDRs in one 
generation families, P = 0.001), indicating that the "generation" variable was not 
independent of the number of affected relatives and their relationship.
It can be concluded from data in this series that if colonoscopy had been offered to all 
individuals with > 2 generations affected by CRC or adenomas, 70% of the 
colonoscopies would have been performed detecting 80% of the total number of 
adenomas and all 7 cancers (Table 4.7).
The fact that only one of the cancers had developed beyond Dukes stage A, suggests 
that screening in these cases, had probably improved the prognosis for these patients. 
With the exception of one cancer ( in a 63 year old woman ), all the cancers were 
proximal in distribution, and none was associated with distal adenomas. Therefore,it 
can be concluded th a t, for those at genetic risk of colorectal cancer, screening by 
total colonoscopy is more sensible than screening by flexible sigmoidoscopy
(112,363).
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Psychological Aspects
The general public's perception of the role of genetic factors in the aetiology of cancer 
may be underestimated. Linn et al studied 120 patients with advanced cancer ( mixed 
site), and compai'ed them with non cancer patients matched for age, sex and 
hospitalisation. Beliefs about the cause of cancer were measured at interview with a 
10 item scale covering smoking, drinking alcohol, diet, inheritance, type of 
occupation, stress, medicine, water, environment, God's will, and 'other'.
Interestingly, for the cancer patients, "God's will" and inheritance were listed among 
the top four "causes"(364). Taylor conducted a similar study among 79 women with 
breast cancer, and found that 26% believed they had inherited their disease (365). 
Even a distant family history of cancer may cause relatives lifelong, if unexpressed, 
anxiety about their own health and that of their children.
The majority of persons attending a family cancer clinic seek the answers to three 
main questions:
• Am I at increased risk of developing cancer relative to the person who does not have 
a family histoiy?
• If so, what positive action can I take to reduce that risk?
• Are my children also at increased risk?
The arrival of specific genetic mai'kers for colorectal cancer should answer all these 
questions for some people. For the remainder, estimation of risk will still laigely 
depend on the taking of an accurate extended pedigree, and a certain amount of 
educated guesswork. Most of the persons attending the St Maik's Family Cancer 
Clinic, the "worried well", appeared to welcome the opportunity to discuss their 
concerns, and felt positive that they were taking action to reduce a perceived risk. A 
compliance rate for colonoscopy of 99% would support this impression.
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Conclusions
• Targeted screening, using family history as a risk factor, has the potential to reduce 
the mortality and morbidity of colorectal cancer. A total of 644 colonoscopic 
examinations were required to diagnose 39 potentially "dangerous adenomas" and 7 
cancers. It is difficult to estimate, how many dangerous adenomas or eaiiy cancers 
would have been detected by randomly screening an equivalent number of adults in 
the general population, but all studies to date support the premise that adenomas are 
more common in persons with a strong family history. Furthermore, only 42/644 
individuals had a second colonoscopy, and it seems probable that the adenoma 
detection rate would increase on repeat screening.
• Including the "number of affected generations" variable in the screening criteria 
appears to increase the detection rate of potentially dangerous adenomas and early 
cancers, although this observation needs to be validated in other studies. It is likely 
that the screening criteria will be further refined with the discovery and wider 
availability of specific genetic markers, increasing the effectiveness of targeted 
screening.
• The psychology of inherited susceptibility to cancer is poorly understood, and 
requires further study. Qualitative factors such as relief of anxiety, reassurance and 
improved well being are notoriously difficult to quantify, but initial impressions 
suggest that family cancer clinics help relieve anxiety and are of psychological 
benefit.
• Public demand for cancer genetic services may be greater than expected. The 
establishment of family cancer clinics nation-wide should be carefully monitored, 
until the effectiveness of such clinics has been fully demonstrated, and major cost- 
benefit issues addressed. Existing clinics require long term funding, to support those 
individuals who have been informed that they are at a significantly increased risk of 
developing colorectal cancer. Self-referral should be permitted in certain
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circumstances, but can be a recipe for an exponentially increasing endoscopy 
workload. For this reason, the advertising of family cancer clinics should be cautious 
and responsible.
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Chapter 5
The Hereditary Mixed Polyposis Syndrome- a New Disorder?
It is an old experience that through her errors, nature often reveals secrets which 
would otherwise remain a closed domain" (366)
I l l
Introduction
The hereditai'y disorders, Familial Adenomatous Polyposis (FAP), Generalised 
Juvenile Polyposis (JP) and the Peutz-Jeghers Syndrome (PJS) seldom present little 
diagnostic difficulty as the polyps that characterise these syndromes are readily 
distinguishable on histological examination. Furthermore, both FAP and PJS have a 
recognisable phenotype. In the case of FAP, the patient usually has congenital 
hypertrophy of the retinal pigment epithelium (CHRPE) and multiple adenomas in the 
rectum, and in the case of the Peutz-Jeghers syndrome the patient usually has a 
histoiy of mucocutaneous pigmentation in and around the mouth or on the fingers. 
Problems with classification can occur however, particularly when an individual has 
polyps of different histology and/or polyps with overlapping histological features. In 
most cases of these "mixed polyposis syndromes", there appeal's to be no hereditary 
component, and it remains to be determined whether these patients have an atypical 
form of a recognised polyposis syndrome, or a distinct clinical disorder. A literature 
search reveals, only two case reports describing a mixed polyposis syndrome with a 
possible familial basis, in which both a parent and child developed either "mixed" 
polyps or colorectal cancer. Gene localisation in these families using the technique of 
linkage analysis would prove extremely difficult on account of their small size (367).
This chapter will describe the clinical, pathological and genetic features of a large 
kindred, St Mai'k's Family 96, who appear to have a dominantly inherited 
predisposition to an atypical polyposis syndrome and early onset colorectal cancer. 
The natural histoiy of this disorder is being documented, and attempts are being made 
to localise the responsible gene, using linkage analysis. For the time being, this 
syndrome will be referred to as the Hereditary Mixed Polyposis Syndrome 
(H.M.P.S.).
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The Proband
A 28 year old man presented in 1956 to St Mark's Hospital, London, with a 6 month 
history of bright rectal bleeding and lower abdominal colic. Abdominal examination 
was unremarkable, but sigmoidoscopy revealed multiple "adenomatous looking" 
polyps in his rectum. A provisional diagnosis of familial polyposis coli (FAP) was 
made, on the grounds that several of the patient's close relatives had died at a 
relatively early age from colorectal cancer. The extra-colonic features commonly 
associated with FAP - such as sebaceous cysts and osteomas - were absent, and 
physical examination was otherwise unremarkable. A subtotal colectomy with 
ileorectal anastomosis was performed and the patient was kept under regular medical 
surveillance. The resected surgical specimen is shown in Figure 5.1. In contrast to 
FAP where the entire colon is usually carpeted with hundreds if not thousands of 
adenomas, only 6 polyps were identified in this specimen, 5 tubular adenomas and 1 
juvenile-type polyp with overlapping histological features (Figs 5.2 and 5.3).
Microadenomas, pathognomonic of FAP were absent. This patient has been followed 
up on an annual basis from 1956-93. He remains asymptomatic, but every so often 
develops further polyps in the rectum which require fulguration by diathermy.
Subjects and Methods
Other members of this kindred were ascertained by communication with the proband, 
and confirmation of disease status was obtained from pathology, medical and 
colonoscopy reports, operation notes, and death certificates. The number, site and 
histology of any polyps were carefully documented, as was the diagnosis of 
malignancy. Where possible, the polyps were classified by three specialist 
pathologists ( Dr Ian Talbot, St Mark's Hospital, Professor Jeremy Jass, University of 
Aukland and Professor Stanley Hamilton, Johns Hopkins University, Baltimore) 
according to WHO criteria (356). Affected individuals were examined for skin 
pigmentation, skin cysts, lipomas, osteomas and CHRPE, all features commonly 
associated with other polyposis syndromes .
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Results
St Mark's Family 96 has been followed up nearly 40 yeai's, and over this period, the 
pedigree has been extended and updated (Fig. 5.4). It consists of 10 second 
generation, 35 third generation, 63 fourth generation and 42 fifth generation 
individuals. All surviving members aie derived from the third, fourth and fifth 
generations, and updated clinical information has been obtained on 71 patients over 
the age of 21 years. The family originated in Lithuania and can be traced back to a 
maiiiage in 1897. They are now spread worldwide, living in the USA, the United 
Kingdom, Australia, Hong Kong, Netherlands, South Africa, Israel and Hawaii.
Some members of the family died in the concentiation camps between 1941-42, and 
possible survivors of this branch of the family are untraceable. Thirty three members 
(13 females, 19 males ) are known to have developed either colorectal cancer or 
colonic polyps. In common with other more cleaiiy defined polyposis syndromes, the 
Hereditary Mixed Polyposis Syndrome appeal's to be inherited in an autosomal 
dominant manner.
Patients presented at a median age of 40 yrs (range 23-65 yrs) with bright rectal 
bleeding, abdominal colic, altered bowel habit, anaemia or intestinal obstruction. 161 
polyps have been examined and classified according to the WHO criteria of Morson 
and Sobin (2). The polyps, usually numbering fewer than 10 at initial examination, 
are disti'ibuted throughout the entire large bowel, as are the colorectal cancers. Polyp 
number and histology vary between patients, but essentially there are 6 types (Table 
5.2):
1) tubular adenomas (Fig. 5.4)
2) villous adenomas
3) hyperplastic polyps
4) atypical juvenile polyps with mixed histological features (Figs 5.6, 5.7,5.8 )
5) peutz-jeghers polyps and ( Fig 5.9,5.10)
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6) the flat adenoma ( Fig.5.11)
One patient had multiple tubular adenomas < 1 cm. scattered throughout the colon, 
which were considered too numerous to count.
Six patients had "mixed" polyps in addition to other polyps, and one patient had 
"mixed" polyps only.
Eleven individuals with multiple polyps have undergone total colectomy and 
ileorectal anastomosis, and the remaining individuals with polyps are presently being 
screened and treated by colonoscopic polypectomy. Several unaffected members of 
the pedigree also undergo régulai* colonoscopies. Thirteen individuals have developed 
colorectal cancer (median age at diagnosis 47 yrs, range 32-74 yeais) and the first 
recorded case was in a woman in her 40s in 1913 (Table 5.1).
There have been two cases of breast cancer in women over the age of 70 yeai’s (113, 
118), but neither was found to have polyps at colonoscopy. One woman (III), a non- 
smoker, developed bronchial cai'cinoma aged 57 years. It is not known whether this 
individual had colorectal polyps, but it seems likely that she was a gene carrier as 4 of 
her children developed multiple polyps and/or colorectal cancer. The possibility 
remains that her bronchial caicinoma was a actually a metastasis from a colorectal 
primary cancer.
There has been no family history of CHRPE, desmoid disease, osteomata or bone 
cysts. One patient had an epidermoid cyst removed from his face, and another was 
known to have a lipoma overlying his left scapula. These skin lesions are associated 
with FAP, but sporadic cases are frequent. The characteristic mucocutaneous 
pigmentation of PJS was absent from the family.
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Fig. 5.2 Low power view of atypical mixed polyp (B)
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Fig. 5.3 A higher power appearance of atyical mixed polyp (X 7) A= 
hyperplastic area, B = juvenile area, C = adenomatous area.
0  €
1— 0
— O
1—0
L -O  —H
—O
 □
— □
o\
co
%I
vi
g '
119
1
Fig. 5.5 Tubular adenoma (X 4)
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Fig 5.6 Polyp with irregularly shaped and focally dilated glands arising from
mucosal surface (M),(X 40). Note, the hyperplastic area with 
characteristic papillary infolding (epithelial serration) adjacent to 
narrow tubular gland {long arrow) and juvenile area with abundant 
lamina propria and retention cystic space {short arrow.)
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Fig. 5.7 A mixed polyp showing glandular crowding with mild epithelial 
dysplasia centrally. Superficially, there is focal gland dilatation 
(short arrow), and irregularly shaped glands (long arrow) (X 44).
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Fig. 5.8 A mixed polyp showing severe epithelial dysplasia. The glands on
the left exhibit nuclear enlargement, stratification and pleomorphism. 
Mitotic figures are readily identified (X 351)
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Fig. 5.9 Part of a Peutz-Jeghers polyp showing typical branch like pattern (X 
10).
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Fig 5.10 High power o f  a Peutz-Jeghers polyp showing typical smooth 
muscle bundles (X 200)
Fig 5.11 A flat adenoma found in the Hereditary Mixed Polyposis 
syndrome ( x 5 )
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Patient Location of Colorectal Cancers Source Age/Sex
12 Ca Colon ( Colostomy) FH 40s/F
E2 Ca Colon ( Colostomy) FH 47/M
115 Ca Sigmoid MR 65/F
IIIO Ca Rectum FH 45/M
n i2 Ca Caecum PR 47/M
III 4 Ca Caecum MR 60/F
III 6 Ca Splenic Flexure MR 74/F
n i7 Ca Transverse Colon PR 49/F
mi6 Ca Sigmoid Colon MR 41/M
mi7 Ca Rectum MR 32/M
III30 Ca Caecum PR 40/M
ni33 Ca Transverse Colon PR 58/M
III35 Ca Caecum PR 51/M
Table 5.1 Colorectal Cancer Site/Chaiacter in St Mark's Family 96
FH = Family History, MR = Medical Report, PR = Pathology Report
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Histology of polyp No. identified/no. patients
Tubular- adenomas 101/20
Villous adenomas 7/4
Hyperplastic Polyps 25/7
Juvenile type polyps with Mixed Features 25/7
Flat adenoma 1
Peutz-Jeghers polyps 2/1
Total 161/23
Table 5.2 Histology of polyps removed from affected members of St Mark's 
Family 96
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Discussion
The recognition of polyposis syndromes is usually sti’aightforwai'd. The three most 
common disorders, familial adenomatous polyposis (TAP), Peutz-Jeghers' 
syndrome(PJS) and juvenile polyposis (JP), have been relatively well defined 
clinically, and the polyps associated with each have characteristic histological 
features. Furthermore, in the case of FAP, presymptomatic diagnosis is now possible 
using genetic markers (237-241).
Occasionally, however, the diagnosis of a polyposis syndrome is less clear-cut, when 
an individual has a mixed pattern of disease, presenting with polyps of different 
histology and/or polyps with "overlapping" histological features. It is unknown 
whether such "mixed" polyposes ar e variants of FAP, PJS or JP, or are truly distinct 
diseases. Adenomatous polyposis, for example, has been described in association with 
PJS polyps (368,369) and JP polyps (370-377), and there have been isolated case 
reports describing patients with all three types of polyp (378) as well as adenomas 
and metaplastic polyps (367,379,380). Furthermore, hyperplastic and adenomatous 
elements have been found within the same polyp (381-383), and exceptionally, 
juvenile polyps have been described which contain dysplastic epithelium (384-387), 
hyperplastic epithelium (388), areas of adenomatous proliferation (371,375,386-388) 
and even adenocarcinoma(75,387,388). Until the underlying germ-line and somatic 
mutations in these patients ar e characterised, it is impossible to determine whether 
mixed polyposis is a separate disease from the other polyposis syndromes.
There are four possible genetic explanations for mixed polyposis. First, an individual 
may have inherited mutations predisposing to more than one type of polyposis: this 
appears unlikely, but mixed polyposis is very rare and there may exist relatively 
common, undiscovered genes predisposing to colorectal polyps. Second, an 
individual may have inherited a mutation predisposing to one type of polyposis (most 
likely JP or PJS) and have acquired another type of polyp by somatic mutation.
(Presumably, it is also possible to acquire more than one type of polyp by somatic
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mutation alone). Third, all mixed polyposis lesions may progress at different rates 
through the same sequence (for example, hyperplastic -> juvenile > Peutz-Jeghers' -> 
adenomatous -> adenoma -> carcinoma): the appearance seen at colonoscopy reflects 
the different stages of progression that polyps have reached. Here, a germ-line 
mutation must be assumed to predipose to the earliest lesion in the pathway. Fourth, a 
germ-line mutation may predispose to polyp formation in general: the subsequent 
somatic mutations determine a polyp's histological type. Possibilities three and four 
are both consistent with those cases in which a single polyp has "mixed" histology.
Family SM96 is inconsistent with the first and second of the above possibilities . The 
pattern of disease segregation does not fit well with the existence, for example, of 
both an APC mutation and a Peutz-Jeghers' mutation in the family. Alternatively, it 
would be necessary to invoke an unrealistically large number of somatic mutations if, 
for example, these had caused the adenomatous polyps seen in the family.
Possibilities three and four are, however, plausible and fit well with the apparently 
Mendelian inheritance of HMPS.
The clinical features of HMPS suggests that it is unrelated to the hereditary non­
polyposis colorectal cancer (HNPCC) syndromes. The number of colorectal polyps is 
not known to be increased in HNPCC and there are no reports of JP polyps in 
HNPCC. HMPS is also clinically dissimilar to FAP: family SM96 has fewer polyps, 
non-adenomatous polyps and little evidence of extra-colonic disease as compared 
with FAP.
The chai’acteristic lesion of family SM96 is the juvenile polyp with mixed features, 
similar to those previously described in an "atypical" juvenile polyposis syndrome 
(372). HMPS may be a variant of JP, but differences exist between the two diseases. 
Firstly, the majority of polyps removed from members of SM96 have been tubular or 
villous adenomas (73%) with no features to suggest that they have arisen within pre­
existing juvenile polyps. Indeed, some members have been found to have tubular-
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adenomas only. This contrasts with juvenile polyposis syndromes, where in a large 
histological review of 1032 polyps removed from such patients, only 21 (2%) were 
adenomas with no residual juvenile features (79). Secondly, patients with juvenile 
polyposis typically have between 50 and 200 polyps (78), although some juvenile 
polyposis patients do have fewer polyps of numbers similar' to those found in some 
members of Family 96. Thirdly, the juvenile polyposis syndromes and HMPS differ 
at the age at presentation and developruent of colorectal cancer. Patients with 
generalised juvenile polyposis tend to present in the second decade and develop 
colorectal cancer in the third decade (78). In one series involving 87 patients with 
JP, 18 developed colorectal cancer at a mean age of 34 years (78). Affected 
members of family 96, on the other hand, tend to present in the fourth decade (mean 
age 40.8 years), and develop cancer much later (mean age 48.3 years).
Variable gene expression is a common feature of many autosomal dominant 
disorders, including the polyposis syndromes. In FAP, for example, some affected 
individuals develop life threatening desmoid disease or duodenal cancer, whereas 
others affected within the same family remain complication-free. The gene 
responsible for HMPS may play an important role in controlling the differentiation of 
the colorectal epithelium, and if so, this gene may be subject to modifying influences. 
Alternatively, the induction and cellular transformation of the polyps in family 96, 
may be under the control of mesenchymal elements (389,390). It remains possible, 
therefore, that mutations in the HMPS gene aie also responsible for other polyposis 
syndromes, although the clinical features of family SM96 suggest that HMPS may be 
a distinct disease.
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The Clinical Management of St Maik's Family 96
Members of Family 96 need to be kept under close medical surveillance, and central 
registration plays a vital role in keeping track of at-risk individuals. The age at which 
colonoscopy should be commenced and the frequency with which it should be 
performed have not yet been established, but some guidelines aie emerging. The 
eaiiiest age at which polyps have been diagnosed in an affected individual is 18 years, 
and this would appeal’ a reasonable age therefore to commence screening. Although 
thiee-yeai’ly colonoscopic surveillance is considered adequate for most members of 
the general population who develop "sporadic" colorectal adenomas (340), one 
individual developed 12 tubular colonic adenomas in a 2 year screening interval. For 
this reason biennial colonoscopy would seem most appropriate until further data on 
the rate of polyp growth in this family is available. A more limited examination of 
the bowel using the 60 cm fibre-optic sigmoidoscope would not be acceptable, as 
half the cancers diagnosed in Family 96 were proximal to the mid transverse colon.
The family described here raises several questions about the classification of 
polyposes, which can only be clai'ified by moleculai' genetic studies. Although the 
HMPS syndrome is likely to be extremely raie, identifying the gene responsible is 
important for the following reasons.
1) Predictive DNA testing would be possible for at risk presymptomatic individuals ; 
those not carrying the gene could avoid unnecessaiy colonoscopic surveillance, and 
be reassured that they had not passed the gene on to their children.
2) Geim-line mutations of the HMPS gene may be responsible for other polyposis 
syndromes, or may contribute to an increased risk of colorectal tumours in the general 
population.
3) Genes that are mutated in the germ-line in hereditary cancer syndromes aie often 
mutated in the sporadic form of the disease. As colorectal cancer is believed to result 
from the stepwise accumulation of rate-limiting genetic mutations, the identification
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of these mutations will be essential for determining the cause of colorectal cancer and 
for planning rational therapy for established disease.
As Garrod stated in 1924," Nature is nowhere accustomed more openly to display her 
secret mysteries than in cases where she shows traces of her workings apai't from the 
beaten path; nor is there any better way to advance the proper practice of medicine 
than to give our minds to the discoveiy of the usual law of Nature, by caieful 
investigations of cases of raier forms of disease " (391).
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Chapter 6
The Search for Colorectal Cancer Genes
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Introduction
Until relatively recently, the isolation and identification of the genes responsible for 
inherited disorders, has been possible only in those raie diseases in which the 
biochemical fault has already been established. In this situation, a knowledge of the 
amino acid structure of the faulty protein permits cloning of the cDNA sequence and 
later, the gene itself. Recent advances in moleculai' biology, however, render it 
possible to isolate genetic mutations without any prior knowledge of the moleculai' 
defect responsible. The overall approach involves mapping of the responsible gene to 
its chromosomal location by linkage analysis, followed by isolation of the gene and 
characterisation of the mutations using a combination of finer resolution techniques. 
Formerly referred to as "reverse genetics", this process is now more accurately 
termed positional cloning (Fig. 6.1). Several steps are involved. Initially, data have 
to be collected on families which have been affected by the disorder under study, over 
two or three generations. An accurate diagnosis of the disorder then has to be made 
using consistent and objective criteria to separate normal from affected individuals. 
Following this, pedigrees are constructed and DNA from family members is analysed 
for linkage to a large panel of informative genetic markers which may span the 
genome. Once linkage has been established, flanking markers aie then developed 
around the disease locus, so that the area of interest can be narrowed, and the region 
of DNA containing the diseased gene, isolated and cloned. The gene of interest can 
then be sequenced and a search can be made for mutations in affected family 
members. Diagnostic tests can then be developed for each family, and a search made 
for drugs or proteins which may minimise or totally correct the adverse effects of the 
faulty protein (392).
Principles
The technique of linkage analysis relies on the principle that genetic mai'kers situated 
close to a disease locus will have an increased chance of being consistently co-
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inherited with the disease at meiosis. Likewise, genes that are far apai't on the same 
chromosome will have a higher probability of being sepaiated by recombination. The 
first report of linkage can be attributed to the Baltimore geneticist, Thomas Hunt 
Morgan, who, in 1900, observed that eye colour in the fruit fly. Drosophila 
Melanogaster, was always co-inherited with the X chromosome, and concluded that 
the particle or gene responsible for eye colour resided on or was linked to this 
chromosome (393,394) In 1911, Wilson et al demonstrated that the gene responsible 
for colour blindness was also cai'ried on the X chromosome (394), and in 1927, 
Haldane reasoned that if it was possible to map 50 or more chaiacters, they could then 
be used as mai’kers to predict whether children were likely to develop important 
genetic diseases (393). In 1955, Morton developed mathematical formulae for 
calculating linkage in humans (395), and in 1956, Edwai’ds pointed out, that with 
sufficient genetic markers, it would be possible to perform prenatal diagnosis, and 
prevent the transmission of many autosomal dominant disorders (393). «
In contrast to reseai’ch on Drosophila, the establishment of linkage between two 
genetic loci in humans can be a painstaking business, involving a large number of 
observations on structured families. Elaborate mathematical methods ai’e required to 
distinguish coincidence and significance, and the situation is further complicated by 
human behaviour. In general, human beings tend to have relatively small families, 
long generation times, often live long distances apai’t making ascertainment difficult, 
and often have far from ideal pedigree structures for statistical analysis.
The term used to describe statistical outcome of linkage in man, the LOD score, 
denoted (Z), is the logai’ithm of an odds ratio and represents the likelihood that two 
loci aie linked at a given recombination fraction to the likelihood that they aie not. 
Since LOD scores aie to the base 10, a value of 3 represents a probability of 1000:1 
that the observation did not occur by chance, a LOD score of -2 means that linkage is 
highly unlikely, and LOD scores between these values are inconclusive and require 
further evaluation. The formal unit used to measure the recombination fraction, i.e..
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the probability of crossing over during meiosis, is the centimorgan (cM), with IcM 
equal to 1% frequency of recombination (396). In physical terms this is equivalent 
approximately to 1 megabase of genomic DNA, although the physical distance will 
vai'y between chromosomes of different size. Once linkage is established, a more 
detailed genetic map can be constructed for other mai'kers in that region using multi- 
locus analysis which is paiticulaiiy useful for identifying double recombinants and 
determining the order of a set of linked mai'kers (397).
Requirements
The presence of a lai'ge kindred with a well defined phenotype greatly facilitates the 
technique of linkage analysis. FAP is an ideal disorder for linkage analysis because 
a) the condition has a well defined phenotype which can be recognised early and 
treated effectively providing two to three generation families with a large number of 
living affected individuals for study and b) many families have been fully ascertained 
through polyposis registries. In other hereditaiy cancer syndromes however, such as 
HNPCC, the nature of the illness means that large kindreds with living affected 
members aie a relative raiity (281,282).
Genetic Markers
A second requirement for linkage analysis is the availability of detailed genetic maps 
and a lai'ge panel of finely spaced genetic markers.
It has been known since Landsteiner discovered the ABO blood group system in 
1900 that human beings may be polymorphic at the protein level (398), but it was not 
until the discoveiy of restriction endonuclease enzymes in the early 1970s that the full 
scale of genetic vaiiation at DNA level became appreciated (399). Although only 
about 20 % of the entire human genome codes for proteins, the remaining DNA 
contains considerable sequence variation , and it is this treasuiy of variation between 
individals, that has proved so invaluable for exploiting linkage analysis.
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Restriction endonucleases aie prokaiyotic enzymes which act as defence mechanisms 
for bacteria, by degrading foreign DNA, such as might derive from an invading 
bacteriophage. The bacterium which produces the particulai" restiiction enzyme 
protects itself by methylating A or C residues within the restriction sequence. These 
enzymes also have the ability to cleave human DNA in a specific, accurate and 
highly reproducible manner, and it is this property which has lai'gely been responsible 
for the present revolution in moleculai* genetic reseaich.
Point Polymorphisms
The human haploid genome is about 3 x 10  ^base pairs long, and it is estimated that a 
base difference occurs between every 200 and 300 base pairs (400) This sequence 
vai'iability can be identified by restriction fragment length polymorphism ( RFLP) 
analysis, a method that detects single nucleotide polymorphisms based on restriction 
enzyme cleavage sites (401). A locus is said to be polymorphic if it contains two or 
more alleles and the frequency of the most common allele is less than 95% " (396). 
Degree of polymoiphism, and its usefulness depends on the number and frequencies 
of the alleles present and the frequency with which the maternal and paternal alleles 
can be differentiated. Most RFLPs are distinguished by Southern Analysis, using 
radioactive labelled probes ( Fig 6.2), but PCR-amplified DNA can also be cleaved 
with restriction enzyme and analysed after electrophoresis using ethidium bromide 
staining (Fig 6.3).
The total number of known RFLP loci is over 2000. Most loci, however, represent 
only two alleles with a heterozygosity lower than 50% , and consequently these loci 
aie poorly informative in linkage studies (283).
Length Polvmoiphism
Scattered throughout the genome aie tandemly repeated sequences whose copy 
number vaiies between people because of unequal recombination and replication 
slippage. A restriction fragment which contains the whole tandemly repeated block
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will be different sizes in different people, and because these mai'kers have several 
alleles, the chances are high, that all 4 chromosomes of an individual's pai'ents will be 
individually identifiable. Two main types of length or repeating unit polymorphism 
have been identified, and these have been used to generate probes known as mini and 
microsatellite markers.
Minisatellite Mai'kers
In 1984, Jeffreys and co-workers reported the discovery of hypervaiiable tandemly 
repeated minisatellite regions or VNTRs. The number of repeat core units may vaiy 
from 3-100 between different individuals, and if a restriction enzyme is chosen which 
cuts outside the repeat region, this vai'iability can be observed as multiple alleles on 
Southern hybridisation (402). The mean heterozygosity of the known VNTR loci is 
over 70%, and VNTRs with heterozygosities of 98% have been reported (403). 
VNTR regions can lie close to mapped genes, but generally they are enriched in non 
coding regions of the genome, being most frequent at the telomeric ends of the 
chromosomes, where the number of recombination events is often increased (404- 
406). The stable inheritance of vaiiable minisatellite fragments with the low 
population frequency of individual fragments makes them excellently suited for 
linkage analysis ( Fig 6.4) (406),
Multilocus Probes
In 1985, Jeffreys described a short minisatellite area consisting of 33bp. nucleotide 
sequence which was repeated four times in the first intron of the myoglobin gene and 
from this region, he prepaied a probe in which the 10-15 bp core sequence was 
repeated several times. When these minisatellite probes were hybridised to human 
DNA they detected several VNTR loci simultaneously, creating a unique pattern or 
"DNA fingeipi'int" for each individual. These multilocus probes can detect about 15- 
20 bands greater than 2 kilobases per individual on Southern analysis (407). 
Combined, it has been estimated that the probes 33.6 and 33.15 can detect
139
Combined, it has been estimated that the probes 33.6 and 33.15 can detect 
approximately 60 hypervariable loci, most of which will be unlinked and scattered 
throughout the genome (407). The disadvantage of using multilocus probes in 
linkage analysis, is that unlike single locus analysis, linkage data cannot be pooled 
between unrelated small pedigrees, since a different minisatellite allele is likely to be 
associated with the disease locus in each pedigree.
Microsatellite Markers
Microsatellite or ( C-A )n repeats are short tandem runs of di-,tri-or tetrameric poly 
(CA), poly ( GT ) nucleotide sequences which occur frequently in mammalian DNA 
(408,409). Blocks of CA repeat units are found in every 30-60 kb. of DNA, and are 
distributed evenly in 5' and 3' untranslated regions and introns. It is estimated that 
there may be between 50,000 - 100,000 blocks of CA repeats scattered throughout the 
genome. If the sequences flanking these repeats aie obtained, primers can be 
synthesised that allow amplification of the repeats by the polymerase chain reaction, 
and the fragments can then be resolved by polyacrylamide gel electrophoresis. 
Several hundred primer sequences have now been assigned to specific chromosomes 
for the identification of blocks of CA repeats (283).
Microsatellite markers have several advantages over conventional markers. Firstly, 
they are highly polymorphic due to length heterogeneity, with over 75% of meioses 
being informative (409). Secondly, analysis requires less than 20 nano grams of DNA 
per marker, as opposed to 5-10 micrograms for Southern analysis, and this means 
paraffin embedded archival histological material can be used for analysis. Finally, 
the alleles can be identified using non-radioactive fluorescent labelled primers and 
automated sequence analysis, enabling hundreds of microsatellite markers to be 
studied in a fraction of the time required previously (410).
140
Genetic Maps
The concept of a genetic map dates to 1911, when A.H. Stnrtevant, an undergraduate 
in TH Morgan's laboratory, realised that linkage information could be used to 
determine the relative position of genes along a chromosome. His paper "The linear 
arrangement of six sex-linked factors in Drosophila, as shown by their mode of 
association" was the first linkage map published, and forms the basis of all modern 
linkage studies (401). In 1979, Solomon and Bodmer proposed the construction of a 
genetic map, based on evenly spaced RFLPS (411), and the following year, White 
and colleagues at the University of Utah reported the assignment of neaidy 500 RFLP 
markers covering 17 chromosomes, based on linkage data from 59 different three 
generation families (401). In 1992, a generation linkage map was described 
consisting of 814 highly polymorphic microsatellite markers spanning 90% of the 
estimated length of the genome (412).
Data Analysis
Linkage analysis is one area of medical research that is almost totally dependent on 
powerful computer technology. Most linkage studies use either the LIPED or 
LINKAGE software progrannnes. _
Limitations of Linkage Analysis
Phenocopy.
Phenocopy is a phenotype produced by environmental factors that mimics a 
genetically determined trait. In disorders such as retinoblastoma, or multiple 
endocrine neoplasia (MEN), the issue of phenocopy, seldom, if ever presents a 
problem, because such disorders are relatively raie and the chances that affected 
individuals within the same family will not cmry the mutant allele are extremely 
small. However, in common malignancies, such as colorectal cancer it may be 
difficult to separate the hereditary cancer due to a high penetrance mutation, from the
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"sporadic" cancer due to some other cause. Some families with multiple cases of 
colorectal cancer may arise as a result of chance clustering, and some patients with 
colorectal cancer in susceptible families may not carry the mutation responsible. This 
fact has major implications for linkage studies because misclassification of disease 
status within the pedigree can lead to a significant loss of LOD score (397).
Penetrance
Penetrance is the probability that a person carrying the gene for a dominant disease 
will manifest the signs and symptoms of the disease. In some forms of hereditary 
colorectal cancer, gene expression will be age-dependent so that young gene carriers 
may appear unaffected, contributing little linkage information. If the hypothesis that 
most colorectal cancer is due to the inheritance of a common low penetrant gene 
therefore, identifying the gene(s) responsible using conventional linkage analysis may 
prove difficult if not impossible.
Definition of Phenotype
Accurate definition of phenotype is crucial to any linkage study. This is not a 
problem in disorders with a clearly defined phenotype such as FAP, but can be 
troublesome in disorders such as HNPCC where the phenotype be less than typical, 
Defining the phenotype too broadly in colorectal cancers studies by classifying 
individuals with adenomas as affected could destroy or create spurious linkage if the 
individuals concerned do not carry the mutant allele. It is customary in this situation, 
therefore, to eliminate uncertainty by adopting only the narrowest definition of 
phenotype. Definition can then be expanded at a later date to include other features 
once linkage has been established.
Genetic Heterogeneity
Different genes in different families may cause the same disease, invalidating the 
summation of LOD scores in small families. This can be minimised by studying
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mainly lai'ge families with many living affected individuals, an uncommon situation 
in the context of hereditaiy non-polyposis colorectal cancer.
Positional
Cloning
T
Mendelian disorderISearch for DNA markers cosegregating with d isease  locusi
Establish linkage to a known genetic markerIContinue search using narrow linked DNA marker to narrow region of interestiU se finer resolution mapping techniques to identify d isease  gene4Clone gene and determine nucleotide sequenceICompare nucleotide seq uence in DNA from affected and unaffected individuals
tInfer amino acid seq uence of normal and d isease gene protein productIIsolate protein product of normal and d isease  gen es
Fig 6.1 Schematic outline of positional cloning
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Chapter 7
A Linkage Study of St Mark's Family 96
148
Introduction
The puipose of this study was to localise the gene that predisposes St Mark's Family 
96 to the development of atypical polyps and early onset colorectal cancer - the 
Hereditary Mixed Polyposis Syndrome discussed in Chapter 5.
St Mark's Family 96 was an ideal family for a linkage study because:
1) Affected individuals developed polyps at a relatively early age, and the phenotype 
in most cases could be readily identified.
2) The disorder appear ed to have a high penetr ance, and autosomal dominant 
inheritance.
3) The family had many living affected individuals and it was therefore possible to 
obtain blood specimens for DNA analysis.
4) The family were cooperative and enthusiastic about the project.
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Linkage Strategy
Cytogenetic clues played a major role in the genetic mapping of both the 
retinoblastoma and APC genes. Such clues are raie, but when present, can 
significantly accelerate any linkage process. Before embarking on an exhaustive 
linkage study, therefore, a decision was made to examine the karyotype of an 
affected individual for any abnormality. Assume the karyotypes are normal, the next 
strategy would involve excluding linkage to the candidate genes, APC,MCC,P53 and 
DCC. Exclusion of linkage to the APC gene would almost completely rule out the 
HMPS as a variant of PAP. Following the exclusion of liirkage to these loci, the next 
step would involve concentrating on those regions of the genome known to be 
associated with a high frequency of allele loss in a panel of colorectal cancer 
specimens, using when possible highly informative VNTR markers. Finally, an 
attempt would be made to identify an allele which was being consistently co-inherited 
with the disease, using a multilocus probe.
Such a study, would not localise the gene responsible per se, but if all affected 
individuals possessed a specific allele, and all unaffected members did not, then a test 
would be available which could identify those at risk.of developing polyps within the 
family.
All the linkage experiments were performed by the author between June 91- 
November 93, with the exception of the multilocus probe experiment, which was 
performed by Cellmark Diagnostics, ICI, Abingdon Science Park, Oxfordshire.
Patients and Methods
The section of St Mark's Family 96 used for the linkage study is shown in Fig 7.1. 
DNA was available from 37 individuals. All family members were drawn from tlie 
third and fourth generations. No tissue was available for DNA extraction from the 
fkst and second generation as the individuals concerned were deceased, and it proved
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were considered too young for accurate assessment of disease status. Twelve family 
members lived in the United Kingdom, nine lived in Soutli Africa, six hved in Israel, 
five hved in New York, three lived in AustraHa, one hved in the Netherlands and one 
hved in Hong-Kong. Blood specimens from individuals hving in South Africa were 
collected by Professor Trefor Jenkins, Department of Human Genetics, University of 
Johannesburg.
Definition of Phenotvpe.
For the purposes of linkage analysis, any patients who developed polyps under the 
age of 50 year's or colorectal cancer under the age of 55 year’s was considered a gene 
carrier.
Those patients who did not have polyps on colonoscopy examination by the age of 40 
years were considered not to carry the gene.
Cvtogenetic examination.
The chromosomes were prepared according to standard techniques (413). They were 
then G-banded using Wright's stain in 50% Sorenson buffer ( diluted one part stain to 
three parts buffer). This was performed by Miss Tanya Jones, Cytogenetics Lab, 
ICRF.
Blood Collection
A 50ml Falcon tube containing 25ml of blood collection media was brought to room 
temperature and 25ml of fresh blood was added. The tube was then inverted to mix, 
and the sample was maintained at room temperature.
Sterile Separation of Lvmphocytes
The contents of each blood collection bottle was poured into a 250ml flask and the 
blood bottle was rinsed with 4ml of RPMI/HEPES. 20 sterile glass beads were then 
added to the flask, followed by 0.6ml of sterile IM calcium chloride through the foil
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top of the flask, and the blood was defibrinated for 15 minutes at 250 r.p.m. on a 
gyratory shaker. 20ml RPMI/HEPES was then added to the flask and the defibrinated 
blood was carefully overlayed on two 50ml tubes each containing 14ml of 
Lymphprep (Nyegaai'd). The cells were then separ ated by centrifugation at 700g for 
20 minutes. The interface between the 'Lymphprep' and the serirm was removed and 
diluted 1:1 with RPMI/HEPES. The cells were then counted on a haemocytometer. 
The cells were then spun at lOOOg for 10 minutes and the supernatant aspirated. The 
cell pellets were then frozen in 1ml of foetal calf serum plus 10% Dimethyl 
sulphoxide at -70^ C.
Epstein-Barr Transformation of Lymphocytes
This was performed by Miss Cynthia Dixon (Cancer Genetics Laboratory, ICRF) 
according to the protocol of Pelloquin et al (414).
DNA Extraction
20 luls of blood was collected into EDTA (0.5ml of 0.5M EDTA pH 8.0 ). The 
solution was then transferred to a 50ml. Falcon tube and made up to 50ml with lysis 
buffer, and left on ice for 10 minutes until the red cells had lysed. The cell nuclei 
were then collected by centrifugation at 2000 ipm for 10 minutes at 4^ C. The 
supernatant was drained off, and the residual pellet was resuspended in 3 ml of 
salt/EDTA buffer and vortexed. 150 microlitres of 20% SDS and 30 microlitres of 
lOmg/ml proteinase K was added. The solution was then left overnight in a water 
bath at 37^ C. 3 ml of phenol/chloroform was then mixed with the solution for 5-10 
minutes using the tube rotator, and then spun at 2000 rpm for 5 minutes at room 
temperature. The upper aqueous phase was removed and the procedure repeated.
The aqueous phase was then extracted with 3ml of chloroform/isoamyl alcohol 25:1, 
using the same centrifuge procedure, 1/10 volume of 3M sodium citrate was added 
followed by 2 volumes of cold absolute alcohol, and the solution was hand mixed.
The precipitated DNA was hooked out with a glass rod, rinsed in 70% alcohol, dried 
briefly, resuspended ini-2ml of T.E., and rolled overnight in the cold room at 4° C. A
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dilution of the DNA, 10 microlitres: 1000 microlitres, was made in distilled water, and 
the optical density (OD) was measured at 260 and 280 nm against a distilled water 
blank in a silica cuvette. The ratio of OD260nm/OD280nm should ideally be 1.8.
The concentration of the DNA solution was calculated with the knowledge that a 
solution of DNA at 1 mg/ml is equivalent to 200 OD units. A working solution of 
DNA concentration 200 micrograms/ml was made, and the remainder was stored as 
stock at -200 C.
For extraction of DNA from lymphoblastoid cell lines, approximately 10  ^cells were 
spun down at 1000 r.p.m. for 5 minutes, resuspended and then washed in PBS ( 1ml 
of cell culture contains about 0.5 X 10  ^cells). The solution was respun, and the cell 
resuspended in a salt/EDTA/proteinase K solution as described above. The procedure 
was then identical to that described for DNA extraction from blood.
Restriction endonuclease digestions
This was carried out in the buffers and at the temperatures recommended by the 
suppliers of the restriction endonucleases. The amount of enzyme used in each case 
was 1-6 fold over that required to complete the digestion in one hour under optimal 
conditions. Due to the inhibitory effect of the glycerol present within restriction 
enzyme storage buffers, on no occasion was this component allowed to constitute 
more than 10% of the reaction volume. Reactions were incubated for 1-2 hours for 
cloned DNA and for at least 3 hours for genomic DNA. After digestion was 
completed, approximately 1 p.g of DNA was taken from each tube to check digestion 
and run with 1/10 loading buffer on a test minigel. If digestion was thought to be 
complete, the Gyrovap was used to concentrate the samples to about 25 microlitres or 
to dryness and water was added. If digestion was incomplete, more enzyme was 
added and reaction volume was incubated for a longer period. If digestion was still 
incomplete after this, the sample was re-extracted and precipitated. Incomplete 
digestions after this time were phenol/chloroform extracted and precipitated prior to a 
second digestion. Multiple digestions were conducted simultaneously if the reaction
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conditions required by each enzyme concerned are similar. If not the DNA was 
ethanol precipitated after each restriction and resuspended in an appropriate buffer for 
a subsequent digestion. Aliquots of all digestions were separated on appropriate 
percentage agarose gels to determine the completeness of the digestion.
Agarose gel electrophoresis
This was performed using 0.7-1.4% agarose gels of 200 or 300 ml volume poured 
upon 20 xl5 cm or 25 x 15 cm perspex trays respectively. Various plastic well- 
formers were employed to make gel slots. The gel was prepared in 1 x TAB (stock 
50x). 3.2 grams of agarose were then added to 300 mis of TAB buffer, and
microwaved for 5-10 minutes until gel had boiled and the agarose dissolved. When 
the gel was about 60^C, it was poured evenly into the mould without making bubbles, 
and left to set for about 30 minutes. The gels were then submerged under a 1 cm 
depth of electrophoresis buffer and after loading the DNA in 20% (v/v) loading 
buffer, a constant voltage of 0.5-3 V/cm was applied. Ethidium bromide at 0.5 mg/ml 
was included in both the gel and the electrophoresis buffer to permit visualisation of 
the nucleic acids under ultraviolet light. A 2 kb marker was also loaded onto the gel 
and was allowed to migrate at least 9cm. on a 20 cm. gel. This was estimated by 
photographing a ruler by the side of the marker lane.
Southern Blotting
The marker track was cut off, and the gel was depurinated by immersion in 0.25M 
HCL for 10 minutes. The gel was then neutralised in distilled water. The gel was 
then placed into a blotting tray containing 0.4M NaoH with a double thickness of 
Whatman 3MM wick. The gel was then transferred to the surface of the blotting 
wick, and air bubbles removed using a plastic roller. A sheet of Hybond-N+ 
membrane and 4 layers of Whatman 3MM paper were then placed on the gel. The 
membrane was rolled flat to ensure good contact with overlying paper, and a stack of 
paper towels towels was placed on top of filter to a depth of about 10cm. The edges
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of the gel were masked with paiafilm strips. A plate of glass was then placed on top 
of the stack, and the appai'atus was left for 4 hours to allow complete DNA transfer. 
When the membrane was removed it was rinsed several times in 2 x SSC.
Processing of Genetic Probes
Most probes were provided by the UK. DNA Probe Bank (I.C.R.F.,Clai'e Hall) at a 
concentration of approximately 0.5 mgs /ml, more than an adequate amount for 
restriction digestion. However, some probes were in short supply and required further 
transformation..
Plasmid Transformation
A 200 microlitre volume of frozen competent Escherichia Coli bacterial cells was 
allowed to thaw gradually on ice. The tiansformed DNA (plasmid plus insert) was 
then mixed with the competent cells and left on ice for 20 minutes, before adding 
calcium chloride. The mixture was allowed to stand at room temperature for 10 
minutes. 0.7 mis of prewarmed L broth was added and incubated for shaking for 1 
hour at 37° C. The transformed bacterial solution was then plated out on L- 
broth/ampicillin plates using a glass spreader sterilised with alcohol and flaming. The 
inoculated plates were then inverted and incubated overnight at 37^ C. The plates 
were then removed and stored at 4^ C to arrest bacterial growth. The incubated plates 
were viewed, colonies selected using a sterile loop and then transferred to 100 mis. of 
L-broth/ampicillin in sterile flasks and incubated in the shaker at 37° C. overnight.
Alkaline Lvsis
10 mis of an overnight culture was added to 1 litre of L-Broth plus antibiotic ( usually 
ampicillin 25-50 g/ml for pBR322 type plasmids or 100-150 g/ml for pBluescript, 
pTZ etc.). 250-500 mis of this culture was then grown at 37^C. and shaken overnight. 
The culture was then cooled on ice, and the cells were spun down in GS A tubes at 
3000 rpm for 10 minutes at 4^ C. The supernatant was drained off and the cells were
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10 mis of an overnight culture was added to 1 litre of L-Broth plus antibiotic ( usually 
ampicillin 25-50 g/ml for pBR322 type plasmids or 100-150 g/ml for pBluescript, 
pTZ etc.). 250-500 mis of this culture was then grown at 37^C. and shaken overnight. 
The culture was then cooled on ice, and the cells were spun down in GSA tubes at 
3000 rpm for 10 minutes at 4^ C. The supernatant was drained off and the cells were 
resuspended in 7.5 mis of ice cold GTE solution. 0.5 mis of lysozyme (lOmgs/ml) 
was then added to the solution, and the cells were allowed to sit at room temperature 
for 10 minutes, following which 15 mis of 0.2M NaOH/1% SDS solution was added, 
and the solution was left on ice for 5 minutes, 10 mis of ice cold 5M KOAc pH 4.8 
was then added and the solution left on ice for a further 15 minutes. The solution was 
then spun at 10,000 rpm for 5 minutes at 40C, and the supernatant drained into a 250 
ml graduated cylinder. Isopropanol ( 0.6 of total volume was then added, the solution 
was transferred to a clean GSA tube, and stored at -20^C. for 1 hour. The solution 
was then spun for 10 minutes at 6,000 rpm at 4^ C, and the supernatant drained off.
Caesium Chloride Gradient
The pellet was resuspended in 10 mis of TE pH8, and the solution transferred to a 
SS34 tube, Ig/ml of caesium chloride was then added and allowed to dissolve, and 
when this was complete, 200 microlitres of Ethidium Bromide (lOmg/ml )was added. 
The solution was then left on ice for 30 minutes, and then spun at 10,000 rpm at 4  ^C. 
for 10 minutes to remove most of the RNA. The supernatant was then transferred to a 
Ti80 quickseal tube, balanced and sealed. The solution was then then spun in the 
ultra-centrifuge at 55,000 rpm for 18-20 hours, then 40,000 rpm for 2 hours, and then 
stopped without a break. The band of interest was then aspirated using a 16 gauge 
needle attached to a 5 ml syringe, and added to an approximately equal volume of 
water saturated butanol. The plasmid solution was then extracted until no longer pink 
in appearance, and then separated from the caesium chloride over a large A50M
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Preparation of Insert DNA
Approximately 2 g of plasmid DNA were digested with the appropriate restriction 
enzyme as described above, and then resolved on low-melt ultra-pure agarose gel 
over a 2-3 hour period at 60-90 Volts. Included on the gel was 1 g of a lambda-Hind 
III size marker. The relevant band was then identified under U-V light, cut out with a 
scalpel, placed in an Eppendorf tube and then weighed. Thiee times the gel weight of 
distilled water was added. The first time the probe was labelled, it was boiled for 7 
minutes, and the solution was dispensed into convenient aliquots.
Filter Hybridisations
Filters were prehybridised in glass bottles containing hybridisation buffer plus heat 
denatured competitor DNA as required at 65°C for a minimum of 2-4 hours.
Denatured double-stranded DNA probes were radio-labelled according to the oligo- 
labelling method of Feinberg and Vogelstein using ^2p dCTP (415). This involved 
boiling the probe for 3 minutes in an Eppendorf tube (after piercing the top of the 
cap), then cooling to 37^ C. if in agarose or on ice if not. OLE, BSA, 2^ p-dCTP and 
Klenow were then added and the mixture was left to incubate at 37° C. or at room 
temperature overnight. A typical labelling reaction would consist of:
34 microlitres of probe in agaiose or less if very concentrated or
20-50 nanograms of pure DNA plus water to 34 microlitres.
10 microlitres of OLB
2 microlitres of BSA
3 microlitres of ^^P-dCTP
1 microlitre of Klenow fragment.
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To remove unincorporated nucleotides, probes in 250 microlitres of IM TES were 
passed through a Sephadex G-50 (fine) column prepared in a 1 ml syringe by 
centrifugation of the column for 5 minutes at lOOOg. The degree of radionucleotide 
incorporation was assessed with a 1ml aliquot. After dénaturation at lOO^C for 5-8 
minutes probes were added to hybridisation buffer and then added to the glass bottles. 
The process was then allowed to proceed at 65°C for 16 hours in a rotating 
hybridisation oven.
Removal of the non-specifically bound probe was achieved by successive washes at 
65°C in 0.1% SDS buffers containing 2x SSC, Ix SSC and O.lx SSC. Several further 
washes at this final stringency were applied, and when the filter had been washed 
down to less than 10 counts/second over its entire surface, an autoradiograph was set 
up.
Hvbridisation with Competitor DNA
Probes containing highly repetitive sequences were incubated with human placental 
competitor DNA prior to hybridisation. 200mg of competitor DNA will be added to 
the probe and heated at lOO^C for ten minutes, and then the solution was incubated 
for two hours at 65^C before being added to the hybridisation mixture (416).
Autoradiography
Filters were placed between sheets of polythene and exposed to Kodak X-ray film 
between intensifying screens in X-ray cassettes. A radio-opaque mai'ker was included 
to help with orientation of film when it was developed. The autoradiographs, were 
exposed at -70^C. overnight or longer of alleles were not clearly visible.
Stiipping of Filters
To enable re-examination of the filters by other probes the filters were stripped of 
hybridised probe by immersion in boiling 0.5% SDS solution. When the filters were 
"cool" in a radio-active sense, they were stored damp in polythene bags at 4^ C.
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Oligonucleotide Synthesis
Oligonucleotides were synthesised by the Human Genetic Resources Laboratory 
(ICRF, Clai'e Hall). The melting temperature (Tm) of the oligonucleotides was 
estimated by multiplying the number of A + T residues by 20C and the number of G + 
C residues by 40 C. and adding the two numbers (417).
Polymerase Chain Reaction
A 2ml PCR reaction mixture was made up, which was sufficient for 40 x 50 
microlitre reaction volumes.
This consisted of:
1672 microlitres of H2 0
40 microlitres of Primer A ( 0.5 mgs/ml)
40 microlitres of Primer B ( 0.5 mgs/ml)
40 microlitres of dNTP
8 microlitres of Taq Polymerase ( 40 units)
200 microlitres of Taq Polymerase Buffer ( lOX)
Approximately, lOOng of tai'get DNA was added to a 50 microlitre aliquot of this 
reaction mixture and the reaction mix was covered with paraffin oil. The PCR 
reaction was performed on a programmable heating block (Programmable Dri-block, 
Techne). Exhaustive trials of PCR conditions for each tai'get sequence were often 
required until the ideal conditions for specific amplification were obtained, but 
generally the reaction was denatured at 94^C and reannealed at 8®C less than the 
calculated Tm of the oligonucleotide primers, the polymerisation temperature was 
usually at 72^C. Extension times varied between 0.5 and 4 minutes, depending on the 
size of the desired PCR product, and 30 cycles were usually performed. After
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completion of the reaction a 10 microlitres aliquot will be run out on an agarose gel 
and a photograph taken of the ethidium-stained gel.
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Construction of a 10% polyacrylamide gel
The following components were mixed in a fume cupboard:
30% polyaciylamide 44 mis.
lOXTBE 13.2 mis
Distilled water 75 mis
20% Ammonium persulphate 300 microlitres
120 microlitres of NNNN tetra-ethylenediamine (TEMED) were added prior to 
injection into the gel mould.
Constr uction of the gel mould
A mould was constructed between two thick glass plates and plastic spacers, sealed 
with silicon tape and held in place between metal clips. The freshly prepared gel 
solution was then injected into the mould via a 60 ml syringe, until completely filled, 
taking care to make sure all bubbles were removed. Sharks tooth combs were then 
inserted into the top of the gel and the gel was then left to polymerise at room 
temperature for approximately one hour. The silicon tape was then removed from the 
bottom of the mould, and the mould was placed in the electrophoresis apparatus ( Life 
Technologies) and immersed in TBE buffer. The PCR samples were added to 
loading buffer, and then pipetted into spaces formed by comb, using a fine pipette tip. 
The power supply was connected and a constant power of 11 watts was used over a 
running time of 6 hours. Every effort was made to keep the running temperature of 
the gel at 55^C.
Drying of Gel
The gel was then dried onto 3MM Whatman paper using a commercial drier and 
autoradiography was performed as previously described.
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Data Management
Data generated by this work was stored on an Apple McIntosh LCII computer, and 
analysed using the ICRF Main Frame Computer. An appropriate LOCUS and 
PHENOLIB file were generated for the marker details, and a FAMILY file was 
constructed to include details of pedigree, disease status, and typing with respect to 
the markers for each individual. From this database, input files for the linkage 
analysis programmes of LIPED and LINKAGE were generated.
Buffers and Solutions
50x Electrophoresis Buffer Tris base 
Sodium acetate 
EDTA
242g
20.5g
18.6g
Glacial acetic acid to 
pH 7.8 to IL with H20
Hybridisation Buffer Dextran Sulphate 
Denhar'dt's solution 
SDS 
SSC
Tarula Yeast RNA
10%
5x
0.5%
6x
1 mg/ml
Denhar'dt's Solution(50x) Bovine serum albumin 5g
Ficoll 5g
Polyvinyl pyrrolidine 5g
made to 500ml with H20
Loading Buffer Bromophenol blue 0.25%
Xylene cyanol 0.25%
30% Glycerol in H20
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Phenol Phenol
plus 300ml of: 
Tris-HCl pH 8.0 
Na2EDTA.2H20 
NaCl
Hydroxyquinoline
500g
500mM
lOmM
lOmM
SOOmg
Chloroform Chloroform 
Iso amyl alcohol
96ml
4ml
SSC (20x) NaCl
Sodium Citrate
adjusted to pH7.0
with NaOH and autoclaved
175.3g
88.2g
TE Tris-HCl pH 7.4 
Na2 EDTA.2H20 
autoclaved
lOmM
ImM
TES Tris-HCl pH 7.4 
Na2 EDTA.2H20 
SDS
lOmM
ImM
0 .1%
TEN NaCl
Tris-HCl pH 7.4 
Na2 EDTA.2H20
O.IM
lOmM
ImM
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PBS
PCR Buffer (lOx)
High Salt Buffer
Medium Salt Buffer
NaCl lOg
KCl 0.25g
KH2P04 0.25g
Na2HP04 1.43g
CaC12 1.334g
MgC12 l.Og
made up to IL with H20
(NH4)2 S04 166mM
Tris-HClpH 8.8 0.67M
MgC12 67mM i
2 Mercaptoethanol lOOmM j
Na2 EDTA.2H20 67mM
BSA 1.7mg/ml
Tris-HCl pH7.5 lOmM
MgC12 lOmM
NaCl lOOmM
Tris-HCl pH7.5 lOmM
MgC12 lOmM
NaCl 50mM
Dithiothreitol ImM
Media
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L Broth
Restriction Enzymes
Blood Collection Media
Bacto Tryptone lOgms
Yeast Extract 5gms
NaCl lOgms
pH7.2 in IL H20
New England Biolabs and
Boehringer Mannheim
RPMI 1640 HEPES Buffered Medium 200rnl
3.3% Trisodium Citrate40ml
5mM Mercaptoethanol 2ml
25ml aliquotted into 50ml sterile blood bottles.
Penicillin 5000 units/ml (Flow Laboratories)
165
Oligonucleotide Primers
Locus
D8S88
D8S133
TP53P
THRB gene
LPL-Tet
Primer Sequence
TCCAGCAGAGAAAGGGTTAT (CA strand)
GGCAAAGAGAACTCATCAGA (GT strand)
CAGGTGGGAAAACTGAGGGA (CA strand)
AGCAACTGTCAACATATTGCT (GT strand)
GAAGAGCCTCGGTTATGGGTATACA (CR81)
TCAGAAGGAAGTAGGAAGGACTCAG (CR82)
GCTAATCTAGAAATGTATTTACTATAGG(EA2R- 
TTTACTTCATGAAGCTGGCACG ( EA2R-2)
ATCTGACCAAGGATAGTGGGATATA (GZ-14) 
CCTGGTTAACTGAGCGAGACTGTGTC ( GZ-15)
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Results
Cytogenetic Studies
A karyotype of affected individual 11X17 ( Fig.7.1) raised the suspicion of a 
constitutional deletion on chromosome 18p ( Fig. 7.2). The karyotypes of three other 
affected individuals, however, were reported as normal, and it was concluded that the 
"deletion" probably represented a chromosomal polymorphism. Furthermore, two 
markers mapping to chromosomal region 18pl 1, (D18S32 and the Thymidylate 
Synthetase gene) were not linked to the disease locus (Figs.7.3,7.4).
Linkage Studies
A linkage study was carried out between the HMP syndrome locus and 77 marker loci 
spanning 16 chromosomes ( Table 7.1). Details of the markers are readily available 
in the Genome Database(283).
Linkage was excluded in 34 genomic regions where a LOD score of -2 or less was 
calculated. In the remaining regions, the LOD score was calculated to lie between -2 
and 1 and linkage could neither be confirmed or refuted. The most positive LOD 
score at zero recombination was 0.69 with marker D6S44, which is known to map to 
chr omosome region 6p21-qter.
Linkage to the candidate genes, APC, DCC, hMSH2 and P53 was convincingly 
excluded with LOD scores at zero recombination of -2.38, -2.13, -2.05 and -6.25 
respectively! Figs.7.5-7.13).
Linkage to a highly informative tetranucleotide repeat marker within the LPL gene on 
chr omosome 8p, the third highest region of allele loss in a panel of colorectal cancer 
specimens, was also excluded with a LOD score of -5.20 at zero recombination 
(Fig.7.14).
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Hybridisation with the multi-locus probe 33.15 revealed a band that was present in 
10/16 unaffected individuals, but which was only present in 1/17 affected individuals 
(Fig 7.15)
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Table 7.1 Two-point LOD Scores between disease locus and each of 77 genetic 
markers tested.
LOD score at recombination fraction 0  of
Marker Locus 0.00 0.05 0.10 0.15 0.20 0.30 0.40
D1S105 1 -4.18 -2.02 -1.37 -0.90 0.57 -0.19 -0.05
D1S57 Ip35-p32 -2.05 -1.50 -1.04 -0.68 -0.41 -0.11 -0.09
D1S62 lp32 -2.33 -1.32 -0.86 -0.60 -0.42 -0.19 -0.06
D1S58 Iq31-q32 0.27 0.18 0.12 0.06 0.03 0.02 0.003
D1S66 Iq21-q31 0.26 0.20 0.15 0.11 0.08 0.03 0.001
D1S61 Iq21-q31 -6.2 -2.47 -1.56 -1.05 -0.70 -0.28 -0.08
D1S7 Ip35-p33 -INF -4.3 -2.88 -1.87 -1.10 -0.41 -0.10
D1S85 Ip32-p22 0.40 0.31 0.24 0.17 0.12 0.05 0.01
D2S44 2p -INF -2.59 -1.44 -0.89 -0.59 -0.32 -0.17
D2S50 2q -4.46 -1.36 -0.75 -0.34 -0.09 0.10 0.06
D2S123 2pl5-pl6 -2.05 -1.72 -1.15 -0.76 -0.49 -0.17 -0.03
D3S42 3q21-qter -3.82 -0.75 0.02 0.38 0.54 0.49 0.24
THRB 3p22-p24 -1.35 -1.15 -0.70 -0.41 -0.22 -0.04 -0.02
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M arker Locus 0.00 0.05 0.10 0.15 0.20 0.30 0.40
D4S10 4pl6.3 -1.90 -0.69 -0.43 -0.28 -0.20 -0.10 -0.04
D4S124 4p -7.2 -2.7 -1.4 -0.7 -0.36 -0.04 0.00
D4S13 4pl5-q21 -2.75 -1.43 -0.90 -0.59 -0.39 -0.16 -0.05
D5S98 5ql5-q21 -1.82 -1.04 -0.69 -0.47 -0.31 -0.13 -0.04
D5S43 5q35-qter -3.71 -1.02 -0.67 -0.34 -0.01 0.12 0.14
APC-FB40 5q21-q22 -2.38 -0.58 -0.35 -0.24 -0.17 -0.07 -0.01
D5S135 5q 0.10 0.07 0.05 0.04 0.02 0.01 0.003
D5S81 5q21-q22 -2.23 -0.53 -0.30 -0.20 -0.13 -0.04 0000
D5S84 5q21-q22 -2.00 0.06 0.20 0.23 0.20 0.11 0.025
MCC 5q21-q22 -2.40 -0.40 -0.20 -0.11 -0.07 -0.03 -0.02
D5S347 5 -13.2 -4.64 -2.61 -1.56 -0.54 -0.21 -0.13
D6S44 6p21-qter 0.69 0.55 0.42 0.31 0.22 0.09 0.02
PIM 6p21 0.15 0.07 0.04 0.02 0.01 0.00 000
D6S133 6q27 -INF -1.52 -0.56 -0.15 0.04 0.12 -0.02
D7S439 7P -9.24 -3.33 -2.15 -1.43 -0.96 -0.36
D7S370 7pter-pl4 -0.63 -0.37 -0.15 -0.04 0.005 0.02 0.017
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M arker Locus 0.00 0.05 0.10 0.15 0.20 0.30 0.40
NEFL 8p21 0.63 0.51 0.41 0.03 0.02 0.11 0.03
LPL-TET 8p22 -5.20 -3.33 -2.24 -1.63 -1.12 -0.58 -0.21
D8S133 8p -0.49 -0.27 -0.14 -0.06 -0.02 0.04 0.07
D8S88 8 -2.97 -2.19 -1.63 -1.16 -0.77 -0.26 0.00
D9S10 9q34.3 -1.52 -1.07 -0.75 -0.54 -0.39 -0.21 -0.85
D9S7 9q34 -INF. 0.06 0.16 0.15 0.12 0.05 0.00
D10S90 10q26 -1.30 -0.84 -0.48 -0.02 -0.09 0.02 0.03
D10S92 10pl5 -1.95 -0.39 -0.01 0.15 0.02 0.18 0.07
D10S25 10q26 -0.26 0.10 0.31 0.40 0.42 0.31 0.13
D10S32 10pter-pl3 -1.27 -0.53 -0.21 -0.05 -0.03 0.07 0.06
D10S13 10q21-q23 -0.06 -0.03 -0.15 -0.08 -0.05 -0.04 -0.03
RPB3 10qlL2 -1.46 -1.12 -0.82 -0.57 -0.37 -0.12 -0.02
CD20 Ilq l2 -q l3 -1.3 -0.93 -0.75 -0.57 -0.40 -0.16 -0.03
D12S42 12 -INF. -5.29 -3.33 -2.27 -1.56 -0.67 -0.19
D12S40 12 -4.46 -1.36 -0.75 -0.34 -0.09 0.10 0.06
D15S86 15 -1.56 -1.13 -0.69 -0.39 -0.19 -0.01 0.00
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Marker Locus 0.00 0.05 0.10 0.15 0.20 0.30 0.40
D17S34 17pl3.3 -9.14 -4.27 -2.15 -1.14 -0.36 -0.11 -0.02
D17S180 17ql2-q21 -2.13 -1.27 -0.70 -0.48 -0.26 -0.11 -0.03
D17S308 17q21-qter -6.94 -3.52 -2.50 -1.73 -0.78 -0.29 -0.06
D17S579 17 -2.17 -1.79 -0.79 -0.37 -0.05 0.04 0.03
TP53CA 17pl3.1 -6.25 -2.27 -0.76 -0.01 0.46 0.39 0.15
D17S5 17pl3.3 -5.22 -1.48 -0.24 0.16 0.33 0.24 0.10
D17S28 17pl3.3 0.68 0.66 0.55 0.44 0.24 0.11 0.04
D18S8 18q21.3 -2.13 -1.80 -1.22 -0.80 -0.51 -0.18 -0.04
D18S32 18pll.3 -4.48 -1.69 0.29 0.45 0.46 0.29 0.04
D18S7 18q ll.1-11.2 -1.66 -0.26 -0.10 -0.04 -0.02 0.00 0.00
D18S3b 18qll.3 -1.85 -0.79 -0.51 -0.34 -0.23 -0.08 -0.02
T.S. 18pll.32 -INF. -0.68 -0.34 -0.18 -0.10 -0.04 -0.01
D22S164 22 -0.52 -0.50 -0.28 -0.02 0.14 0.24 0.15
D22S163 22 -1.23 -1.02 -0.57 -0.28 -0.12 -0.09 000
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Discussion
Before the advent of automated sequence analysis and microsatellite markers, linkage 
analysis was often a painstaking and laborious process. Restriction Fragment Length 
Polymorphic Markers often provide little linkage information and the number of 
readily available VNTR markers was limited. The whole undertaking was further- 
complicated by the sheer size of the human haploid genome, estimated to be 3 billion 
base pairs long.
The presence of a cytogenetic clue can greatly accelerate the linkage process. In St 
Mar'k's Family 96, the finding of a possible deletion on clir omosome 18p 11.3 in the 
karyotype of individual III-7 was considered sufficiently interesting to study genetic 
mar’kers in this region for linkage, while awaiting the results of confirmatory 
cytogenetic studies in other affected family members. Disappointingly, negative 
LOD scores excluding linkage were obtained for two markers, D18S32 and the 
thymidylate synthetase cDNA, which mapped to this region (Figs 7.3,7.4). 
Furthermore, high resolution banding kar-yotypes of three other affected members 
were found to be normal suggesting that the observed "deletion" was a 
polymorphism.
At the commencement of this project, the APC gene had been localised but not 
cloned. Six useful markers were readily available for linkage analysis in this area 
(D5S98, D5S43, D5S81, D5S84, D5S135, SW15), and all yielded negative LOD 
scores with the exception of D5S135 which gave an ambiguous LOD score of 0.1 at 
zero recombination (Figs 7.5-7.10). Subsequently, when the APC gene was cloned, 
linkage to an intragenic marker FB40 gave a LOD score of -2.38 at zero 
recombination, demonstrating convincingly that HMPS is not an atypical variant of 
FAP(Fig.7.11).
Linkage to other candidate genes, namely DCC ( Fig.7.12 ), P53 and neighbouring 
region (Fig 7.13 ) and hMSH2 was also excluded. At the time of this study, other
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genes which predispose to HNPCC, the hMLHl, PMSl and PMS2 genes had not 
been identified.
Regions of high allele loss in DNA extracted from colorectal cancer specimens 
include the short and long aim of chromosome 6, the short aim of chromosome 8, and 
the short aim of chromosome 1. All readily available mai'kers were tested for these 
regions, including a tetrameric microsatellite repeat maiker for the LPL gene mapping 
to 8p21 (Fig 7.14), but again no linkage was demonstrated.
The complexity of DNA fingerprinting detected with multilocus probes usually 
precludes its use in linkage analysis studies between families. However, within a 
very large kindred such as St Mark's Family 96, a single band can be assumed to 
represent a single locus. If a band is then found to segregate with the disease 
phenotype, theoretically it would then bepossible, to isolate and clone the band DNA 
to make a locus specific probe which could confiim or refute linkage. The allele 
pattern obtained with probe 33.5 was paiticulai'ly interesting, in that the vast majority 
of affected patients appealed to have a missing band, as illustrated in (Fig 7.15). 
Unfortunately, this observation was not all or none in nature and probe 33.5 could not 
be used,therefore, for predictive testing.
In any linkage analysis study, even the most advanced technology is of little value in 
the presence of inaccurate pedigree information. In one experiment involving a 
highly polymorphic VNTR maiker, it appealed in one sibship, that a son had inherited 
a raie allele not possessed by either of the parents. This raised questions about the 
accuracy of the remainder of the pedigree, possible non-paternity and the mislabelling 
of DNA samples. It subsequently transpired that both the father and son in the 
sibship in question had an identical name, and that blood samples had been 
mislabelled. When this situation was claiifed, inheritance with this and several other 
VNTR and microsatellite mai'kers was found to be Mendelian, thus stiengthening 
confidence in the accuracy of the pedigree.
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The localisation of the gene responisble for disease in St Mark's Family 96 was a 
highly ambitious project that was not achieved within the two year time limit of this 
research project. Nonetheless, it has been shown unequivocally that the Hereditary 
Mixed Polyposis syndrome is not a variant of familial adenomatous polyposis, and 
linkage to other candidate genes, notably p53, MCC, DCC, hMSH2, NM23, and 
8p21“22 has been excluded. Interestingly, the highest LOD score obtained in this 
study with the marker ( D6S44) which maps to chromosome 6p21-qter (see below).
Postscript
Following this period of research. Dr Huw Thomas and Sally Cottrell from the 
Cancer Genetics Laboratory, ICRF, took the DNA samples from St Mark's Family 96 
to the Genethon Genotyping Laboratory in Paris. This laboratory has robotic sample 
and reagent handling facilities capable of setting up multiple PCR reactions for 
genetic markers spanning the entire genome. Sixteen filters from 256 microsatellite 
markers were made, which were then hybridised back at the ICRF laboratories, 
Lincoln's Inn Field, London, using one of the PCR primers as a probe in the 
Amersham ECL direct labelling and detection system. After hybridising 84 of these, a 
LOD score of 2.2 was obtained with the marker D6S283 and efforts were then 
focused on the region 6ql6-21. A significant LOD score of 3.45 was obtained with 
the marker D6S301 mapping to 6q21. Analysis of recombinants and multipoint 
linkage analysis suggests that the HMPS locus lies in a 4-cM interval containing the 
D6S283 locus and flanked by markers D6S468 and D6S301.
Thus, the hereditary mixed polyposis syndrome is a distinct autosomal dominant 
disorder linked to a mutated gene on chr omosome 6q21.
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Chapter 8
A Search for Attenuated Familial Adenomatous Polyposis in a Cohort of 
Patients with Colorectal Cancer
191
Introduction
A less severe, but phenotypically distinct variant of FAP, known as attenuated 
adenomatous polyposis coli (AAPC), has been described, in which patients develop a 
relatively low number of adenomatous polyps in the colon ( usually less than 100 ) 
(418). The number of polyps in A APC tends to vary markedly within members of the 
same family, complicating recognition of the phenotype. Like FAP, these patients 
retain an increased risk of developing colorectal cancer, but the average age at 
diagnosis is 15 year's later than in its classical form, and 10 years earlier than in 
individuals with"sporadic" colorectal cancer. A series of linkage studies in AAPC 
families have now mapped the mutant alleles to the APC locus. In total, four distinct 
mutations in the APC gene have now been identified in seven unrelated AAPC 
families . These mutations differ to those observed in classical FAP in that they are 
located very close to one another, in exons 3 and 4 near er the 5' end of the APC gene
(419,420).
A variety of methods are now available to detect point mutations in genes. The 
technique of Single Strand Conformational Polymorphism (SSCP) analysis relies on 
the fact that single stranded DNA has a folded conformation as a result of intr a-strand 
base-pairing. The electrophoretic mobility of these sequences is dependant on these 
secondary structures, which in turn are determined by the nucleotide sequence of the 
PCR products synthesised from the region of interest. If the PCR products are 
electrophoresed on denaturing polyacrylamide gels, and if the secondary structure of 
the single stranded products is altered by a mutation, a mobility shift will result, 
which can be observed as a band shift on the autoradiograph. The position of the 
single nucleotide change is then confirmed by sequence analysis, using the PCR 
primers as sequencing primers (421).
The purpose of this study was to investigate whether a small subset of ’sporadic" 
colorectal cancer might be due to mutations in exons 3 and 4 of the APC gene. SSCP
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Introduction
A less severe, but phenotypically distinct variant of FAP, known as attenuated 
adenomatous polyposis coli (AAPC), has been described, in which patients develop a 
relatively low number of adenomatous polyps in the colon ( usually less than 100 ) 
(418). The number of polyps in AAPC tends to vary markedly within members of the 
same family, complicating recognition of the phenotype. Like FAP, these patients 
retain an increased risk of developing colorectal cancer, but the average age at 
diagnosis is 15 years later than in its classical form, and 10 year's ear'lier than in 
individuals with"sporadic" colorectal cancer. A series of linkage studies in AAPC 
families have now mapped the mutant alleles to the APC locus. In total, four distinct 
mutations in the APC gene have now been identified in seven unrelated AAPC 
families . These mutations differ to those observed in classical FAP in that they are 
located very close to one another, in exons 3 and 4 near'cr the 5' end of the APC gene
(419,420).
A variety of methods are now available to detect point mutations in genes. The 
technique of Single Strand Conformational Polymorphism (SSCP) analysis relies on 
the fact that single stranded DNA has a folded conformation as a result of intra-strand 
base-pairing. The electrophoretic mobility of these sequences is dependent on these 
secondary structures, which in turn are determined by the nucleotide sequence of the 
PCR products synthesised from the region of interest. If the PCR products are 
electrophoresed on denaturing polyacrylamide gels, and if the secondary structure of 
the single stranded products is altered by a mutation, a mobility shift will result, 
which can be observed as a band shift on the autoradiograph. The position of the 
single nucleotide change is then confirmed by sequence analysis, using the PCR 
primers as sequencing primers (421).
The purpose of this study was to investigate whether a small subset of ’sporadic" 
colorectal cancer might be due to mutations in exons 3 and 4 of the APC gene. SSCP
193
dryers, and autoradiographed. The sample with an altered band was sequenced with 
the Sequenase 2.0 system ( USB, Cleveland,USA) with a single strand direct PCR 
product immobilised on streptavidin beads (Dynol,Oslo,Norway). The PCR product 
was generated with one biotinylated primer from the original DNA sample exhibiting 
the altered band.
Ologonucleotide Primers
Exon 3 Primer 1- ATGATATCTTACCAAATGATATAC
Primer 2- TTATTCCTACTTCTTCTATACAG
Exon 4 Primer 1- TACCCATGCTGGCTCTTTTTC
Results
Primer 2- TGGGGCCATCTTGTTCCTGA
SSCP analysis of exons 3 and 4 failed to demonstrate any convincing evidence of a 
mutation in the constitutional DNA of any of the 18 patients examined (Figs 8.5 and 
8.6 ). Although there was a suggestion of a band shift in lane 8 of Fig 8.6, sequence 
analysis revealed that this was aitefactual with no evidence of a nucleotide alteration.
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Patient Age Sex Pathology
1 46 F Carcinoma of Caecum
2 40 F Carcinoma of Rectum
3 44 M Carcinoma of Caecum
4 69 F Car cinoma of Sigmoid
5 50 F 50-100 Adenomas
6 51 M Carcinoma of Rectum
7 50 F Carcinoma of Rectum
8 52 F Carcinoma of Sigmoid
9 34 F Carcinoma of Rectum
10 40 F Carcinoma of Rectum
11 47 M Carcinoma of Rectum
12 26 F Car cinoma of Rectum
13 46 M 10 Adenomas
14 43 M Carcinoma of Rectum
15 41 F 6 Adenomas
16 35 M Carcinoma of Rectum
17 27 F Car cinoma of Rectum
18 40 M Car cinoma of Caecum
Table 8.1 Clinico-pathological Features of Study Population.
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Discussion
It has been speculated that AAPC may be under-recognised in the general population, 
accounting for a higher percentage of colorectal cancer than is generally appreciated. 
The patients in this study either developed colorectal cancer at a relatively eaiiy age 
or were found to have relatively few adenomas in the presence of a family history of 
CRC, and it might be anticipated that germ-line mutations in exons 3 or 4 of the APC 
gene might be present in some members of this cohort. No mutations in exons 3 or 4 
were detected by SSCP, although the study population was small, and this perhaps 
precludes any firm conclusions about the "subset" hypothesis. Some of these patients 
may have germ-line mutations in other parts of the APC gene, in the MCC gene 
nearby or even in one of the mismatch repair genes which had not been localised or 
cloned at the time of this study.
Several possibilities exist to explain why a mutation at the beginning of the APC gene 
may predispose the individual to less adenomas than is seen in mutations affecting 
exon 15. Olschwang has suggested that the two groups of mutations may define a 
functional boundary within the APC gene that determines phenotypic differences 
between APC and AAPC families (422). Most of the mutations identified in classical 
FAP have been found in exon 15 and are of the " knock-out " or nonsense variety, in 
which no useful gene product is produced. This product however may retain the 
capacity to homodimerise or complex with the normal APC gene product, causing 
almost total abolition of function. A mis sense mutation right at the start of the APC 
gene on the other hand, may generate a stop codon, leading to the formation of a very 
short peptide which is unable to complex with the APC protein, or alternatively to no 
protein product. In this event, only 50% of APC protein would be available for cell 
utilisation (222,423), leading to uncontrolled proliferation of the colorectal epithelium 
and formation of polyps. Affected individuals in the same family, however, can 
exhibit maikeds variation with regai'd the number of adenomas they develop in the
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Discussion
It has been speculated that AAPC may be under-recognised in the general population, 
accounting for a higher percentage of colorectal cancer than is generally appreciated. 
The patients in this study either developed colorectal cancer at a relatively early age 
or were found to have relatively few adenomas in the presence of a family history of 
CRC, and it might be anticipated that germ-line mutations in exons 3 or 4 of the APC 
gene might be present in some members of this cohort. No mutations in exons 3 or 4 
were detected by SSCP, although the study population was small, and this perhaps 
precludes any firm conclusions about the "subset" hypothesis. Some of these patients 
may have germ-line mutations in other parts of the APC gene, in the MCC gene 
nearby or even in one of the mismatch repair genes which had not been localised or 
cloned at the time of this study.
Several possibilities exist to explain why a mutation at the beginning of the APC gene 
may predispose the individual to less adenomas than is seen in mutations affecting 
exon 15. Olschwang has suggested that the two groups of mutations may define a 
functional boundary within the APC gene that determines phenotypic differences 
between APC and AAPC families (422). Most of the mutations identified in classical 
FAP have been found in exon 15 and are of the " knock-out " or nonsense variety, in 
which no useful gene product is produced. This product however may retain the 
capacity to homodimerise or complex with the normal APC gene product, causing 
almost total abolition of function. A missense mutation right at the start of the APC 
gene on the other hand, may generate a stop codon, leading to the formation of a very 
short peptide which is unable to complex with the APC protein, or alternatively to no 
protein product. In this event, only 50% of APC protein would be available for cell 
utilisation (222,423), leading to uncontrolled proliferation of the colorectal epithelium 
and formation of polyps. Affected individuals in the same family, however, can 
exhibit marked variation with regard to the number of adenomas they develop in the
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Chapter 9
Psychological Aspects of Familial Adenomatous Polyposis and Attitudes to
Predictive DNA Testing
" Life is not just a matter of holding a good set of cards, but of playing a poor hand
well"
Robei't Louis Stevenson
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Introduction
The cloning of the APC gene now means, that in a high percentage of cases, 
presymptomatic and even prenatal diagnosis can be offered for FAP using either 
linkage or mutational analysis (238,424). An at-risk individual who does not have the 
genotype segregating with the disease within the family has a veiy low risk of 
developing FAP, and this risk becomes even less if an integrated approach combining 
the presence of CHRPE and linked mai'kers is adopted (425). Where the mutation has 
been identified in the family, a direct test for this can be offered to at-risk relatives, 
with a very high degree of accuracy. Two questions now need to be addressed.
What do people with FAP think the best age to offer predictive DNA testing for FAP 
in their at-risk children is?
How acceptable is antenatal testing and selective termination of pregnancy for FAP 
for couples at risk of having affected children?
The answers to these questions will undoubtedly be influenced by psychological 
factors, perception of disease severity and philosophical, personal and religious 
attitudes to predictive DNA testing and termination of pregnancy. In turn, the 
perception of the severity of the disease and its subjective effects, ai'e likely to be 
sti'ongly affected by the individual's previous experience of FAP. In haemophilia, it 
has been shown that a woman's perception of the pros and cons of prenatal diagnosis 
is sti'ongly influenced by personal experience of the course of the disease in closest 
male relatives (426).
This study was initiated before predictive DNA testing for FAP was readily available 
and was still a relatively new concept. Its puipose was to assess the psychological 
impact of FAP and patient attitude to predictive testing.
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Patients and Methods
Sixty-three patients with FAP who attend the out-patient department of St Mark's 
Hospital, London on a régulai' basis, were invited to paiticipate in the study and 62 ( 
33 male, 29 female) agreed. The median age of the patients was 38 year's (range 19- 
67 year's). Each patient had undergone prophylactic colectomy. 55 patients had an 
ileorectal anastomosis, 4 patients had a restorative proctocolectomy with ileoanal 
pouch formation, and 3 patients had a panproctocolectomy with formation of a 
permanent end ileostomy. 29 patients had children, of whom 10 had children in 
whom FAP had been diagnosed. The remainder had children whose disease status 
was still uncertain.
The Modified Illness Effects Questionnaire
Psychological responses were elicited in a semi-structured interview using the 
Modified Illness Effects Questionnaire (MIEQ), a 20 item scale that assesses the 
individual's perception of how the subject's illness interferes with, or affects personal 
and social behaviour ( Table 9.1). The statements were specifically designed to 
assess feelings of anxiety, depression, relationship disturbance, preoccupation with 
illness and alienation with the health professions. The MIEQ was based on a 
previously validated Illness Effects Questionnaire (427) which has been shown 
accurately to assess cognitive depression (428). It was modified and tailored to assess 
emotional problems specifically anticipated to be relevant to FAP patients. Level of 
psychological distress was quantified using a scoring system, ranging from zero, 
correlating with no distress, to 60, correlating with maximum distress. The 
statements were read to the patients who were asked to respond ; the same clinician 
interviewed all 62 patients. Only 4 possible response options -agree, strongly agree, 
disagree and strongly disagree-were offered to the patients to minimise " fence- 
straddling", and several statements were polaiised e .g ., " Having polyposis is the 
biggest difficulty in my family" or "Having polyposis has helped me get more out of
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life". Each patient was given the opportunity to discuss their illness openly, and any 
additional anxieties were documented.
Patients were also asked if they understood the chances of their children inheriting 
polyposis.
Attitude to Predictive DNA Testing
The following questions were employed in a semi-structured interview by the same 
interviewer;
If you knew it was possible to diagnose FAP in the early weeks of pregnancy, would 
you ask your doctor if you could have the antenatal test, and if so, why?
If the test showed that the unborn baby was affected by polyposis would you proceed 
to termination of pregnancy, and if so, why?
If it was possible to diagnose polyposis in eaiiy childhood by performing a blood test, 
would you want your own children tested at:
a) Birth b) Infancy c) 10-14 years d) never e) don't know?
At what age do you think children should be intr oduced to the concept of polyposis?
Statistical Analysis:
This was performed using the Mann-Whitney U test and Chi squared test with Yates 
correction.
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Results
The Effect of FAP on Relationships
Fifty patients ( 80%) stated that FAP caused no tension between themselves and other 
members of their family, while thirty-four (54%) felt that FAP had actually drawn 
the family closer together. Twelve patients (19%) felt that a significant degree of 
tension had been created between family members, and five (12%) directly attributed 
the disintegration of their families to FAP. Two girls in their late teens ran away from 
home because they thought they would develop FAP, and one patient stated that her 
sixteen yeai' old son would leave a room whenever the disorder was mentioned. 
Another woman's husband left home, the day she told him of her diagnosis. Four 
patients volunteered that relationships outside the family had been discouraged by 
prospective in-laws when the genetic and premalignant nature of FAP was explained 
to their partner.
Satisfaction with Medical Caie
Twenty patients (32%) felt that the doctors looking after them did not understand 
what it was like to suffer from FAP. Five patients (8%) were resentful that 
unnecessaiy suffering had been endured as a result of delayed diagnosis in other 
hospitals, or their illness mismanaged as they perceived it, expressing feelings of 
insecurity when being treated by doctors other than those associated with St Mark's 
Hospital.
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Preoccupation with Illness and Anxiety
Twenty-five patients (40%) stated that polyposis was always at the back of their 
mind, and twenty patients (32%) stated that Polyposis made them very concerned 
about the future.
Depression
Twenty patients (32%) stated that having polyposis occasionally made them feel 
depressed, but only three (4%) stated that it often made them depressed.
Hobbies and Jobs
Eight patients (12%) felt that post-operative side effects of colectomy significantly 
interfered with their work, jobs or hobbies. One patient treated by subtotal colectomy 
and ileorectal anastomosis, experienced problems of diairhoea postoperatively and 
was sacked by his employer because of frequent visits to the toilet. Another patient 
gave up his job as a postman because frequency of diarrhoea episodes made it 
impractical for him to continue.
Guilt and Blame
Six out of ten individuals with affected children spontaneously volunteered that they 
had strong guilt feelings about passing on the gene.
The response of the study population to the statements in the MIEQ is shown in Table 
9.1, and the correlation of MIEQ scores with variable studied is shown in Table 9.2.
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Attitudes to Prenatal DNA Testing
Forty patients (64.5%) stated that they would request prenatal testing if it was 
possible to diagnose polyposis in the eai'ly weeks of pregnancy; of these, fifteen 
(24%) (7 men, 8 women) stated that they would proceed to termination of pregnancy 
if the unborn baby was affected.
Of the 15 patients who said they would opt for prenatal testing and termination of 
pregnancy if the unborn baby was diagnosed as likely to be affected, 2 (13%) were 
under 30 years. Of the 39 who would not consider termination, 23 ( 59%) were under 
30 years ( p < 0.01).
Individuals who stated that they would opt for termination had significantly increased 
MIEQ scores relative to those who would not ( p < 0.005).
Six of the 15 (40%) of the patients who said they would opt for termination had 
affected children compared to 4/39 (10%) who would not ( p < 0.01 ).
Ten of the 15 patients (66%) who would opt for termination had at least one FAP 
related death in the family compared to 13/39 (33%) who did not ( p < 0.05).
These results are summarised in Table 9.3.
Reasons volunteered for opting for prenatal testing and termination were as follows:
Six patients who had previously refrained from having children for fear of passing on 
the polyposis gene, felt that the option of prenatal testing would enable them to 
consider planning a family, which they would otherwise not have done.
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Six patients who had affected children stated that they felt very guilty about passing 
on the polyposis gene, and felt that had the prenatal option been available, a great deal 
of unnecessary suffering might have been prevented.
Three patients who had children of unknown disease status said that they were very 
worried about the possibility of passing on the faulty gene, and felt that prenatal 
testing could have removed this chionic source of worry from their lives.
Patient opinion on the most suitable age to introduce the subject of polyposis to their 
children.
51/62 patients discussed this issue. The results are summarised in Table 9.5.
211
Table 9.1 Response of Subjects to Statements in Modified Illness Effects 
Questionnaire;
SD = strongly disagree, D = disagree, A = agree, SA = strongly agree
1) Having polyposis has caused tension between myself and at least one member 
of my family.
Response SD D A SA
Total 44 6 7 5
Men 22 3 3 5
Women 22 3 4 0
2) Having polyposis has drawn me closer to some members o f my family. 
Response SD D A SA
Total 19 9 13 21
Men 11 7 9 6
Women 8 2 4 15
3) Having polyposis has affected my decision to have children 
Response SD D A SA
Total 21 17 15 9
Men 9 8 9 7
Women 12 9 6 2
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4) Having polyposis prevents me from enjoying life to the fu ll  
Response SD D A SA
Total 45 12 1 4
Men 24 7 0 2
Women 21 5 1 2
5) Having polyposis has helped me to get more out o f life, and has put 
other problems in perspective.
Response SD D A SA
Total 24 12 6 20
Men 12 7 5 9
Women 12 5 1 11
6) Having polyposis makes me worty about the future.
Response SD D A SA
Total 21 21 6 14
Men 10 10 4 9
Women 11 11 2 5
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7) Having polyposis isn't such a big deal
Response SD D A SA
Total 14 15 14 19
Men 5 9 5 14
Women 9 6 9 5
8) The thought o f polyposis is always at the back of my mind. 
Response SD D A SA
Total 12 25 11 14
Men 7 12 4 10
Women 5 13 7 4
9) Having polyposis is not as bad as having some other conditions. 
Response SD D A SA
Total 1 4 40 17
Men 0 1 18 14
Women 1 3 22 3
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10) Having polyposis occasionally causes me to get depressed.
Response SD D A SA
Total 13 29 17 3
Men 7 15 10 1
Women 6 14 7 2
11) Having polyposis often causes me to get depressed.
Response SD D A SA
Total 36 23 1 2
Men 19 13 0 1
Women 17 10 1 1
12) Coming to hospital at regular intejwals for a check-up is stressful.
Response SD D A SA
Total 15 28 6 13
Men 8 19 3 3
Women 7 9 3 10
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13) Doctors do not understand what it is like to have polyposis 
Response SD D A SA
Total 13 23 11 15
Men 6 13 8 6
Women 7 10 3 9
14) Having an internal examination when 1 come to hospital is stressful 
Response SD D A SA
Total 6 26 12 18
Men 4 15 7 7
Women 2 11 5 11
15) Coming to hospital for regular check-ups makes me feel emotionally 
dependant on other people
.Response SD D A SA
Total 33 21 8 0
Men 18 10 5 0
Women 15 11 3 0
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16) Having an opera tion for polyposis was the worst thing that ever happened to 
me.
Response SD D A SA
Total 16 22 8 16
Men 11 12 5 5
Women 5 10 3 11
17) Having an operation for polyposis has left me with symptoms which 
significantly affect my quality o f life.
Response SD D A SA
Total 21 27 10 4
Men 13 15 4 1
Women 8 12 6 3
19) Because of polyposis, I don't work as well at my job, work or hobbies.
Response SD D A SA
Total 36 18 4 4
Men 17 12 2 2
Women 19 6 2 2
I l l
20) All things considered, polyposis is the biggest difficulty in my life 
Response SD D A SA
Total 34 20 3 5
Men 16 14 2 1
Women 18 6 1 4
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Those who said 
they would opt for 
selective 
termination of 
pregnancy
Those who would 
not consider 
termination of 
pregnancy
Undecided
Number 15 39 8
Age of patients
< 30 yeai’s 2 (13%) 23 (59%) 5 (63%)
30-50 yeai's 5 (33%) 10 (26%) 3 (38%)
> 50 years 8 ( 53%) 6 (15%)
No. who had 
children
9 (60%) 20(51% )
No. who had one 
affected child
4 ( 26%) 2 (5%)
No. who had more 
than one affected 
child
2 ( 13%) 2(5%)
No. who had an 
extracolonic 
complication 
themselves
2 (13%) 1 (2.6%)
No. who had FAP 
related death in 
family
10 (67%) 13 (33%) 1 (12.5%)
Table 9.3 A suminaiy of features in relation to patient attitude to prenatal testing 
and termination of pregnancy.
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Age of Child( yeai's) Number of Patients
Under 10 3
10 20
11 2
12 6
10-12 7
13-14 13
Over 14 1
Table 9.4 Patient opinion on most suitable age to inform children about 
polyposis.
221
Discussion
Although, the psychology of some genetic diseases has been well documented, as has 
the emotional trauma associated with a cancer diagnosis, surprisingly little is known 
about the psychological impact of FAP on affected individuals and their families. An 
FAP patient has to cope with both the genetic and cancer aspects, so clearly FAP 
could have a devastating effect on the lives of some patients. Indeed an increased 
incidence of suicide in this disorder has been noted by some authors (15,429).
The newly diagnosed FAP patient has many conflicting emotions to cope with.
Firstly, the majority of patients diagnosed by screening in a family with other affected 
relatives, are asymptomatic at diagnosis, and cannot be expected to find it easy to 
adopt the "sick role" associated with symptomatic illness. Accepting that colectomy 
is necessary may cause resentment, and denial may become a dominant feature of the 
coping response. Secondly, patients with FAP may be confronted with the 
possibility of cancer when they ar e children. For most people, cancer continues to 
have alarming connotations, creating considerable uncertainty and fear- and this may 
be exacerbated by memories of cancer death or prolonged illness within the family. 
Finally, the patients will facethe possibility of passing the polyposis gene on to their 
own children. This may become a source of agonising choices and guilt, particulalry 
if the patients have suffered some serious complications of FAP. Taken in 
combination, these factors might be expected to reduce self esteem and cause 
depression .
Being an hereditary disorder, it might be anticipated that FAP would generate 
emotional tension within the family unit. Affected children might blame their parents 
for inheriting the gene, and parents might feel guilty about passing the gene on. 
Surprisingly, the majority of patients in this study stated that FAP had either drawn 
the family closer together or caused no tension, an effect observed in non-hereditary 
illness (430). A significant minority (20%) however felt that tension had been created
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between family members, and the fact that two individuals felt that their families had 
disintegrated as a result of FAP, illustrates the devastating effect this illness can 
have in some cases. FAP may also have an effect on inter-personal relationships 
outside the family, as four patients stated that their prospective in-laws had 
discouraged the relationship when the genetic and premalignant nature of FAP was 
raised, illustrating the often underestimated stigmatising effect of genetic disease. 
Complicating the issue further is the ambivalent attitude of some FAP patients to 
having children. Hence, relationship problems may only be experienced by a 
minority, but when they do, they may have far reaching consequences.
Most patients in this study did not perceive themselves as being depressed. 
Nonetheless, there was a significant degree of illness preoccupation and concern 
about the future, suggesting that FAP directly affects emotional well being.
The presence of a family history of FAP per se did not significantly raise 
psychological distress ( p = 0,76), but there was a strong correlation between distress 
and FAP related death with the family ( p = 0.0001). Previous unpleasant experience 
of an ileostomy within the family, or a perception of receiving inadequate or 
inappropriate medical treatment at some stage, was also significantly associated with 
higher MIEQ scores ( Table 9.2)
It has now become routine practice at St Mai'k's Hospital to refer all FAP patients or 
at-risk individuals for professional genetic counselling. At the onset of this study, 
some affected individuals had not received such counselling, and neaiiy 20% of the 
those interviewed did not understand the manner in which FAP is inherited. Some 
patients believed that only boys could be affected, while others thought that they 
could not pass on the gene again if they already had an unaffected child. A poor 
understanding of the mode of ti'ansmission of FAP cleaiiy aggravates emotional 
distress, as all the patients in this categoiy had significantly raised MIEQ scores (p =
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000.1). This illustrates that even disorders with an apparently straightforwai'd mode 
of transmission may be difficult for patients to understand.
Attitudes to Predictive Testing.
Individuals with FAP may wish to know the results of their children's predictive tests, 
in order to spare those found to be at low risk unnecessary screening procedures and 
to relieve personal guilt and uncertainty. Adults at risk of developing FAP are clearly 
concerned about their own risk of developing cancer, and this may explain the high 
uptake of DNA testing in this group which at St Mark's Hospital approaches 100%.
By compar ison, the uptake of predictive testing in Huntington's Disease (HD) may be 
less than 20%, this difference being due to the fact that people consider FAP treatable, 
whereas there is currently no treatment for HD (431,432).
With regar d to prenatal testing, although 40 patients (64%) in this study stated that 
they would make use of prenatal testing if it was available, only 15 (24%) said that 
they would consider termination of pregnancy if the unborn baby was affected. This 
finding is similar' to a previous report of a cohort of people with FAP, where 15/25 
(60%) affected individuals said they would consider prenatal testing, but only 4(16%) 
would consider the termination option (433). Individuals who were over 30 years, 
who already had an affected child or had a history of FAP related death in the family 
were more likely to state that they would opt for prenatal testing and termination, and 
it is possible that these patients perceived FAP differently as a result of the emotional 
distress they associated with the disorder. In practice, none of affected individuals 
attending the St Mark's Polyposis Clinic in the last 4 years has requested prenatal 
testing, although only 2/62 interviewed, have yet to be in a position to request this 
service. A marked discrepancy between statement of intent and actual uptake in 
clinical practice has been observed in Huntington's disease, and it is possible that this 
also may occur in FAP (434). Factors influencing patient opinion may change over a
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period of time. Most patients under 30 yeais in this study do not know yet whether 
their children aie affected, and more complete ascertainment of at-risk individuals by 
polyposis registries should reduce death from colorectal cancer. The prenatal option 
may be taken up by the small group of patients who had previously refrained from 
having children for fear of passing on the gene.
There was a widespread feeling among the interviewees that children should not be 
told about polyposis until they were "old enough to understand Most parents 
considered between 10-12 years to be the most appropriate age to introduce the 
subject, as they did not feel it was fair to "spring" the diagnosis at the often 
emotionally turbulent time of puberty. However, it is interesting that 58/62 (93%) 
wished to test their children at birth and withold this information from them for a 
decade.
The predictive testing of children for adult onset disorders is a complex issue. Present 
consensus is that it cannot be justified ethically or morally for disorders such as 
Huntington's Disease where symptoms are raie in childhood and there is no treatment 
(435). In the case of FAP however, diagnosis before 18 yeai's is frequently necessary 
to prevent the onset of colorectal cancer, and screening in most centres, already 
begins before the legal age of consent. It is thus logical to test them at least by the 
time clinical screening would be instigated.
A majority of parents (58/62) stated that they would request testing of their children 
at birth/infancy if it was available, and this finding was consistent with a previous 
report from Germany, where most parents wanted testing performed before the age of 
10 year's (436). Reasons given included 1) removing ambiguity about the disease 
status of their children, which some par ents felt was a chronic source of stress and 2) 
satisfying parental curiosity. Medical management before puberty however is 
unlikely to be altered by the information predictive testing provides, and it is difficult 
therefore to envisage any clear' advantage for the child. Furthermore, ear'ly testing 
may distort par ent-child or sib-sib relationships, damage the child's self esteem,
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remove the child's right to decide about testing at a later age and generate 
unwarranted anxiety about unrelated symptoms. Who is to judge what is in the best 
interests of the child in this situation, and what limits, if any, should be placed on 
parental autonomy?
Conclusions
In the majority of cases, FAP would appear to have a fairly minimal impact on the 
everyday life of the patient. However, in a significant minority ( 20%), a diagnosis of 
FAP can have a devastating effect on psychological well-being. Factors which might 
be important include previous unpleasant experience with an ileostomy, history of 
cancer death within the family, a poor understanding of the mode of transmission of 
FAP, delayed diagnosis and perceived medical mismanagement.
Hopefully, with earlier diagnosis, the widespread establishment of polyposis 
registries, improved genetic counselling and an increased awareness of genetic illness 
in general by general practitioners, it might be possible to prevent some of this 
distress in the future, and identify those who require additional psychological support.
The majority of patients stated that they would not consider prenatal testing and 
termination of pregnancy under any circumstances, but a significant minority (25%), 
felt that they would take up such testing. However,in practice, nobody has yet taken 
up this option.
Although, most parents stated that they would like their children to have DNA testing 
at birth or in infancy, in general such testing should probably be deferred until the 
age at which endoscopic surveillance was to commence- about 10 years- unless 
clinical symptoms suggest eaily onset of FAP polyps which can occasionally occur 
before 10 years. However, there are as yet no data to support any view regarding the 
optimum age to perform predictive testing.
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Cai'eful long term assessment and documentation of the impact of predictive testing 
will be needed in FAP, as in the rapidly increasing number of other single gene 
disorders for which DNA testing is now available.
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Chapter 10 
The Prognostic Value of Allele Loss in Colorectal Cancer
" Malignancy is essentially a clinical concept; in research it becomes a menace if it implies
an indivisible, invariable entity or quality It is not enough to label a tumour malignant;
it is necessary to specify which characteristics, and the degree of each of them, that make it 
malignant " (437)
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Introduction
The ideal prognostic indicator in colorectal cancer would be one which was able to predict 
with a high degree of accuracy the likelihood of survival after " curative" surgery. Such a 
rnar'ker would enable patients to be polarised to favourable and poor prognostic groups, and 
statistical benefit for new treatment modalities could be demonstrated in studies with fewer 
patients over a shorter time period. Identifying such an indicator has proven an elusive 
goal. Dukes' staging, described over sixty year s ago, remains the mainstay of prediction in 
everyday practice (438) yet predicts by implication only, the presence of distant occult 
métastasés, now recognised as the principal determinant of survival in this malignancy 
(305). The Jass pathological scoring system provides more accurate prognostic information 
for rectal cancer in some hands (439), but still suffers from problems of subjective 
interpretation (440).
The idea that molecular markers may be valuable in assessing cancer prognosis was first 
proposed in the 1970s (441,442). Most interest has centred on the value of DNA ploidy, 
cell cycle kinetics and irmnunohistochemical detection of oncogene products, but these 
par ameters have yielded conflicting and contradictory results, and are not considered yet 
reliable enough for routine clinical practice (443-447).
The predictive value of tumour suppressor gene inactivation, on the other hand, 
measured by loss of heterozygosity (LOH) or allele loss on Southern blot analysis, 
has received relatively scant attention, being the subject of only 5 reports in the 
literature (179,448-450). These studies have focused on chromosomal regions 17p,
18q and 5q which contain genes directly implicated in colon carcinogenesis (148).
The purpose of this study was to investigate further the prognostic significance of allelic 
deletion at the P53, APC DCC and Nm23 loci in colorectal cancer.
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Materials and Methods
Material for this study was obtained from 70 patients with colorectal cancer admitted to St 
Mai'k's Hospital, London between 1987 and 1990. It included 40 male and 30 female 
patients with a median age of 65 years (range 27-103 yeai’s). Follow up was based on 
regular clinical examination, liver ultrasonography and computerised tomographic scanning 
when indicated. Median observation time was 36 months (range, 2-66 months ). Six 
patients, who lived abroad, were lost to follow-up, and one patient, who died from a 
pulmonary embolism on the second post-operative day, were excluded from the study. 
Tumours were located proximal to the mid-transverse colon in 8 cases, in the sigmoid in 23 
cases, and in the rectum in 32 cases. Ten percent of the tumours were Dukes' stage A, 43 % 
stage B, 30% in C l, and 16% in C2. 55% fell into Jass staging system groups III and IV, 
and the remainder into groups I and II.
Tumour tissue and normal mucosa was obtained from each patient at surgery, snap frozen 
and stored in liquid nitrogen at -700 q Necrotic and non neoplastic tissue was removed 
from the tumour samples as completely as possible, and tissue adjacent to the tumour 
sample from which the DNA was extracted was sent for histological confirmation of 
malignancy.
DNA Extraction.
Tissue specimens were bathed with liquid nitrogen and ground to a powder. High molecular' 
weight DNA was extracted from each tissue specimen using phenol-chloroform and 
precipitated with ethanol as previously described.
Southern Blot Analysis
This was performed as previously described.
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Genetic Probes
Six probes were chosen to investigate LOH at the APC, DCC, P53, and NM23 loci.
These were: YNZ22 (D17S5), YNH37.3 (D17S28) P144D6 (D17S34), OLVIII 10 
(D18S8), FB40 (D5S135) and Nm23-Hl (D17S308).
Densitometric Scanning of Autoradio graphs
When LOH was not obvious on visual inspection, LOH was quantitated by scanning of the 
autoradiograph using an imaging analysis system ( Imaging Research Inc.) consisting of an 
IBM PC AT computer linked to a Sony CCD video camera and running BRS2 image 
analysis softwai*e. From the scans the ratios of the two alleles in tumour material to those in 
normal matched tissue were estimated (T1/T2 divided by N1/N2) (125). A cut-off level of 
50% or more reduction in intensity of the bands was taken as evidence of LOH.
Clinical Data
This was obtained by reviewing clinical and out-patient records. In some cases survival data 
was obtained by contacting the patient's general practitioner.
Statistical Analysis
To determine whether any of the genetic abnormalities detected were related to the clinical 
variables, tables of these parameters were constructed, and Chi square tests ( or Fisher exact 
tests where numbers were small ) calculated. To determine whether allelic deletion was 
prognostic for survival, Kaplan-Meier curves were drawn and the log rank test was 
calculated for all the gene abnormalities and the clinical features. For the purpose of 
analysis, tumour site was coded as Rectum, Sigmoid or Other, Dukes' stage as A, B, Cl and 
C2, and site of metastasis as liver or other. Those variables with a p value of less than 0.1 
were put into a stepwise Cox regression model to determine which, if any, was 
independently prognostic for survival. The end date for analysis was taken as February 93.
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Results
Genetic Alterations in Tumours
Tliis study included 63 coloreetal cancers. In total 25 patients developed distant métastasés 
(16 liver, 6 peritoneum, 1 lung, 2 brain). Overall median survival of this group was 21 
months (range 2-70 months). Hepatic métastasés, were diagnosed at the time of surgery in 
12 patients; 2 of which aie alive and well at 47 and 70 months.
All the patients were informative for at least one marker, and of these 37 (58.7%) 
demonstrated LOH. A moleculai' genetic profile for tumour 529 which was informative for 
all 6 markers is shown in Fig. 10.1. .Ninety-eight per-cent of patients were informative for a 
mai’ker on 17p. LOH was seen more commonly on 17p (48.3%) than at the APC locus 
(38.8%), but was relatively infrequent at the DCC locus (38,7%). No LOH was observed at 
the Nm23 locus. (Table 10.1). Only 5 tumours had LOH at the loci on chromosomes 5q,
17p and 18q (Fig 10.1). On chromosome 17p, the highest percentage of LOH was observed 
with probe YNZ22, the maiker in this study lying most close to the p53 gene. No difference 
was observed in the moleculai* genetics of those with métastasés diagnosed at operation and 
those with occult métastasés.
Genetic Alterations in Relation to Clinical Valuables.
There were 48 patients with Dukes’ B or C tumours who were informative for a 17p marker, 
and who did not have evidence of distant métastasés at the time of surgery. Twenty-two 
patients had 17p LOH and of those 8 (36%) developed métastasés. Twenty-six patients 
retained the 17p alleles, and of these 5(19%) developed métastasés (p = 0.003)
LOH on chromosome 17p was also found to be significantly associated with Dukes' stage 
and Jass seore. LOH at chiomosomes 5q and 18q was not found to be associated with any 
of the clinical variables studied (Table 10.2).
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Genetic Alterations in Relation to Post-operative Survival
Univariate analysis of survival was performed for each of the genetic abnormalities and 
Kaplan-Meier curves were constructed. 17p LOH had prognostic significance ( Fig 10.2 ), 
as did age, Dukes' staging and Jass score (Table 10.3 ). LOH at the 5q andlSq loci was not 
related to survival ( Figs. 10.3,10.4). The tumour of the patient who survived 47 months, 
exhibited LOH at both the 17p and 18q loci, while the tumour of the patient alive and well 
at 70 months retained 17p, but was uninformative at thelSq locus.
Prognostic value of Jass scoring svstem versus Dukes' staging
In this small series, the Jass scoring system proved to be slightly better at predicting 
prognosis than Dukes’ staging ( p < 0.0001 vs. p = 0.0006 respectively) ( Figs. 10.5,10.6)
Multivariate Analysis.
Age, Jass score and LOH 17p were found to have a p value < 0.02 on univariate analysis for 
survival, and were therefore entered into Cox's regressional model. In this analysis only age 
and Jass score were independently prognostic (Table 10.4)
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Figure 10.1 The Molecular Profile o f Tumour 529. T = Tumour, N = Normal.
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Specimen Genetic Marker
D5S135 D17S34 D17S28 D17S5 DÎ7S308 D18S8
324 0.97 1.00 0.98 0.99 H 1.03
338 0.95 0.92 0.89 0.32 H 1.00
344 0.41 0.33 0.96 0.88 1.01 0.39
406 H 0.58 0.86 1.01 H
456 1.03 0.23 H 0.97 H 0.44
500 H H H 0.96 H H
506 H 0.46 0.40 0.39 0.87 H
509 0.76 0.82 1.01 H 1.00 0.91
522 1.00 0.95 H H H H
529 0.18 0.23 0.16 0.26 H 0.14
533 0.14 0.21 0.15 0.12 H 0.22
540 H 0.92 0.97 0.97 0.97 1.02
556 0.22 0.40 0.99 0.96 H H
562 H 1.00 0.98 0.99 0.88 0.34
563 H 0.33 0.25 0.31 H H
Table 10.1 Scanning Densitometry Measurements of matched
Tumour/Normal DNA pairs . H = Homozygous.
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Specimen Genetic Mai'ker
D5S135 D17S34 D17S28 D17S5 D17S308 D18S8
571 0.88 H 0.91 H H H
587 0.32 H H 0.36 0.99 H?
596 H H H H 1.03 1.04
638 H 0.96 0.32 0.23 H 0.96
708 0.85 0.90 H 0.24 0.95 0.29
715 H 0.98 H 0.31 H 0.92
717 H 0.90 H 0.88 0.94 0.94
734 H 0.33 H 0.28 0.94 H
762 0.41 H 1.01 H H H
769 0.34 0.38 0.24 0.31 H H
776 H 0.86 H 0.79 H H
778 H 1.00 1.01 H H 0.93
838 0.90 H H 0.96 1.02 H
860 0.45 1.01 H 0.99 H 0.79
864 H H 0.83 H H H
Table 10.1 Scanning Densitometry Measurements of matched Tumour/Normal 
DNA pairs
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Specimen Genetic Marker
D5S135 D17S34 D17S28 D17S5 D17S308 D18S8
880 0.37 1.17 H H H H
890 0.95 0.93 H H H H
904 H 0.22 H H 0.93 H
906 H 0.98 H H H H
927 0.88 0.91 H H 0.90 H
930 1.00 0.96 0.98 1.02 0.99 0.98
937 0.25 0.97 0.89 0.21 H 0.31
960 H 1.03 1.01 0.97 H 0.91
961 H 0.13 H 0.17 H H
966 0.99 0.49 0.86 0.88 H H
968 0.98 H H 0.34 0.96 H
973 0.91 H 1.02 0.40 H H
980 0.96 0.93 H 0.96 1.00 H
982 0.35 1.04 0.99 1.00 H 0.84
1000 H 0.98 H 0.93 H 0.28
1011 0.38 0.42 0.36 0.40 H H
Table 10.1 Scanning Densitometiy Measurements of matched Tumour/Normal 
DNApairs
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locus probe location No. of tumours No.(% )with
informative LOH
D17S5 YNZ22 17pl3.3 48 (76%) 23 (47.9%)
D17S34 P144D6 17pl3 52 (82.5%) 21 (40.3%)
D17S28 YNH37.3 17pl3 30 (47.6%) 10 (33.3%)
D17S308 Nm23-Hl 17q21 24 (34.7%) 0
D5S135(APC) 54D 5q21 36(57%) 14 (38.8%)
D18S8 (DCC) OLVHEIO 18q21.3 31 (49.2%) 12 (38.7%)
Table 10.2 Loss of heterozygosity in colorectal cancer specimens.
clinico-pathological features 17p 18q 5q
p value from exact test
sex 0.2 0.3 0.07
site 0.8 0.7 0.8
Jass 0.002 0.4 0.6
Dukes 0.004 0.1 0.7
distant metastasis 0.003 0.06 1
metastasis site 0.03 1.0 0.6
Table 10.3 Summaiy of univaiiate analysis relating molecular genetic findings 
to clinical variables.
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clinical feature X2 df P
17p 5.7 1 0.02
18q 1.1 1 0.3
5q 0.2 1 0.7
sex 0.0 1 1.0
age 8.2 2 0.02
site 0.9 2 0.6
Jass 21.4 3 < 0.0001
Dukes 14.8 2 0.0006
Table 10.4 Summary of univaiiate analysis relating histo-patliologicai variables 
with survival.
variable coding hazai'd ratio 95% Cl P
age continuous 1.05 (1.01,1.09) 0.01
Jass I vs. IV 11.7 (2.5,54.2) < 0.001
II vs. IV 3.9 (1.5,15.3)
III vs. IV 6.5 (1.7, 11.6)
Table 10.5 Summaiy of multivariate analysis investigating relative prognostic 
value of 17p, age and Jass scoring system. The p value given for 
Jass is that for linear trend across all Jass scores.
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Discussion
The molecular genetics of colorectal cancer is possibly the most well characterised of any 
common adult malignancy, yet the precise biological mechanisms which underlie metastasis 
of these tumours, remain poorly understood. It is hypothesised that certain alterations in 
DNA sequence in a sub-population of cells within the tumour, may confer an increased 
capacity for metastasis (451). Identification of such alterations may lead to the development 
of more accurate prognostic indicators.
Loss of heterozygosity (LOH) can be detected either by Southern analysis (199) or by the 
polymerase chain reaction by examining DNA from matched tumour/constitutional samples 
(135). This study is one of 6, collectively involving over 400 patients, that have addressed 
the possibility of using LOH at candidate loci as prognostic indicators of survival in 
colorectal cancer (179,448-450,453,). A further study has looked at the relationship 
between LOH and the development of metastasis, but contains no information about patient 
survival (454). Two studies have observed that LOH on chromosome 17pl3 is 
independently associated with shortened survival, thiee have found a similar* association 
with LOH at the DCC locus on chromosome 18q, and one study has reported an association 
between survival and LOH at the NM23 locus on chromosome 17q (Table 10.6).
The observed frequency of LOH at thel7p and 18q loci ( Table 10.3) was similar* to that in 
some reports (454,455), but less than reported in other series. A frequency of LOH at the 
APC locus of 38% was broadly consistent with other published data (144,454,449,) 
suggesting that stromal contamination of the tumour specimen with normal tissue, which 
might mask LOH, was not the main reason for the lower* than expected LOH observed at the 
17p and 18q loci.
On univariate analysis, 17p LOH was found to be statistically related to age at diagnosis, 
Dukes' staging and Jass score (Table 10.4), and these factors were also related to shortened 
survival (Table 10.4). However, the 17p LOH correlation disappeared when entered into the
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multivariate regressional analysis model (Table 10.6), supporting the findings of two other 
reports (448,450).
The lack of relationship between 5q LOH and survival ( Fig. 10.3) was consistent 
with all previous reports, and was expected as the APC gene is believed to mutate at 
an early stage in the adenoma-carcinoma sequence. In contrast to three other studies 
(448,449,453)no relationship was noted between 18q LOH and survival ( Fig. 10.4), 
although the data set was too small for detailed evaluation.
In one report involving 21 large bowel cancer patients with no evidence of distant 
métastasés at the time of initial operation, 8 of 11 patients whose tumours had LOH at 
the Nm23 locus, subsequently developed metastatic liver disease (450). Yet in a 
further study, using a ribonuclease protection assay, no mutations were detected at the 
Nm23 locus in 26 metastatic colon cancers, 17 non metastatic colon cancers, or 43 
matched normal controls (455). Furthermore, Nm23 gene expression was elevated 
almost as often in metastatic as in non-metastatic cancer. Twenty-four of the patients 
(34.7%) in our study population were informative for the Nm23-Hl probe, but no 
LOH was detected. Other investigators, using microsatellite repeat markers for the 
Nm23 gene, have also been unable to demonstrate LOH at this locus (456).
Although, the use of LOH at specific loci as prognostic indicators is still in its 
infancy, it is cleai*, that the results of these studies are fai* from reproducible between 
different centres. One explanation may be that the moleculai* genetics of proximal 
and distal cancers of the colon differs (178) and there was mai*ked vaiiation in tumour 
distribution between the studies and/or vaiiable length of follow-up ( Table 10.7). 
Nonetheless, a pattern may be emerging in that 18q LOH had prognostic value in the 
studies with a high proportion of right sided cancers, while 17p LOH had some 
prognostic value in those studies in which the majority of tumours were left sided 
(Table 10.7).
247
In conclusion, this study is suggestive but not confirmatory that LOH on the short aim 
of chromosome 17 may serve as an independent marker of tumour aggressiveness in 
colorectal cancer. The data set was of insufficient size to fully evaluate genetic 
changes at the 5q or 18q loci, but there was no evidence that analysis of the Nm23 
gene would provide any useful prognostic information.
Further studies involving a much lar ger series of patients, which stratify genetic 
alterations by site, and use standardised methodology, are now needed to claiify 
whether such data can be interpreted in a meaningful manner for routine use in 
clinical practice.
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Chapterll 
Future Prospects
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The combined tools of moleculai’ genetic markers and fibre-optic technology now 
provide us with an unpaialleled opportunity to reduce morbidity and mortality from 
colorectal cancer.
Presymptomatic diagnosis is now possible for the majority of individuals at risk of 
developing FA? and for many individuals at risk of developing HNPCC. It seems 
probable that in the near future, predictive DNA testing will also be possible for the 
other highly penetrant hereditary colorectal cancer syndromes such as juvenile 
polyposis and the Peutz-Jeghers syndrome. This will enable gene carriers to be 
identified eaiiy and treated appropriately, while those not carrying a predisposing 
mutation can be spared many years of unnecessary anxiety about their health, as well 
as that of their children. Many questions remain unanswered, however, regarding the 
most appropriate way to apply this technology. Genetic epidemiologists need to 
determine the exact population frequency and penetrance of the different mutations 
within families before accurate prediction can be made for gene carriers, and 
functional assays will have to be developed to distinguish true nrutations from 
harmless polymorphisms. Furthermore, safeguards will need to be put in place to 
prevent uncontrolled predictive DNA testing leading to stigmatisation in 
employment, insurance and interpersonal relationships. The issue of genome 
"ownership" awaits resolution.
The management of the individual who has a "weaker" family history of colorectal 
cancer also needs to be clarified. The majority of people falling into this category 
will develop their cancers over the age of 50 year's, and there are presently no genetic 
markers to identify those individuals who may have inherited a common low 
penetrant gene. Most benefit, in terms of reduced colorectal cancer incidence 
appears to result from periodic screening accrued at the initial screen. As a result, 
sorue authors have advocated that a single 60 cm flexible sigmoidoscopic 
examination performed at the age of 55 years, followed by a single diagnostic 
colonoscopy to detect and treat proximal as well as distal neoplasia, may be sufficient
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to achieve a cost-effective reduction in cancer mortality (457). In one study, less than 
1% of persons whose only lesions at sigmoidoscopy were small tubular adenomas had 
an advanced lesion proximally (458). The endoscopic workload created by 
introducing such a programme would be formidable but some ai'gue that this 
workload could be met by the employment of specialist nurse endoscopists and 
general practitioners who have been trained to perform flexible sigmoidoscopy (459).
Alternatively, it might be possible to develop a test which can detect genetic 
mutations which is present in all lai'ge adenomas and eai'ly cancers in stool DNA. 
Sidransky et al have reported the identification of ras oncogene mutations in the stool 
DNA from shed epithelial cells in patients with colorectal cancer , and eventually 
tests with greater sensitivity and specificity may be developed (181).
Genetic counselling is a time-consuming process, and a designated family cancer 
clinic is probably a more appropriate setting than a busy surgical out-patient clinic. 
Presently, most counselling is provided by clinical geneticists, but in future, this role 
might be filled also by an interested surgeon or gastroenterologist with appropriate 
training in cancer genetics. Public demand for cancer screening may be greater than 
is generally appreciated, and may be"news sensitive". When President Ronald 
Reagan had colorectal cancer diagnosed in 1985, the health insurance company 
Medicare computers noticed a 300% increase in the demand for colonoscopic 
services (460).
Gene therapy is perhaps one of the most exciting prospects for the treatment of 
colorectal cancer (461-463. Many obstacles remain to be overcome, not least of 
which, is the possibility of insertional mutagenesis and the activation of oncogenes 
leading to neoplasia.. Nonetheless, several gene therapy trials in oncology have been 
approved in the U.S.A. and Europe. In FAP, it is possible that gene therapy may be 
used to reduce the tendency for adenomas to form in the duodenum and in the rectal 
stump.
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Other therapeutic strategies include the insertion of genes which would enhance the 
expression of cytokines (464) and the suppression of oncogene expression (465). 
Methods might be discovered to make tumours expressing the Multidrug Resistance 
Gene, p-glycoprotein, more responsive to chemotherapy, or it may be possible to treat 
the cancer patient's normal bone marrow with this gene, abrogating maiTOW 
suppression, a major side effect of chemotherapy (466).
The search for the ideal prognostic molecular marker will no doubt continue. To date, 
attempts to identify the specific property of the cancer cell, which makes it more 
likely to metastasise, have been disappointing. Cellular' heterogeneity within tumours 
remains a probleru and studies analysing molecular markers are often qualitative 
rather than quantitative in nature. Furthermore, it is always possible that métastasés 
may result from the random survival of shed epithelial cells (467). In 1986, Nobel 
Prize-winning virologist, Renato Dulbecco, stated " We have two options: either to 
discover the genes involved in cancer by a piecemeal approach, or to sequence the
whole genome.................I think it would be far' more useful to begin by sequencing
the cellular genome. The sequence will make it possible to prepare probes for all
genes.................. Classification of the genes will facilitate the identification of those
involved in cancer progression " (468). The Human Genome Project is targeted for 
completion by the year' 2005. Hopefully, by this time, we will know whether the 
reductionist approach of Dulbeccco was correct.
Medical historians may look back on the last twenty years, as one of the most exciting 
periods in colorectal cancer research. In the past 8 years, 9 genes directly implicated 
in the carcinogenic process have been identified, and the part that each of these plays 
in the cancer jigsaw is presently being unravelled. The assertion of Bailar' and Smith 
that " we are losing the war against cancer" may yet be disproved (300).
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